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ABSTRACT 
 
Nicotine dependence is responsible for perpetuating the adverse health effects 
due to tobacco use, the leading cause of preventable death worldwide. Nicotine 
is an agonist for nicotinic acetylcholine receptors, which are enriched in the 
mesocorticolimbic and habenulo-interpeduncular circuitries, underlying nicotine 
reward and withdrawal, respectively. Drugs of abuse, including nicotine, induce 
stable neuroadaptations, requiring protein synthesis through regulation of 
transcription factors, epigenetic mechanisms, and non-coding RNAs. It also been 
shown that miRNAs in brain are regulated by nicotine and that miRNA 
dysregulation contributes to brain dysfunction, including drug addiction. While 
much is known about the neurocircuitry responsible for the behaviors associated 
with nicotine reward or withdrawal, the underlying molecular mechanisms of how 
these changes in behavior are induced are less clear. 
Using miRNA-/mRNA-Seq, we demonstrate that there are widespread changes 
in both miRNA and mRNA expression in brain regions comprising the 
mesocorticolimbic circuit after chronic nicotine treatment, and the habenulo-
interpeduncular circuit during acute nicotine withdrawal. Conserved, differentially 
expressed miRNAs were predicted to target inversely regulated mRNAs. We 
determined that expression of miR-106b-5p is up-regulated and Profilin 2 (Pfn2), 
an actin-binding protein enriched in the brain, is down-regulated in the 
interpeduncular nucleus (IPN) during acute nicotine withdrawal. Further we show 
	 ix 
that miR-106b-5p represses Pfn2 expression. We demonstrate that knockdown 
of Pfn2 in the IPN is sufficient to induce anxiety, a symptom of withdrawal. This 
novel role of Pfn2 in nicotine withdrawal-associated anxiety is a prime example of 
this dataset’s utility, allowing for the identification of a multitude of 
miRNAs/mRNA which may participate in the molecular mechanisms underlying 
the neuroadaptations of nicotine dependence. 
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CHAPTER 1 
Introduction 
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1.A.  Nicotine Dependence and Current Therapeutics 
 
Prevalence and Mortality of Tobacco Use 
Globally, tobacco use remains a prevalent health problem with more than 
900 million daily smokers of all ages (Peacock et al. 2018). It is estimated that 
15.2% of adults are daily smokers worldwide (Peacock et al. 2018). Smoking is 
the leading cause of preventable death and tobacco has the highest rate of age-
standardized substance-attributable mortality, responsible for 110 per 100,000 
deaths (Peacock et al. 2018). It is estimated tobacco-related illnesses are 
responsible for 6 million deaths annually (WHO 2012).  
Smoking (including second hand smoke exposure) is the leading risk 
factor for disease burden in North America and Western Europe (Lim et al. 2012). 
It is estimated smoking shortens life expectancy by 10 years compared to those 
that have never smoked (Jha et al. 2013). The death rate for smokers aged 25-
79 is about three times that of people that have never smoked, and this 
increased mortality is largely a result of neoplastic, respiratory and vascular 
diseases (Jha et al. 2013). In addition to lung cancer, development of other 
cancers including liver, colorectal, prostate, breast has been attributed to 
smoking (USDHHS 2014). Respiratory illnesses caused by smoking include 
chronic obstructive pulmonary disease, asthma, and increased susceptibility to 
respiratory infections such as tuberculosis (USDHHS 2014). Cigarette smoking 
increases the risk of vascular disease, including events such as myocardial 
	 3 
infarction (fatal and non-fatal) and stroke (Jha 2009). In fact, cardiovascular 
disease is the leading cause of death attributable to smoking, accounting for 1.5 
million annual deaths worldwide (Jha 2009).  
In addition to the direct exposure to smokers, non-smokers in the 
population are exposed to the toxic chemicals in second-hand smoke (SHS). In 
fact, 43% of the population has detectable levels of cotinine, a biomarker of 
tobacco exposure, in their blood (Pirkle et al. 2006) and SHS is estimated to 
contribute to over 53,000 deaths in the United States annually (Jacobs et al. 
2013). Second-hand smoke increases the risk of tobacco-related cancers and 
other diseases in non-smokers (USDHHS 2006). For example, it is estimated 
that the risk of stroke is increased 20-30% in non-smokers exposed to second-
hand smoke (Malek et al. 2015). In addition, second-hand smoke puts children at 
increased risk for sudden infant death syndrome, acute respiratory infections, 
and asthma (USDHHS 2006).  
On top of the disease burden and lost years of human life, smoking and 
tobacco-related illnesses have a significant economic impact. Some estimate that 
$170 billion is spent on health care costs associated with diseases caused by 
smoking in the United States each year (Xu et al. 2015). In addition to the direct 
healthcare costs, the negative health effects of smoking result in lost productivity. 
For instance, it is estimated that there is $151 billion in lost productivity in the 
United States when only the years of productive life lost due to premature 
smoking-related deaths are considered (Ekpu and Brown 2015). If other factors 
	 4 
such as disability leaves and sick days were considered, the economic toll of 
smoking would certainly be even larger. 
 
The Cycle of Nicotine Addiction 
Despite the adverse health and financial consequences of tobacco use, 
daily smokers find cessation difficult, even when motivated to quit. This is 
because smokers become addicted to nicotine, a tertiary alkaloid present in 
tobacco (Russell 1971, Dani and Balfour 2011). Smokers often attempt to quit 
multiple times with a low probability of success (Peacock et al. 2014). This can 
best be explained by thinking of nicotine addiction as a chronically relapsing 
disorder (Koob and Le Moal 2008) (Figure 1.1).  
In general, the rewarding properties of intoxication dominate the early 
stages of drug addiction (Koob and Le Moal 2008). Patients report that tobacco 
use results in various positive symptoms such as pleasure, relaxation, improved 
mood, arousal, improvement in attention and memory, and appetite suppression 
(Benowitz 1999, Benowitz 2010). The rewarding or motivating properties of 
nicotine are also evidenced by behavioral experiments in rodents. For example, 
mice and rats will self-administer nicotine intravenously (Corrigall and Coen 1989, 
Fowler and Kenny 2011) and condition a place preference to nicotine injection 
(Risinger and Oakes 1995, Le Foll and Goldberg 2005, Grabus et al. 2006), and 
these behavioral paradigms continue to be used to study mechanisms of nicotine 
addiction.  
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The repeated exposure to drugs, including nicotine, leads to the 
development of tolerance. The DSM-V defines tolerance as “a need for markedly 
increased amounts of the substance to achieve intoxication or desired effect” and 
“a markedly diminished effect with continued used of the same amount of the 
substance.” Rodents display tolerance to nicotine in locomotor activity, analgesia, 
and body temperature assays (Collins et al. 1988, Grabus et al. 2005). Once 
dependent on a drug, abstinence during a voluntary attempt to quit or involuntary 
inaccessibility to the drug induces a withdrawal state marked by negative somatic 
and affective signs (Koob and Le Moal 2008). The somatic, or physical, 
symptoms associated with nicotine withdrawal include bradycardia, 
gastrointestinal upset, and increased appetite (Jackson et al. 2015). The affective, 
or emotional, symptoms include anxiety, depression, dysphoria, irritability, 
difficulty concentrating, and craving (Hughes 2007, Jackson et al. 2015). 
Symptoms peak within the first week and are generally estimated to last for 2-4 
weeks (Hughes 2007). In order to relieve these negative symptoms, many 
smokers will often relapse and resume tobacco use. For example, one study 
showed that in a group of female smokers, craving and withdrawal symptoms 
increase 2-5 days prior to relapse and drop over the course of 2 days 
subsequent to relapse, suggesting that escalation of withdrawal symptoms 
contribute to relapse (Allen et al. 2008). Despite the unpleasantness of the 
somatic symptoms, it is the affective symptoms that dominate the preoccupation 
with drug seeking and relapse (Hughes 2007, Piper et al. 2011, Aguirre et al. 
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2015). Taken together, while the rewarding properties of nicotine dominate initial 
drug-taking, avoidance of the negative affective symptoms experienced during 
withdrawal promote relapse and the habitual use of a tobacco (Allen et al. 2008, 
Koob and Le Moal 2008).  
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Figure 1.1. The cycle of addiction. Addiction is chronically relapsing disorder 
that occurs in three main stages: 1. Binge/intoxication, 2. Withdrawal, 3. 
Preoccupation/Anticipation.  Adapted from Koob and Le Moal (Koob and Le Moal 
2008). 
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Current Therapeutics For Smoking Cessation 
 Various studies conclude that smokers have a low probability of 
successful cessation. The CDC found that according to the 2015 National Health 
Interview Survey of adult smokers, 68% want to quit, 55.4% made an attempt 
within the past year, and only 7.4% have recently quit (Babb et al. 2017). 
Similarly, a study done in 1996 in the United Kingdom found that 31% of smokers 
will make an attempt to quit and only 29% of those who made a quit attempt (or 
~10% of all smokers) remained abstinent for at least 3 months (West et al. 2001). 
There are great health benefits to smoking cessation and it is estimated that 
quitting by age 40 reduces the risk of death associated with continued smoking 
by 90% (Jha et al. 2013). 
The few pharmacological cessation aids currently available have limited 
efficacy. One of the mainstays of smoking cessation is nicotine replacement 
therapy via patch or chewing gum. Meta-analysis indicates that only 27% of 
smokers are able to remain abstinent for at least 6 months while using a nicotine 
patch, compared to 13% in a placebo patch control group (Fiore et al. 1994). 
Nicotine replacement does not represent a long-term maintenance treatment 
option, as they are not efficacious beyond 24 weeks of use (Prochaska 2015). In 
recent years, electronic cigarettes (e-cigarettes) which allow for the inhalation of 
aerosol containing nicotine without the tobacco smoke have become popular, 
especially in adolescents (CDC 2013). Studies on the use of e-cigarettes as an 
effective method of nicotine replacement therapy are inconclusive due to the 
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poor quality of currently available data (Malas et al. 2016). In fact, e-cigarette use 
in youth aged 12-17 actually increases the chances of smoking traditional 
tobacco cigarettes in the future (Watkins et al. 2018). 
The most commonly used non-nicotine pharmaceutical smoking cessation 
aids are bupropion and varenicline. Bupropion is an anti-depressant that exerts 
its effects by inhibiting norepinephrine and dopamine reuptake (Stahl et al. 2004). 
In addition to its anti-depressant effects, bupropion also acts as an antagonist for 
specific subtypes of nicotinic acetylcholine receptors (nAChRs), making it useful 
in the treatment of nicotine addiction (Slemmer et al. 2000). However, studies 
show that only about 20% of smokers remain abstinent for one year with the 
sustained-release bupropion (bupropion-SR) at various doses (Hurt et al. 1997), 
and this success rate is only marginally increased to about 30% by the addition 
of behavioral counseling (Swan et al. 2003). Varenicline is a partial agonist for 
the high affinity α4β2-contiaining nAChRs (Mihalak et al. 2006). In randomized 
control trials, varenicline has been shown to be more effective than bupropion-
SR (Jorenby et al. 2006). However, still only 23% of patients on varenicline 
remain abstinent at one year compared to 14.6% taking bupropion and 10.3% in 
the placebo group (Jorenby et al. 2006). It is clear that these treatments increase 
the success rate of quitting compared to those attempting without the use of 
smoking cessation aids, but the overall success rates remain low regardless of 
the treatment choice. Without the development of new effective treatments 
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smokers will continue to struggle with cessation and a continued rise in tobacco-
related deaths is anticipated (WHO 2012).   
Interestingly, nicotine is often abused in conjunction with other substances, 
including alcohol (Falk et al. 2006, Cross et al. 2017). Continued cigarette 
smoking or initiation of smoking is associated with increased odds of substance 
use disorder relapse (Weinberger et al. 2017). Combining effective smoking 
cessation with the treatment of simultaneously occurring substance abuse 
disorders may be important for improving the chances of successful long-term 
outcomes for patients suffering from multiple addictions. 
 
1.B.  Neuronal Nicotinic Acetylcholine Receptors (nAChRs) 
 
Structure of nAChRs 
 Nicotine is an agonist for nicotinic acetylcholine receptors (nAChRs), 
ligand-gated ion channels endogenously bound and activated by acetylcholine 
(Dani and De Biasi 2001, Benowitz 2009). Neuronal nAChRs are pentamers 
assembled from various combinations of transmembrane subunits arranged 
around a central, water-filled pore (Cooper et al. 1991, Dani and Bertrand 2007, 
Albuquerque et al. 2009). To date, eleven subunits, α2-α7, α9, α10 (encoded by 
genes Chrna2-7, Chrna9, Chrna10) and β2-β4 (Chrnb2-4), have been identified 
in mammalian neuronal nAChRs (Albuquerque et al. 2009). Each subunit 
contains four transmembrane (TM) domains, with the second TM domain lining 
the central pore, and extracellular N- and C-terminus domains (Albuquerque et al. 
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2009). The N-terminus of α subunits contains a cysteine loop, formed by two 
cysteines separated by 13 amino acids, which participates in agonist binding 
(Albuquerque et al. 2009). 
 Receptors can be heteromeric, containing both α and β subunits, or 
homomeric, the most common being α7 (Hurst et al. 2013). Different subunit 
combinations confer different affinities and functionalities to the receptor. For 
example, nAChRs containing α4 and β2 subunits (designated α4β2* to indicate 
that other subunits may be present) have relatively high affinity for nicotine 
compared to low-affinity homomeric α7 nAChRs (Dani and Bertrand 2007, 
Albuquerque et al. 2009). nAChR subunits are differentially expressed 
throughout the mammalian brain, with α4, β2, and α7 subunits showing the 
widest distribution and highest density of expression overall (Fowler et al. 2008). 
The heterogeneous distribution of nAChR subtypes throughout the brain 
modulates the activity of specific regions and circuits, contributing to their 
functions. 
 
Function of nAChRs 
When activated by ligand, nAChRs allow the influx of monovalent and 
divalent cations (Na+, K+, and Ca2+) (Galzi et al. 1992, Dani and Bertrand 2007). 
This influx of cations then can enhance the Ca2+-induced Ca2+ influx by activation 
of voltage-gated Ca2+ channels in the presynaptic terminal (Tredway et al. 1999, 
Dani and Bertrand 2007, Albuquerque et al. 2009). In mammals, neuronal 
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nAChRs of the central nervous system are located at pre-synaptic, pre-terminal, 
and extra-synaptic locations, and the intracellular Ca2+ signal resulting from their 
activation induces the release of neurotransmitters including dopamine, GABA, 
glutamate, and norepinephrine depending on the type of neuron on which they 
are located (Lena and Changeux 1997, Guo et al. 1998, Salminen et al. 2004, 
Azam et al. 2010, Garduno et al. 2012, Wang et al. 2014). 
In addition to the increased release of neurotransmitters, the increased 
intracellular Ca2+ is an activator of other downstream effectors, including Ca2+-
dependent kinases and transcription factors. For example, nicotine is thought to 
regulate the phosphorylation of extracellular-regulated protein kinase (ERK) 
signaling proteins and the transcription factor cAMP response element binding 
protein (CREB), contributing to the mechanisms underlying neuroplasticity 
associated with nicotine dependence (Brunzell et al. 2003, Brunzell et al. 2009). 
 
I.C.  The Neurocircuitry of Nicotine Reward 
 
The Mesocorticolimbic Pathway  
 The mesocorticolimbic dopamine pathway constitutes the brain circuitry 
responsible for the positive emotions and goal-directed motivations of rewarding 
stimuli, including pyschostimulant drugs of abuse (Koob and Volkow 2010, De 
Biasi and Dani 2011). The most important connections consist of dopaminergic 
(DAergic) neurons originating from the ventral tegmental area (VTA) and 
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projecting to the nucleus accumbens (NAc) and prefrontal cortex (PFC) (De Biasi 
and Dani 2011, Pistillo et al. 2015) (Figure 1.2). In general, the rewarding 
properties of addictive drugs, including nicotine, result from their ability to 
increase extra-cellular DA in the nucleus accumbens (NAc), located in the ventral 
striatum. (Di Chiara and Imperato 1988, Pontieri et al. 1996). Specifically, 
nicotine activates neurons within the VTA via nAChRs, stimulating increased 
release of DA within the NAc (Corrigall et al. 1994, Sombers et al. 2009, De Biasi 
and Dani 2011). Demonstrating the essential role of this circuit in nicotine 
reinforcement, lesioning of the NAc or blockade of nAChRs in the VTA reduces 
nicotine self-administration (Corrigall et al. 1992, Corrigall et al. 1994). 
Importantly, the mesocorticolimbic reward pathway is conserved among humans 
and rodents  (Figure 1.2), and activation of this circuit is likely responsible for the 
initiation of addiction (Laviolette and van der Kooy 2004).  
 While this work will focus on the mesocorticolimbic DAergic reward 
pathway, it is important to note that this is not the only DAergic circuit contributing 
to behaviors associated with drug addiction. For instance, the dorsal striatum 
(caudate nucleus and putamen) is proposed to contribute to the compulsive drug-
seeking exhibited in advanced addiction through its role in habit formation and 
storage of information about fixed action patterns (Gerdeman et al. 2003). The 
medium spiny neurons (MSNs) and interneurons of the dorsal striatum receive 
strong DAergic input from another midbrain region, the substantia nigra pars 
compacta (Lovinger 2010). High frequency stimulation of glutamatergic synapses 
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onto neurons in the dorsal striatum results in long-term depression (LTD), 
increasing extracellular dopamine and activating cholinergic interneurons 
(Partridge et al. 2002). Furthermore, activation of nAChRs expressed on the 
dopaminergic terminals in the dorsal striatum plays a role in the induction of LTD, 
and these mechanisms of synaptic plasticity may contribute to the formation of 
habits associated with nicotine addiction (Partridge et al. 2002).  
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Figure 1.2. The mesocorticolimbic pathway. A sagittal representation of the 
reward circuit, consisting of dopaminergic neurons projecting from the VTA 
(green) to the NAc (orange) and the PFC (blue). This circuitry is conserved in 
humans (A) and rodents (B). Abbreviations: VTA: Ventral tegmental area, NAc: 
Nucleus accumbens, PFC: Prefrontal cortex. Adapted from Laviolette and van 
der Kooy (Laviolette and van der Kooy 2004).  
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The Nucleus Accumbens (NAc) 
 The NAc is a bilateral nucleus residing in the ventral striatum, long 
considered a major center responsible for motivation and reward, including the 
effects of drugs of abuse (Salgado and Kaplitt 2015). The NAc is composed of 
about 90% GABAergic projection medium spiny neurons (MSNs) (Tepper and 
Bolam 2004, Sesack and Grace 2010). The remaining populations of neurons 
represent GABAergic and tonically active cholinergic interneurons (Tepper and 
Bolam 2004, Pistillo et al. 2015). 
 The NAc can be anatomically divided into two main sub-regions, the shell 
and the core, which also display differences in their afferent and efferent 
connections (Zahm and Brog 1992). There is a body of evidence indicating the 
shell is more important than the core for the rewarding and motivational 
properties of drugs, including nicotine (Ikemoto 2007). For example, rats will self-
administer agonists for DA D1 and D2 receptors in the NAc shell but not the core 
(Ikemoto et al. 1997). Furthermore, microinfusion of DA receptor antagonists or 
lesions of DAergic terminals in the NAc shell disrupt conditioned place 
preference to nicotine and other drugs (Sellings and Clarke 2003, Fenu et al. 
2006, Spina et al. 2006). However, the core also contributes to cue-conditioned 
motivated behaviors, including those in the context of drug addiction (Sesack and 
Grace 2010). 
 The main modulatory afferents to the NAc are DAergic inputs originating 
from the VTA, which is the central component of the reward circuit mediating 
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behavioral responses to natural rewards and drugs of abuse (Sesack and Grace 
2010, De Biasi and Dani 2011). In addition to the DAergic input received from the 
VTA, the NAc receives excitatory glutamatergic afferents from limbic brain 
regions, including the PFC, basolateral amygdala, and the ventral subiculum of 
the hippocampus (Sesack and Grace 2010). These inputs likely contribute to 
goal-directed behaviors and positive reinforcement learning, providing executive 
control, affective motivation, and contextual information, respectively (Kalivas et 
al. 2005, Ambroggi et al. 2008, Gruber et al. 2009, Sesack and Grace 2010, Britt 
and Bonci 2013). The NAc also receives glutamatergic afferents from various 
thalamic subregions which may contribute to arousal and attention to rewarding 
stimuli (Smith et al. 2004).  
 The major efferent projections of the NAc include the substantia nigra, 
(through the ventral pallidum and the subthalamic nucleus), the VTA, 
hypothalamus, and brainstem (Sesack and Grace 2010, Pistillo et al. 2015). This 
reciprocal connection with the VTA allows the limbic regions to influence the 
activity of the basal ganglia controlling motor-related functions (Sesack and 
Grace 2010). 
  
The Ventral Tegmental Area (VTA) 
 The VTA is a bilateral region of heterogeneous cellularity located in the 
ventral midbrain (Pistillo et al. 2015). Approximately 60% of the cells in the VTA 
are DAergic projection neurons (Pistillo et al. 2015). These DAergic neurons 
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exhibit a tonic firing pattern during resting conditions and display phasic burst 
firing in response to a rewarding experience (Schultz 1986). The phasic burst 
firing is capable of releasing more DA in projection areas (Schultz 1986, 
Pignatelli and Bonci 2015) and is sufficient to condition a place preference (Tsai 
et al. 2009).  
The VTA can be subdivided into anatomical sub-regions, including the 
anterior and posterior regions (aVTA and pVTA, respectively). The aVTA and 
pVTA respond differently to drugs of abuse, including nicotine, opiates, and 
alcohol (Ikemoto et al. 2006, Ericson et al. 2008, Shabat-Simon et al. 2008, 
Zhao-Shea et al. 2011). For instance, rats self-administer nicotine into the pVTA, 
but not the aVTA (Ikemoto et al. 2006). DAergic neurons within the aVTA and 
pVTA differ in size distribution, density, and expression of nAChR subtypes 
(Zhao-Shea et al. 2011). Importantly, nicotine directly and preferentially activates 
DA neurons in the pVTA through its action on α4α6* nAChRs (Zhao-Shea et al. 
2011). The efferent and afferent connection of the aVTA and the pVTA also differ. 
The aVTA projects to the NAc lateral shell and core, while the pVTA projects to 
the NAc medial shell and core, PFC and basolateral amygdala (Ikemoto 2007, 
Pistillo et al. 2015). These differences between the pVTA and aVTA may account 
for the differences in behavioral responses to nicotine.  
Neurons releasing the inhibitory neurotransmitter GABA are also present 
in the VTA, representing 20-40% of the neurons in this region (Lammel et al. 
2014). Both GABAergic projection neurons and interneurons are present and 
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enriched in the pVTA (Pistillo et al. 2015). A portion of these GABAergic neurons 
project to other brain regions including the PFC, NAc and lateral habenula (LHb) 
(Taylor et al. 2014, Pistillo et al. 2015). In fact, the majority of VTA projections to 
the PFC derive from GABAergic neurons (Carr and Sesack 2000). However, the 
majority of GABAergic neurons in the VTA are interneurons, synapsing with 
DAergic neurons within the VTA and tonically inhibiting their activity. In vitro 
studies suggested that nicotine exposure desensitizes nAChRs on these 
GABAergic interneurons, disinhibiting the activity of the DAergic VTA neurons 
(Mansvelder et al. 2002). Further supporting the prevailing ‘disinhibition’ 
hypothesis, in vivo activation of the GABAergic neurons in the VTA using 
optogenetics suppressed activity of neighboring DAergic neurons and disrupted 
reward behavior (van Zessen et al. 2012). In fact, optogenetic stimulation of 
GABAergic neurons in the VTA is sufficient to drive conditioned place aversion 
(Tan et al. 2012). However, additional in vivo studies have found that concerted 
activation of GABAergic neurons within the VTA are necessary for the induction 
of burst firing in the DAergic neurons important for reward behaviors (Tolu et al. 
2013). Additionally, functional up-regulation of α4* nAChRs in GABAergic 
neurons within the VTA is sufficient to increase sensitivity to nicotine reward 
(Ngolab et al. 2015). Taken together, these data support a complex regulatory 
role of GABAergic neurons in the modulation of VTA DAergic transmission and 
its importance for nicotine reward. 
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Finally, there is a small population (~2-9%) of glutamatergic, non-DAergic, 
non-GABAergic neurons in the VTA (Nair-Roberts et al. 2008, Taylor et al. 2014, 
Pistillo et al. 2015). Additionally, a subpopulation of VTA DAergic neurons also 
express glutamate transporters and release glutamate in the NAc and PFC 
(Chuhma et al. 2004, Kawano et al. 2006, Gorelova et al. 2012). 
The VTA receives input from throughout the CNS (Pistillo et al. 2015). 
Afferents from the striatum, including the NAc, directly project to both the DAergic 
and GABAergic neurons within the VTA (Watabe-Uchida et al. 2012). Forebrain 
areas projecting to the VTA include medial and lateral preoptic areas, LHb, 
medial and lateral hypothalamus, and the medial septum (Geisler et al. 2007, 
Watabe-Uchida et al. 2012). Ascending brainstem projections originate in regions 
including the pedunculopontine and laterodorsal tegmental (LDTg) nuclei and 
median raphe (Geisler et al. 2007, Watabe-Uchida et al. 2012). Glutamatergic 
afferents have been detected projecting from all regions except the NAc and the 
septum (Geisler et al. 2007). The cholinergic input to VTA DAergic neurons 
largely originates from the LDTg (Oakman et al. 1995, Omelchenko and Sesack 
2006). These glutamatergic and cholinergic afferents modulate the activity of the 
VTA. Release of glutamate and acetylcholine from various afferents has been 
shown to activate the DAergic neurons within the VTA, modulating reward 
behaviors. For example, stimulation of LDTg neurons releases glutamate and 
ACh, activating DAergic VTA neurons that project to the NAc and inducing a 
conditioned place preference (Lammel et al. 2014). Finally, the aVTA receives 
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GABAergic inputs from the rostromedial tegmentum (RMTg) (Pistillo et al. 2015). 
The RMTg sends GABAergic projections to DAergic neurons in the VTA, 
inhibiting their activity and playing a role in aversive behaviors (Jhou et al. 2009, 
Barrot et al. 2012).  
 While traditionally considered a reward center, the VTA also has an 
important role in the affective symptoms of nicotine withdrawal. It is theorized that 
withdrawal from drugs induces an over-activation of the stress circuitry of the 
brain (Koob and Volkow 2010). DAergic neurons in the VTA also express 
corticotrophin-releasing factor (CRF), a prominent stress modulator (Grieder et al. 
2014). DAergic neurons from the VTA expressing CRF project to the 
interpeduncular nucleus (IPN), and increased CRF signaling within the IPN 
triggers anxiety during nicotine withdrawal (Zhao-Shea et al. 2015, Molas et al. 
2017). 
 
nAChRs in the Mesocorticolimbic Pathway 
Nicotine modulates the activity of neurons within the mesocorticolimbic 
reward pathway through interaction with nAChRs. The soma and dendrites of 
DAergic neurons in the VTA predominantly express α4β2* (with or without  α5) 
and α4α6β2* nAChRs (Klink et al. 2001, Champtiaux et al. 2003, Gotti et al. 
2010). GABAergic interneurons and terminals in the VTA also express α4β2* and 
α6β2* nAChR subtypes and their activation promotes the release of GABA (Klink 
et al. 2001, Pistillo et al. 2015). In the NAc, no functional nAChRs have been 
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detected in MSNs (Pisani et al. 2007). Striatal DAergic terminals express β2* 
nAChRs, allowing for cholinergic interneurons to regulate the probability of DA 
release in the NAc (Cachope et al. 2012, Threlfell et al. 2012). Additionally, 
GABA release by interneurons or projection neurons in the striatum is modulated 
predominantly by α4β2* nAChR receptors (Grilli et al. 2009, Pistillo et al. 2015).  
Genetically modified mouse models provide evidence that different nAChR 
subunits play distinct roles in nicotine reward-associated behaviors. For example, 
β2, α4, or α6 nAChR subunit knockout (KO) mice do not systemically self-
administer nicotine, and this behavior is rescued when the subunit was re-
expressing in the VTA (Pons et al. 2008). However, α7-KO mice did not affect 
systemic nicotine self-administration, suggesting that α4β2* and α6β2*, but not 
α7, nAChRs are necessary and sufficient for nicotine self-administration (Pons et 
al. 2008). Further supporting the necessary role of β2* nAChRs in nicotine 
reward, β2 KO mice also do not condition a place preference to nicotine, while α7 
KO mice do not show any deficit in this behavior (Walters et al. 2006). In addition, 
mice expressing hypersensitive α4* nAChRs condition a place to concentrations 
of nicotine 50-fold lower than WT mice (Tapper et al. 2004). Taken together, the 
heterogeneous expression of nAChR subunits and their distinct roles in nicotine 
reward behaviors illustrates the role of nAChRs in modulating the activity of the 
mesocorticolimbic reward circuit. Yet, there is still much to be elucidated about 
the up-stream regulators and down-stream effectors of nAChR expression and 
activity during nicotine exposure and reward.  
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I.D.  The Neurocircuitry Of Nicotine Withdrawal  
 
The Habenulo-Interpeduncular Pathway 
The habenulo-interpeduncular circuit consists of neurons projecting from 
the medial habenula (MHb) to the interpeduncular nucleus (IPN) via the 
fasciculus retroflexus (Fr) (Antolin-Fontes et al. 2015, Molas et al. 2017) (Figure 
1.3A). This circuit modulates basal negative emotional responses and is 
essential for nicotine withdrawal-induced anxiety (Molas et al. 2017). Both the 
MHb and IPN are enriched in nicotinic acetylcholine receptors and withdrawal 
symptoms can be precipitated by blockade of these receptors via microinfusion 
of mecamylamine, a non-selective nicotinic antagonist, into either region of 
nicotine dependent mice (Salas et al. 2009, Zhao-Shea et al. 2015). 
Pharmacological and optogenetic studies have shown that glutamatergic 
stimulation from the MHb activates specific sub-regions of the IPN, resulting in 
the somatic and affective symptoms of nicotine withdrawal (Zhao-Shea et al. 
2013, Zhao-Shea et al. 2015). Specifically, GABAergic neurons in the IPN are 
activated during precipitated nicotine withdrawal and optogenetic activation of the 
GABAergic neurons in the IPN is sufficient to induce somatic withdrawal signs 
(Zhao-Shea et al. 2013). Pharmacologic blockade of the excitatory glutamatergic 
inputs to the IPN via infusion of the NMDA antagonist AP5 is sufficient to 
alleviate somatic and affective signs of precipitated withdrawal (Zhao-Shea et al. 
2013, Zhao-Shea et al. 2015). Finally, optogenetic silencing of the 
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cholinergic/glutamatergic MHb-IPN inputs alleviates nicotine withdrawal-
associated anxiety (Zhao-Shea et al. 2015). Overall, these studies show that 
glutamatergic inputs from the MHb activate GABAergic neurons in the IPN, 
inducing somatic and affective withdrawal symptoms in nicotine dependent mice. 
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Figure 1.3. The habenulo-interpeduncular pathway. (A) A sagittal 
representation of the mouse habenulo-interpeduncular withdrawal circuit, 
consisting primarily of neurons projecting from the MHb to the IPN (red arrow). 
Abbreviations: DR: dorsal raphe, DTg: dorsal tegmental nuclei, HPC: 
hippocampus, Hyp: Hypothalamus, IPN: interpeduncular nucleus, LHb: lateral 
habenula, LC: locus coeruleus, LDTg: laterodorsal tegmental nuclei, MHb: medial 
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habenula, MnR: median raphe, PAG: periaqueductal grey, Thal: Thalamus, VTA: 
ventral tegmental area, Adapted from Antolin-Fontes et al. (Antolin-Fontes et al. 
2015) and Molas et al. (Molas et al. 2017) (B) A coronal representation of the 
mouse habenulo-interpeduncular microcircuit. Substance P neurons (red) project 
from the dMHb to the IPL and ACh/Glu+ neurons (blue) project from the vMHb to 
the central IPN along the fasciculus retroflexus (fr). Abbreviations: dMHb: Dorsal 
medial habenula, IPDL: Dorsolateral IPN, IPDM: Dorsomedial IPN, IPI: 
Intermediate IPN, IPL: Lateral IPN, IPR: Rostral IPN, vMHb: Ventral medial 
habenula. Adapted from Molas et al. (Molas et al. 2017). 
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The Medial Habenula (MHb) 
 The habenula is a broadly conserved bilateral structure residing on the 
dorsomedial surface of the caudal thalamus that can be further subdivided into 
the medial and lateral habenula (MHb and LHb, respectively) (Hikosaka 2010). 
While the LHb projects densely to the RMTg inhibiting the firing of midbrain DA 
neurons (Jhou et al. 2009, Picciotto and Kenny 2013), the MHb projects almost 
exclusively to the IPN via the Fr (Hikosaka 2010) The medial habenula can be 
subdivided into the dorsal (dMHb) and ventral (vMHb) sub-regions, differentiated 
by neuron type, source of afferent projections and pattern of efferent projections 
to the IPN (Qin and Luo 2009, Molas et al. 2017). Afferents from the bed nucleus 
of the anterior commissure project to the dMHb while the vMHb receives 
glutamatergic and cholinergic input from the triangular septum (Qin and Luo 2009, 
Yamaguchi et al. 2013). The dMHb sends substance P fibers to the ipsilateral 
lateral portions of the IPN, while the cholinergic and/or glutamatergic neurons 
project from the vMHb to the central portion of the IPN (Molas et al. 2017) (Figure 
1.3B). There is also evidence for unidirectional afferents from the MHb to the LHb, 
suggesting that the MHb may regulate the activity of the LHb (Sutherland 1982, 
Kim and Chang 2005), representing indirect intersection with the activity of the 
VTA.  
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The Interpeduncular Nucleus (IPN) 
 The IPN is a single midline nucleus in the posterior midbrain that lies 
ventral to the VTA (Klemm 2004). The IPN can be further subdivided into four 
paired (dorsolateral [IPDL], dorsomedial [IPDM], intermediate [IPI], and lateral 
[IPL]) and three unpaired (apical [IPA], central [IPC], and rostral [IPR]) sub-
regions based on neuron type, afferents, and efferents (Hamill and Lenn 1984, 
Antolin-Fontes et al. 2015, Molas et al. 2017) (Figure 1.3B).  
 As discussed above, the major inputs to the IPN come from the MHb 
(Figure 1.3). Additional sources of neural projections include forebrain nuclei and 
midbrain nuclei (Antolin-Fontes et al. 2015) (Figure 1.3A). Forebrain nuclei 
afferents originate from regions such as the septum, ventral thalamus, and 
hypothalamus (Contestabile and Flumerfelt 1981, Jennes 1987, Villalobos and 
Ferssiwi 1987, Vertes and Fass 1988, Moore et al. 2000, Antolin-Fontes et al. 
2015). Midbrain nuclei projections to the IPN include the dorsal tegmental nuclei 
(DTg), LDTg, dorsal (DR) and median raphe (MnR), periaqueductal gray, and 
locus coeruleus (Hamill and Jacobowitz 1984, Satoh and Fibiger 1986, Cornwall 
et al. 1990, Antolin-Fontes et al. 2015). As previously discussed, the VTA also 
projects to the IPI and modulates activity of the IPN through CRF signaling 
(Zhao-Shea et al. 2015).  
IPN is composed predominantly of densely populated GABAergic neurons 
(Kawaja et al. 1989). The IPN sends efferent projections primarily to the MnR, 
DR, DTg and LDTg (Hamill and Lenn 1984, Groenewegen et al. 1986). The IPN 
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also sends efferent projections to regions including the septum, hypothalamus, 
thalamus, and hippocampus (Hamill and Lenn 1984, Vertes and Fass 1988, 
Antolin-Fontes et al. 2015).  
Different sub-regions within the IPN mediate different aspects of nicotine 
withdrawal behaviors. The activation of the IPR during nicotine withdrawal 
triggers somatic withdrawal signs (Zhao-Shea et al. 2013). The IPI is activated 
during nicotine withdrawal, in part by CRF signaling from the VTA, inducing 
increased anxiety (Zhao-Shea et al. 2015). Additionally, through the complicated 
network of direct and indirect efferent and afferents, the MHb-IPN is 
interconnected with the classical anxiety circuitry, including the amygdala and 
bed nucleus of the stria terminalis (BNST), modulating negative emotions and 
anxiety (Molas et al. 2017). 
 
nAChRs in the Habenulo-interpeduncular Pathway 
The mHb and IPN exhibit the highest [+H]-nicotine binding in the brain, 
suggesting high levels of nAChR expression in these regions (Marks et al. 1998). 
The MHb and IPN are enriched in nAChRs containing α5, α3, and β4 subunits, 
which are expressed by the CHRNA5-A3-B2 gene cluster (Picciotto and Kenny 
2013, Lassi et al. 2016). Interestingly, genome-wide association studies have 
identified associations between CHRNA5-A3-B2 gene cluster and the risk of 
nicotine addiction and the heaviness of smoking habit (Saccone et al. 2007, 
Thorgeirsson et al. 2008). This enrichment of nAChR subunits in the withdrawal 
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circuit is supported by single-cell RT-PCR and electrophysiological experiments 
suggesting that ~90-100% of MHb neurons express the α3, α4, α5, β2, and β4 
nAChR subunits (Sheffield et al. 2000). Additionally, ~40% of neurons in the MHb 
express α6, α7, and β3 nAChR subunits (Sheffield et al. 2000).	 
Genetic mouse models with various nAChR subunits knocked out shed 
light on the roles of specific nAChR subtypes in nicotine aversion and withdrawal. 
Mice lacking the α5 subunit display increased nicotine intake in a self-
administration paradigm. When α5 is re-expressed in the MHb, nicotine self-
administration returns to the level of a WT mouse, indicating α5* nAChRs 
participate in an inhibitory motivational signal that acts to limit nicotine intake 
(Fowler et al. 2011). Studies suggest that the different nAChR subtypes are 
responsible for the somatic and affective signs observed during nicotine 
withdrawal. For example, somatic signs observed during withdrawal precipitated 
with non-selective nAChR antagonist mecamylamine are decreased in α2 KO, α5 
KO, α7 KO, and β4 KO mice (Salas et al. 2004, Jackson et al. 2008, Salas et al. 
2009). β2 KO mice do not exhibit affective withdrawal signs such as anxiety or 
conditioned place aversion (Jackson et al. 2008). While much of the focus has 
been on determining the expression patterns and behavioral consequences of 
nAChR subtypes in the MHb-IPN axis, there remains much to be elucidated 
concerning the up-stream regulators and down-stream effectors activated by 
these nAChRs and their roles in nicotine withdrawal. 
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I.E.  Neuroadaptations of Nicotine Dependence 
 
nAChRs and Nicotine Dependence 
The neurocircuitry controlling the behaviors associated with nicotine 
reward and withdrawal are well defined, but the cellular mechanisms underlying 
these behavioral changes are less clear. The most extensively studied 
phenomenon is the up-regulation of nAChRs after chronic nicotine exposure. It is 
well established that nAChRs, predominantly α4β2*, are up-regulated in the brain 
following chronic exposure to cigarette smoke or nicotine in both rodents and 
humans (Schwartz and Kellar 1983, Benwell et al. 1988, Yates et al. 1995, Flores 
et al. 1997, Nguyen et al. 2003). While not completely understood, it has been 
suggested that nicotine-induced up-regulation of nAChRs is thought to contribute 
to nicotine dependence by altering the neural network, possibly resulting in 
altered sensitivity to nicotine (Govind et al. 2009). When chronically stimulated by 
nicotine, nAChRs enter a deep state of desensitization, which may contribute to 
acute tolerance and promote nAChR up-regulation (Dani and De Biasi 2001).  
In the mesocorticolimbic reward circuitry, desensitization of α4β2* 
nAChRs on GABAergic neurons of the VTA disinhibits DAergic projections to the 
NAc, leading to rewarding behaviors (Mansvelder et al. 2002, van Zessen et al. 
2012). Additionally, chronic nicotine exposure leads to up-regulation of α4β2* 
nAChRs primarily on GABAergic neurons (Nashmi and Lester 2007). The 
restoration of nAChR function during nicotine abstinence leads to amplified 
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GABAergic activity by endogenous ACh, possibly contributing to nicotine 
withdrawal symptoms (Pistillo et al. 2015). Other studies have found that 
repeated nicotine exposure and withdrawal leads to increased density of nAChRs 
in the striatum and enhanced nicotine-conditioned placed preference in mice 
(Hilario et al. 2012).  
In the habenulo-interpeduncular withdrawal circuit, chronic nicotine 
functionally up-regulates α6/α4* nAChRs in the cholinergic/glutamatergic 
neurons in the vMHb (Shih et al. 2015, Pang et al. 2016). During nicotine 
abstinence, this up-regulation of nAChRs in the MHb presumably results in 
increased cholinergic activation of glutamatergic neurons projecting to the IPN, 
inducing withdrawal-associated symptoms including anxiety (Pang et al. 2016, 
Molas et al. 2017).  
 The current prevailing hypothesis is that nAChR up-regulation results 
from post-transcriptional mechanisms including slowed rate of cell surface turn 
over, increased rate of subunit maturation and assembly, blockage of subunit 
degradation, changes in receptor stoichiometry, and changes in the conformation 
of nAChRs (Govind et al. 2009). It is generally accepted that nAChR up-
regulation is not a result of an increase in transcription, as in situ hybridization 
experiments have indicated no increase in mRNA encoding nAChR subunits, 
including α4 and β2, in the brains of mice exposed to nicotine for 10 days (Marks 
et al. 1992).  However, conflicting evidence from our laboratory showed there 
was an up-regulation of the Chnrb2 transcript in the VTA of WT mice after 
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chronic nicotine treatment via osmotic minipump (Hogan et al. 2014). In light of 
this conflicting evidence, there is much yet to be elucidated concerning the 
complex mechanisms underlying the nicotine-mediated up-regulation of nAChRs 
in a subtype and sub-region specific manner.  
 
Nicotine-induced Neuroadaptations and Transcriptional Regulation 
Neuroplasticity describes the brain’s ability to remodel the structural and 
functional connections in response to stimuli, from the level of the synapse to the 
circuit (Korpi et al. 2015). In general, chronic exposure to drugs of abuse induces 
stable neuroadaptations underlying the compulsion for continued drug use and 
susceptibility to relapse. These neuroadaptations are evidenced by many 
examples of drug-evoked long term potentiation and depression, strengthening 
and weakening synapses in the VTA and NAc (Madsen et al. 2012). These long-
lasting changes in the addicted brain’s function are thought to require alterations 
of gene expression and de novo protein synthesis through regulation of 
transcription factors, epigenetic mechanisms, and non-coding RNAs (Robison 
and Nestler 2011, Madsen et al. 2012).  
Research has predominantly focused on the nicotine-induced nAChR up-
regulation and its effects on nicotine reward and withdrawal behaviors, but other 
targets with a variety of regulatory functions at the synapse are also subject to 
regulation by nicotine. For example, expression of glutamatergic receptors 
(GluRs) is altered in a region-specific manner following chronic nicotine treatment 
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and withdrawal (Pistillo et al. 2016). These effects are long lasting, especially in 
the midbrain (Pistillo et al. 2016). Chronic nicotine exposure also increases the 
levels of high-affinity DA D2 receptors (Novak et al. 2010) and regulates of 
synaptic scaffolding proteins (Rezvani et al. 2007). Overall, nicotine employs a 
multitude of mechanisms to modify the synapse, possibly underlying the 
behaviors associated with nicotine reward and withdrawal. 
Several studies have revealed that nicotine induces changes in the 
expression and activity of transcription factors. Most notably, levels of CREB and 
phosphorylated CREB, a constitutively expressed transcription factor, are altered 
in brain regions of the mesocorticolimbic pathway in mice exposed to nicotine 
and withdrawal (Pandey et al. 2001, Brunzell et al. 2003). Furthermore, activation 
of CREB in the NAc shell is required for the formation of a nicotine conditioned 
place preference (Brunzell et al. 2009). The Fos family of immediate early genes, 
including c-Fos and FosB, represents additional examples of transcription factors 
regulated by nicotine treatment or withdrawal (Marttila et al. 2006). Nicotine’s 
regulation of the levels and activity state of transcription factors allows for 
widespread downstream regulation of the transcriptome in response to the 
nicotine stimulus, contributing to neuroadaptations at the synapse. 
There is a limited body of work examining transcriptome-wide expression 
changes in the brain following nicotine exposure and withdrawal. Most studies 
employ microarrays to measure gene expression in various brain regions. Neural 
focused microarrays showed that specific regions of the rat mesolimbic circuit, 
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including the PFC, NAc, VTA, and amygdala, exhibit divergent transcriptional 
responses to chronically self-administered nicotine (Konu et al. 2001). Similarly, 
microarrays identified 4.1-14.3% of genes were modulated in the PFC, NAc, VTA, 
amygdala, and hippocampus of C57BL/6J mice receiving nicotine in their 
drinking water for two weeks (Wang et al. 2008). Interestingly, only a small 
number of genes were altered in more than one brain region, suggesting 
changes in transcription occur in a brain-region specific manner (Wang et al. 
2008). Alterations in transcription also follow distinct time-courses, over the 
course of hours following a single sub-cutaneous nicotine injection (Chen et al. 
2007) and days/weeks of continued nicotine injections (Li et al. 2004). 
While the majority of studies investigate transcriptome-wide expression 
changes in specific regions of the brain, one study used single cell RNA-seq to 
investigate differential gene expression in specific neuron-subtypes. Nicotine 
induces differential expression of 129 genes in DAergic neurons of the substantia 
nigra pars compacta as determined by single cell RNA-Seq, many of which were 
related to the ubiquitin-proteosome pathway, cell cycle regulation, chromatin 
modification, DNA binding and regulation of transcription, and RNA processing 
(Henley et al. 2013). In addition, DAergic and GABAergic neurons have distinct 
transcriptome phenotypes in response to nicotine exposure (Henley et al. 2013).  
Several studies have investigated the transcriptional effects of various 
modes of nicotine exposure on brain regions of the mesocorticolimbic reward 
pathway, but relatively little is known about alterations in gene expression at the 
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mRNA level within the MHb-IPN withdrawal axis in response to nicotine exposure. 
One study measured differential expression by microarray, finding that 615 
mRNAs in the habenula were altered by self-administration of nicotine (Lee et al. 
2015). However, the effect of withdrawal on the transcription of mRNAs in this 
circuit has not been pursued.  
 
 
I.F.  MicroRNA (miRNA) Biogenesis and Function  
 
Canonical Biogenesis of miRNAs 
 miRNAs are non-coding RNA molecules ~22 nucleotides in length that 
direct Argonaute silencing complexes to repress the expression of mRNA targets 
by promoting mRNA decay or translational repression (Bartel 2018) (Figure 1.4). 
miRNA genes may be intergenic or reside in introns, using the same or distinct 
promoter of their host gene (Ozsolak et al. 2008). Primary transcripts, called pri-
miRNAs, are transcribed from miRNA genes by RNA polymerase II (Lee et al. 
2004) and form a hairpin structure. Drosha, a nuclear RNAse III endonuclease, 
forms the Microprocessor complex with two molecules of DGCR8 (DiGeorge 
syndrome critical region 8), a cofactor that possess two double-stranded RNA-
binding domains (Han et al. 2004, Nguyen et al. 2015). The Microprocessor 
cleaves pri-miRNAs ~11 nucleotides away from the ssRNA-dsRNA ‘basal’ 
junction (Han et al. 2006). This cleavage generates ~60 nucleotide pre-miRNA 
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hairpin molecules with a 2 nucleotide 3'-overhang (Lee et al. 2003). Importantly, 
this cleavage defines the terminus of a miRNA, and thus its specificity (Ha and 
Kim 2014). The pre-miRNA is then exported to the cytoplasm by Exportin 5 
(Xpo5) (Yi et al. 2003) where it is further processed by Dicer, an RNAse III 
endonuclease. Dicer cuts both RNA strands by the loop of the pre-miRNA 
leaving another 2 nucleotide 3'-overhang and generating the miRNA duplex 
(Bartel 2018). To achieve precise cleavage of ~22 nucleotide dsRNAs, it is 
hypothesized that Dicer acts as a ‘molecular ruler’ (Ha and Kim 2014). A PAZ 
(PIWI-AGO-ZWILLE) domain binds to the 5'-terminus of the pre-miRNA and 
Dicer’s catalytic center, separated by a helical domain, cleaves the pre-miRNA at 
a fixed distance near the loop (Macrae et al. 2006, Park et al. 2011). The miRNA 
duplex is loaded into the AGO protein to form a RNA-induced silencing complex 
(RISC), and the passenger miRNA* is expelled and degraded (Kawamata and 
Tomari 2010), leaving the targeting guide strand. In principle, either strand may 
be loaded as the guide strand, so strand selection must be tightly regulated. The 
thermodynamic stability and sequence bias at the 5'-terminus of the miRNA 
duplex is thought to regulate guide strand selection (Schwarz et al. 2003, Hu et al. 
2009, Meijer et al. 2014). 
 Biogenesis of miRNAs can be regulated at each step. Nuclear control 
points include pri-miRNA transcription by RNA Pol II and the localization, stability, 
and affinity of the Drosha/DGCR8 Microprocessor (Ha and Kim 2014). In the 
cytoplasm, miRNA biogenesis may be regulated at the level of Dicer processing, 
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AGO proteins and other members of the RISC, and miRNA stability/decay (Krol 
et al. 2010, Ha and Kim 2014). 
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Figure 1.4. miRNA biogenesis. Pri-miRNAs are transcribed by RNA 
polymerase II (Pol II) in the nucleus and processed by Drosha/DGCR8 to 
generate pre-miRNAs with a stem-loop structure and a 2 nt 3´overhang. Pre-
miRNAs leave the nucleus via exportin 5 (Xpo5) and are cleaved by Dicer in the 
cytoplasm to form a miRNA duplex. The miRNA guide strand is loaded into the 
Argonaute (AGO) silencing complex and directs repression of its mRNA target by 
cleavage, translational repression, or mRNA deadenylation. Adapted from Bartel 
(Bartel 2018) and O’Carrol and Schaefer (O'Carroll and Schaefer 2013).   
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miRNA Function 
miRNAs repress expression of their targets through cleavage, 
deadenylation, or translational repression (Figure 1.4). Microarray and proteomic 
analysis has determined that the repression of mRNAs and protein by miRNAs is 
typically mild, with in vitro over-expression of miRNAs rarely inducing repression 
greater than 2- or 4-fold, respectively (Lim et al. 2005, Selbach et al. 2008). 
miRNAs direct cleavage of their target mRNA transcripts when base-pairing is 
extensive, however this mechanism of silencing has been reported in a few 
select cases in humans and mammals (Bartel 2018).  
In mammals, the most dominant mechanisms of miRNA repression are 
mRNA destabilization and decay (Guo et al. 2010, Eichhorn et al. 2014). GW182 
proteins (also known as TNRC6 proteins) co-assemble with AGO proteins in the 
RISC and are required for miRNA-mediated gene silencing (Jonas and Izaurralde 
2015). GW182 proteins within the RISC recruit PAN2-PAN3 and CCR4-NOT 
deadenylation complexes to mRNA targets which shortens the Poly(A) tail and 
fates the mRNA for degradation (Braun et al. 2011, Chekulaeva et al. 2011, 
Fabian et al. 2011, Wilczynska and Bushell 2015, Bartel 2018).  
miRNAs also act to repress the translation of their targets (Wilczynska and 
Bushell 2015, Bartel 2018). Translational repression by miRNAs is thought to 
occur through inhibition of the initiation step (Pillai et al. 2005, Mathonnet et al. 
2007). The miRNA-RISC prevents recruitment of the pre-initiation complex by 
blocking the assembly of the eukaryotic translation initiation factor (eIF4F) 
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complex, interfering with recognition of the 5'-cap (Mathonnet et al. 2007, Fukaya 
et al. 2014). The RNA helicase activity of the eIF4F complex is thought to 
participate in initiation by unwinding the 5ʹ-UTR into a conformation amenable to 
the binding of the pre-initiation complex (Fukaya et al. 2014). Also, in addition to 
their above roles in mRNA deadenylation, recruitment of GW182 and its 
downstream effector CCR4-NOT by the RISC is also thought to decrease the 
efficiency of translation (Wilczynska and Bushell 2015, Bartel 2018). This occurs 
via the recruitment of DEAD-box RNA helicase (DDX6), a known inhibitor of 
translation (Mathys et al. 2014).   
 
miRNA Targets And Target Prediction 
Despite repressing the expression of their targets by a small amount, 
miRNAs play an important role in the regulation of cellular functions and are 
predicted to regulate more than half of the human genome (Ameres and Zamore 
2013). Each miRNA is predicted to target multiple, distinct mRNA transcripts (Lim 
et al. 2005). Conversely, a single mRNA transcript may be targeted by multiple 
miRNAs (Peter 2010). It is the mechanisms by which miRNAs target mRNAs that 
impart them with this expansive regulatory potential. 
miRNAs recognize their mRNA targets through imperfect base-pairing of 
the miRNA seed region (nucleotides 2-7) with miRNA response elements (MREs) 
within the 3ʹ-UTR of mRNAs (Lewis et al. 2003, Bartel 2009). In addition to the 6 
nucleotide seed, canonical MREs also have an additional base pairing at 
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nucleotide 8 and/or an adenosine (A) at nucleotide 1 (Bennett et al. 2003) (Figure 
1.5).  Seed type efficacy is ranked from highest to lowest: 8mer > 7mer-m8 > 
7mer-A1 (Grimson et al. 2007). Effective non-canonical sites, involving extensive 
base pairing to the 3'-end of the miRNA do exist, however, they are very rare for 
conserved miRNA families in mammals (Friedman et al. 2009). In fact, miRNAs 
will bind to non-canonical sites, however, novel non-canonical sites identified in 
high throughput CLIP and other biochemical studies conveyed no detectable 
repression in target mRNA or protein levels (Agarwal et al. 2015).  
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Figure 1.5. Canonical miRNA response elements (MREs). All canonical seed 
types base pair with nucleotides 2-7 of the miRNA. 7mer-A1 sites have an 
additional adenosine at position 1. 7mer-m8 sites have an additional seed match 
at position 8. 8mer sites contain both the adenosine at position 1 and the 
additional base pairing at position 8. Adapted from Bartel (Bartel 2009).   
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In addition to the base pairing of 7-8 nucleotides in the miRNA seed region 
to the MREs within the 3ʹ-UTR of mRNAs, elements of the UTR context can also 
influence miRNA targeting (Bartel 2009). Position within the 3ʹ-UTR can influence 
the effectiveness of a MRE. For example, more effective and preferentially 
conserved sites occur at least 15 nucleotides past the stop codon (Grimson et al. 
2007). Additionally, sites occurring near either end of the 3ʹ-UTR have improved 
efficacy (Grimson et al. 2007). Finally, occurrence of 2 MREs in close proximity 
to each other can act synergistically, improving their efficacy (Grimson et al. 
2007). 
In an effort to aid in target prediction, several computational algorithms, 
including TargetScan, have been developed. TargetScan v7.0 predicts miRNA 
targets based on seed pairing and ranks them based on a context++ score to 
predict their efficiency. The context++ takes into account a total of 14 features 
which include 3ʹ-UTR target-site abundance, predicted thermodynamic stability of 
seed pairing, identity of nucleotides at position 8 and 1, 3ʹ supplementary pairing, 
predicted structural accessibility, distance from the stop codon or polyadenylation 
site, lengths of the open reading frame (ORF) and 3ʹ-UTR, and site conservation 
(Agarwal et al. 2015). Broadly conserved miRNAs have more conserved targets 
than miRNAs conserved only in mammals (Friedman et al. 2009). Importantly, 
this version of TargetScan ranks predictions by probability of preferential site 
conservation (PCT) (Friedman et al. 2009, Agarwal et al. 2015).  
   
	45 
1.G.  The Role Of miRNAs In Nicotine Dependence 
 
Neuronal miRNAs 
 Regulation of gene expression by miRNAs contributes to neuronal 
development and normal brain function (Im and Kenny 2012). Approximately 50% 
of all miRNAs are expressed in the mammalian brain (O'Carroll and Schaefer 
2013). The brain’s miRNAs are regulated temporally, with varying levels of 
expression throughout development (Krichevsky et al. 2003, Landgraf et al. 
2007). miRNAs display brain region-specific expression profiles (Landgraf et al. 
2007, Bak et al. 2008, He et al. 2012). The spatial patterns of miRNA expression 
in the central nervous system (CNS) contribute to its complex, heterogeneous 
cell-type composition. In addition to the brain region-specificity of miRNA 
expression, different neuronal subtypes also display distinct miRNA expression 
profiles (He et al. 2012). Finally, miRNAs are differentially expressed among 
intraneuronal compartments, and are enriched in the dendritic spines and axon 
terminals of the synapse (Lugli et al. 2008, Natera-Naranjo et al. 2010, O'Carroll 
and Schaefer 2013). Also, synaptic expression of miRNAs is regulated by 
neuronal activity (Eacker et al. 2011, Siegel et al. 2011, Pichardo-Casas et al. 
2012). This spatial and activity-dependent regulation of miRNAs suggests that 
miRNAs contribute to the mechanisms underlying neuroadaptations at the 
synapse.  
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 Dysregulation of miRNAs in the brain have been shown to contribute to 
neurodevelopmental and neuropsychiatric disorders, including drug addiction (Im 
and Kenny 2012). For example, miR-212 expression is up-regulated in the dorsal 
striatum of rats self-administering cocaine (Hollander et al. 2010). Interestingly, 
miR-212 expression in the striatum decreases sensitivity to the motivational 
properties of cocaine, suggesting a miRNA can influence vulnerability to cocaine 
addiction (Hollander et al. 2010). Other drugs of abuse such as amphetamine, 
opioids, and alcohol also induce changes in miRNA expression in various cell 
types (Zheng et al. 2010, Lewohl et al. 2011, Lippi et al. 2011, Balaraman et al. 
2012, Im and Kenny 2012). There are several studies suggesting nicotine 
regulates miRNA expression, however, little is known about the role of miRNAs 
in the mechanisms underlying nicotine dependence and withdrawal. 
 
Regulation of miRNAs by Nicotine 
 Nicotine and tobacco smoke has been shown to regulate miRNA 
expression, contributing to various disease processes associated with smoking. 
Various in vitro studies identify miRNAs that are regulated by nicotine. For 
example, in canine atrial fibroblasts, nicotine down-regulates miR-133 and miR-
590 (Shan et al. 2009). The de-repression of their targets, transforming growth 
factors, contributes to a profibrotic state associated with tobacco abuse (Shan et 
al. 2009). Nicotine up-regulates miR-21 in an esophageal carcinoma cell line, 
EC9706, contributing to the dysregulation of the epithelial to mesenchymal 
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transition observed in tumorigenesis in humans with esophageal cancer (Zhang 
et al. 2014). Use of microarray found that miR-140* was increased in 
undifferentiated rat adrenal pheochromocytoma PC12 cells exposed to nicotine 
(Huang and Li 2009). In vitro, this miRNA down-regulates dynamin 1 (dnm1), a 
regulator of synaptic endocytosis, suggesting a role for a miRNA in nicotine-
induced synaptic plasticity (Huang and Li 2009). 
 In vivo, exposure to cigarette smoke alters the expression of miRNAs in 
the lungs of mice and rats (Izzotti et al. 2009, Izzotti et al. 2011). In humans, 
expression of 43 miRNAs were significantly up-regulated in the plasma of 
cigarette smokers as compared to non-smokers (Takahashi et al. 2013). 
Interestingly, they found that quitting smoking returned miRNA plasma 
expression to levels observed in non-smokers (Takahashi et al. 2013).  
 Limited studies have examined the regulation of miRNAs by nicotine in 
specific regions of the mammalian brain (Lippi et al. 2011, Hogan et al. 2014, Lee 
et al. 2015). Previously, we showed that the expression of miRNAs predicted to 
target MREs within the 3ʹ-UTRs of nAChR transcripts was altered after chronic 
nicotine treatment in whole brain or a specific brain region (Hogan et al. 2014). 
For example, miR-542-3p was down-regulated in the VTA of mice chronically 
exposed to nicotine, while expression of the β2 nAChR subunit, a predicted 
target, was up-regulated (Hogan et al. 2014). When specifically considering the 
withdrawal circuitry, the expression of many miRNAs and mRNAs is altered in 
the medial habenula of mice self-administering nicotine (Lee et al. 2015). 
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However, the targets of these miRNAs and their functions in the context of 
nicotine dependence have not been confirmed. Currently, there remain no 
reports analyzing the differential expression of miRNAs and mRNAs during 
nicotine withdrawal in brain regions comprising the MHb-IPN axis using Next 
Generation sequencing.   
 
 
1.H. Thesis Overview 
 The goal of this work is to understand regulation of the miRNA and mRNA 
transcriptome in the mesocorticolimbic and habenulo-interpeduncular circuits 
during nicotine dependence and its contribution to the affective symptoms of 
nicotine withdrawal. This thesis explores multiple stages of nicotine dependence, 
including chronic exposure and both acute and prolonged withdrawal states, 
using Next Generation sequencing. This dataset reveals differential expression of 
mRNA transcripts that reflect both alterations in the activity of the reward and 
withdrawal circuitry and possible mechanisms underlying the neuroadaptations 
associated with nicotine dependence. In addition, integrated miRNA/mRNA 
differential expression analysis identified a multitude of genes regulated by 
chronic nicotine treatment and acute nicotine withdrawal that were predicted 
targets of inversely regulated miRNAs.  
The brain region-specific analysis of mRNA expression identified a 
plethora of differentially expressed genes during acute nicotine withdrawal. To 
	49 
demonstrate the utility of these differential expression and target prediction 
analyses, I further explored the role of one of these genes in nicotine withdrawal-
associated anxiety behavior. Profilin 2 (Pfn2), a regulator of actin dynamics, was 
down-regulated in the IPN during acute nicotine withdrawal and its expression is 
repressed by an inversely regulated miRNA, miRNA-106b-5p. Further, I show 
that knockdown of Pfn2 in the IPN of WT mice is sufficient to induce anxiety, 
mimicking behaviors observed in acute nicotine withdrawal.  
This work serves as a strong example of the value of this large data set in 
the identification of novel roles for genes previously not considered in the 
mechanisms of nicotine dependence. This large dataset contributes to a greater 
understanding of the neuroadaptations underlying nicotine dependence, beyond 
the well-studied functional up-regulation of nAChRs. Identification of novel 
regulatory mechanisms is essential for the design of more efficacious smoking 
cessation strategies to combat the affective symptoms of withdrawal, such as 
anxiety.  
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Chapter 2 
Integrated miRNA-/mRNA-Seq Analysis of the Mesocorticolimbic Reward Circuit 
During Chronic Nicotine Treatment and Withdrawal 
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2.A.  Introduction 
 
Tobacco use is a prevalent health problem worldwide, with more than 900 
million daily smokers (Peacock et al. 2018) and an estimated 6 million deaths 
due to tobacco-related illnesses annually (WHO 2012).  The few pharmacological 
cessation aids currently available have limited efficacy (Jorenby et al. 2006, 
Cinciripini et al. 2013, Koegelenberg et al. 2014, Kotz et al. 2014), and without 
the intervention of new effective treatments, tobacco-related mortality is 
anticipated to rise to 8 million deaths per year (WHO 2012). 
 The addictive component of tobacco is nicotine, a tertiary alkaloid that is 
an agonist of nicotinic acetylcholine receptors (nAChRs), ligand-gated ion 
channels endogenously activated by acetylcholine (Albuquerque et al. 2009). 
nAChRs are enriched in the mesolimbic and habenulo-interpeduncular circuitries 
underlying nicotine reward and withdrawal, respectively (Dani and De Biasi 2013, 
Picciotto and Mineur 2014, Molas et al. 2017). Cessation of nicotine induces a 
withdrawal syndrome consisting of negative somatic, affective and cognitive 
symptoms. Affective symptoms primarily include depressed mood, irritability, 
craving and anxiety (Hughes 2007, Jackson et al. 2015). While the rewarding 
properties of nicotine dominate initial drug-taking, it is largely avoidance of 
affective withdrawal symptoms that promotes relapse and habitual use (Allen et 
al. 2008, Koob and Le Moal 2008). 
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 The mesocorticolimbic reward pathway is composed mainly of DAergic 
neurons projecting from the VTA to the NAc and PFC (De Biasi and Dani 2011, 
Pistillo et al. 2015). The positive and motivational emotions associated with 
nicotine exposure result from activation of neurons in the VTA, inducing them to 
release increased levels of DA in the NAc (Schultz 1986, Tsai et al. 2009, 
Pignatelli and Bonci 2015). Exposure to nicotine induces neuroadaptations that 
alter the function of this circuit, influencing the sensitivity to the rewarding effects 
of nicotine and contributing to the emergence of a withdrawal syndrome during 
abstinence. For example, chronic nicotine exposure up-regulates and 
desensitizes nAChRs on the GABAergic interneurons within the VTA, 
disinhibiting the activity of DAergic projections to the NAc (Mansvelder et al. 2002, 
van Zessen et al. 2012). However, when nicotine is withdrawn activity of these 
GABAergic neurons is amplified by endogenous cholinergic signaling, inhibiting 
DA output from the VTA (Pistillo et al. 2015). It is thought that this alteration of 
signaling within the reward circuit contributes to induction of withdrawal 
symptoms. The VTA may further contribute to the development of withdrawal by 
direct stimulation of the IPN, a prominent withdrawal and anxiety center, via 
corticotrophin releasing factor (CRF) signaling (Zhao-Shea et al. 2015).  
While much is known about the neurocircuitry responsible for nicotine 
reward and withdrawal-associated behaviors, the molecular mechanisms 
underlying the induction of these behavioral alterations are less clear. Chronic 
drug exposure induces stable neuroadaptations underlying the compulsion for 
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continued use and susceptibility to relapse. These long-lasting changes in the 
function of the addicted brain are thought to require alterations of gene 
expression through regulation of transcription factors, epigenetic mechanisms, 
and non-coding RNAs (Robison and Nestler 2011, Madsen et al. 2012).   
 microRNAs (miRNAs) are non-coding RNA molecules ~22 nucleotides in 
length that repress the expression of mRNA targets by promoting mRNA decay 
or translational repression (Bartel 2018). miRNAs recognize their targets through 
imperfect base-pairing of the seed region (nucleotides 2-7) with miRNA response 
elements (MREs) within the 3ʹ-untranslated regions (UTRs) of mRNAs (Lewis et 
al. 2003, Bartel 2009). Tobacco smoke and nicotine have been shown to regulate 
the expression of miRNAs in various cell lines, organisms, and tissues (Izzotti et 
al. 2009, Shan et al. 2009, Izzotti et al. 2011, Takahashi et al. 2013, Hogan et al. 
2014, Zhang et al. 2014).  
 Dysregulation of miRNAs in the brain have been shown to contribute to 
neurodevelopmental and neuropsychiatric disorders, including drug addiction 
(Hollander et al. 2010, Im and Kenny 2012). However, little is known about the 
role of miRNAs in the mechanisms underlying nicotine dependence and 
withdrawal. Few studies have examined the regulation of miRNAs by nicotine in 
specific regions of the mammalian brain (Lippi et al. 2011, Hogan et al. 2014, Lee 
et al. 2015). Previously, we showed that the expression of miRNAs predicted to 
target MREs within the 3ʹ-UTRs of nAChRs was altered after chronic nicotine 
treatment in whole brain or a specific brain region (Hogan et al. 2014). Nicotine 
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has been reported to regulate miRNAs and mRNAs in the MHb, with microarrays 
detecting expression changes in mice self-administering nicotine (Lee et al. 
2015). However, the targets of these miRNAs and their functions in the context of 
nicotine dependence have not been elucidated. 
 Using integrated miRNA- and mRNA-Seq, we asked whether there are 
changes in miRNA and mRNA expression in the NAc and VTA during chronic 
nicotine treatment and acute withdrawal. We conclude that these sequencing 
datasets represent a valuable resource, aiding the identification of a plethora of 
miRNAs/mRNAs playing a role(s) in the molecular mechanisms underlying the 
neuroadaptations of nicotine dependence. 
 
 
 
2.B. Materials and Methods 
 
Animals and Drug Treatment 
All experiments were conducted in accordance with the guidelines for care 
and use of laboratory animals provided by the National Research Council as well 
as with an approved animal protocol (Protocol A-1788, PI: Andrew Tapper) from 
the Institutional Animal Care and Use Committee of the University of 
Massachusetts Medical School (UMMS). Wild-type (WT) male C57BL/6J mice 
(The Jackson Laboratory) were group-housed in a 12-h light/dark cycle (lights 
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ON at 7 A.M.) with food and water provided ad libitum. At 6 weeks of age, mice 
were treated with nicotine tartrate (200 µg/ml nicotine base) or equivalent tartaric 
acid in their drinking water with saccharine (3 g/L) to make the solutions more 
palatable. After 6 weeks, mice in the withdrawal groups were spontaneously 
withdrawn from nicotine by replacement of their nicotine bottles with tartaric acid 
solution. After a 48-hour or 4-week withdrawal period, mice were tested in 
behavioral assays or sacrificed for tissue collection. 
 
Behavioral Assays  
 All behavioral testing was performed during the light phase in dim white 
light after habituation to the testing room (≥ 30 min). On the first test day, mice 
underwent the marble burying test (MBT) followed by the elevated plus maze 
(EPM). 
MBT. For 2 days prior to testing, mice were habituated to individual 
standard mouse cages, filled 5-6 cm with bedding material, for approximately 1 
hour per day. On the test day, 15 sterilized 1.5-cm diameter glass marbles were 
placed in the cages, equally spaced in a 3 x 5 grid arrangement. Mice were 
placed in the test cage for 30 min. then returned to their home cage. The number 
of marbles buried at least 75% with bedding were counted by an experimenter 
blinded to the treatment groups.  
EPM. Testing was performed on a sanitized, black Plexiglas apparatus 
consisting of 2 open (30 x 5 x 0.25 cm) and 2 closed arms with high walls (30 x 5 
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x 15 cm), arranged in a perpendicular arrangement, 45 cm above the floor. Mice 
were placed individually in the junction (5 x 5 cm) facing the open arms and 
allowed to freely explore the maze for 5 min. Time spent in each arm and the 
number of arm entries was recorded by MED-PC IV software (MED Associates, 
Inc.). 
 
Tissue Collection and RNA Isolation 
Fresh frozen brains were sliced ~1 mm thick and brain regions were 
dissected using a circular tissue punch. The NAc and midbrain (enriched in VTA) 
were dissected by bilateral 1 mm diameter and 0.75 mm diameter circular tissue 
punches, respectively. Punches were expelled into lysis buffer (miRVana miRNA 
isolation kit, Ambion, AM1560). Punches from 4 brains were combined for each 
sample intended for sequencing experiments. Unless otherwise stated, total RNA 
was isolated using the miRVana kit according to manufacturer’s instructions. 
Total RNA concentration and A260/280 were assessed using a NanoDrop2000 
(ThermoFisher Scientific). 
 
Small RNA Sequencing and Analysis 
Total RNA (approximately 2-9 µg, A260/280 > 1.8) was separated on a 15% 
polyacrylamide, 7M urea, 1X TBE gel. Small RNA (18-30 nucleotides) was 
excised and eluted from the gel. Libraries were synthesized using a modified 
protocol for Illumina TruSeq Small RNA Cloning (April 2014, 
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www.zamorelab.umassmed.edu/protocols/). Small RNA was ligated to 3' and 5' 
adapters and cDNA was reverse transcribed by AMV Reverse Transcriptase 
(NEB, M0277S). The cDNA libraries were amplified by Accuprime Pfx DNA 
Polymerase (Invitrogen, 12344-024) for 18 PCR cycles using a common primer 
and a primer containing a 6-nucleotide barcoding index. The libraries were gel-
purified on a 2.5% Low-Range Ultra Agarose (BioRad, 1613106) 1X TBE gel and 
eluted using a QIAquick Gel Extraction kit (Qiagen, 28704). Library sizes and 
quality were assessed by Fragment Analyzer (Advanced Analytical, AATI). 
Library concentrations were determined using KAPA Library Quantification Kits 
(KAPA Biosystems). 
 
Table 2.1. Oligo sequences for miRNA-Seq library synthesis 
Oligo Sequence (5'-3') 
3' Adapter	 rApp/nnntggaattctcgggtgccaagg/ddC/	
5' Adapter	 guucagaguucuacaguccgacgauc	
RT primer	 ccttggcacccgagaattcca	
PCR forward primer	 aatgatacggcgaccaccgagatctacacgttcagagttctacagtccga	
PCR index primers 
(Barcode) 
 
Index Primer 1 caagcagaagacggcatacgagatcgtgatgtgactggagttccttggcacccgagaattcca 
Index Primer 2 caagcagaagacggcatacgagatacatcggtgactggagttccttggcacccgagaattcca 
Index Primer 3 caagcagaagacggcatacgagatgcctaagtgactggagttccttggcacccgagaattcca 
Index Primer 4 caagcagaagacggcatacgagattggtcagtgactggagttccttggcacccgagaattcca 
Index Primer 5 caagcagaagacggcatacgagatcactgtgtgactggagttccttggcacccgagaattcca 
Index Primer 6 caagcagaagacggcatacgagatattggcgtgactggagttccttggcacccgagaattcca 
Index Primer 7 caagcagaagacggcatacgagatgatctggtgactggagttccttggcacccgagaattcca 
Index Primer 8 caagcagaagacggcatacgagattcaagtgtgactggagttccttggcacccgagaattcca 
Index Primer 9 caagcagaagacggcatacgagatctgatcgtgactggagttccttggcacccgagaattcca 
Index Primer 10 caagcagaagacggcatacgagataagctagtgactggagttccttggcacccgagaattcca 
Index Primer 11 caagcagaagacggcatacgagatgtagccgtgactggagttccttggcacccgagaattcca 
Index Primer 12 caagcagaagacggcatacgagattacaaggtgactggagttccttggcacccgagaattcca 
Index Primer 14 caagcagaagacggcatacgagatggaactgtgactggagttccttggcacccgagaattcca 
Index Primer 15 caagcagaagacggcatacgagattgacatgtgactggagttccttggcacccgagaattcca 
Index Primer 16 caagcagaagacggcatacgagatggacgggtgactggagttccttggcacccgagaattcca 
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Libraries were pooled and single-end (75 cycles) sequencing was 
performed on a NextSeq500 (Illumina) in the RNA Therapeutics Institute (RTI) at 
the UMMS.  Reads passing a quality filter of 80% Q30 were used for analysis. 
The 3'-adapter sequence was removed using Cutadapt (version 1.11) with ‘–
overlap’ option 7 bp. Reads between 15-27 nucleotides long were mapped to the 
UCSC mouse reference genome (mm10) using Bowtie (version 1.1.2) allowing 
for no mismatches. miRNA reads ±5 nucleotides from the mature, annotated 5' 
start position were counted. Reads mapping to multiple locations on a single 
mature miRNA were recorded as a single count, and reads mapped to multiple 
mature miRNAs were apportioned by the number of the aligned mature miRNAs. 
Samples with greater than 1 million mappable reads were used in differential 
expression (DE) analysis. Samples were normalized using RUV-Seq (Risso et al. 
2014), removing 3-4 factors of variance. DE was analyzed using DESeq2 (Love 
et al. 2014). In each condition, miRNAs with 0 reads per million (RPM) in more 
than half the samples were omitted. 
 
mRNA Sequencing and Analysis 
RNA > 30 nucleotides long was eluted from the same 15% polyacrylamide, 
7M urea, 1X TBE gel as the small RNA. Approximately 0.5-1.5 µg of RNA were 
used to synthesize sequencing libraries using the TruSeq Stranded mRNA 
Library Prep kit (Illumina, RS-122-2101/2) according to manufacturer’s 
instructions. Libraries were gel-purified on 2% Low-Range Ultra Agarose 1X TBE 
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gels and eluted using a QIAquick Gel Extraction kit. As in miRNA library 
synthesis, mRNA library sizes and quality were assessed by Fragment Analyzer 
and library concentrations were determined using KAPA Library Quantification 
Kits. 
Paired-end (76 cycles x 2) sequencing was performed on a NextSeq500 in 
the RTI at the UMMS.  Reads were mapped to the UCSC mouse reference 
genome (mm10) using STAR (version 2.5.3a) and the mapped reads were 
quantified with RSEM (version 1.3.0). RNA-seq libraries with > 30 million 
mappable reads were used in DE analysis. (Table S2) Samples were normalized 
using RUV-Seq (version 1.8.0) (Risso et al. 2014) removing unwanted variables 
including batch effects. DE analysis was performed using DESeq2 (version 
1.14.1) (Love et al. 2014). In each condition, mRNAs with 0 transcripts per million 
(TPM) in more than half the samples were omitted. Genome Ontology (GO) term 
enrichment for biological processes, molecular function, and cellular component 
was performed on the DE mRNAs using GOseq (version 1.28.0) (Young et al. 
2010). REVIGO was used to reduce GO terms by combining and removing 
closely related terms (Supek et al. 2011). To provide a well-balanced 
representation of reduced GO terms, a simRel cutoff of 0.4 was used (Schlicker 
et al. 2006). 
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Target Prediction Analysis 
TargetScan Mouse 7.1 (http://www.targetscan.org/mmu_71/) was used to 
identify differentially expressed miRNAs that are predicted to target sites within 
the 3ʹ-UTR of inversely differentially expressed mRNAs. Analysis was limited to 
miRNAs conserved in vertebrates and mammals, differentially expressed with an 
FDR < 0.01. Only mRNAs with an FDR < 0.01 and fold change > 2, were 
considered for target prediction.   
 
 
 
2.C. Results 
 
Acute nicotine withdrawal induces anxiety. 
 To assess the validity of our drug treatment paradigm, anxiety was 
measured using the MBT and EPM. Mice were treated with nicotine (Nic) or 
tartaric acid (TA) control solutions in their drinking water for 6 weeks. To induce 
spontaneous nicotine withdrawal, nicotine solution bottles were replaced with TA 
for 48 hours prior to measurement of anxiety behaviors (Figure 2.1A). Mice in 
acute nicotine withdrawal (NAWD) buried significantly more marbles than TA 
controls, indicating increased anxiety (Figure 2.1B). Further indicating an anxious 
phenotype, NAWD mice also spent significantly less time in the open arm of the 
EPM (Figure 2.1C). Importantly, there was no significant difference in the number 
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of total arm entries, indicating there was no effect of acute nicotine withdrawal on 
locomotor activity confounding these results (Figure 2.1D). 
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Figure 2.1. NAWD-treated mice display increased anxiety. Anxiety was 
assayed by the MBT and EPM to compare mice treated with nicotine (Nic, open 
bars) or acute nicotine withdrawal (NAWD, gray bars) to TA controls (filled bars). 
(A) Schematic of nicotine and acute (48-hr) withdrawal treatment. (B) The 
number of marbles buried in 30 min. Statistical analysis by one-way ANOVA 
(F2,26 = 6.974, P = 0.0038) with the Bonferroni’s multiple comparison post-test 
found there are significantly more marbles buried only by NAWD mice compared 
to TA controls. (**) P < 0.01, n = 9-10. (C) Time spent in open arms of the 
elevated plus maze in 5 min as described in the Methods and Materials. 
Statistical analysis by one-way ANOVA (F2,25 = 5.77, P = 0.0087) with 
Bonferroni’s post-test found only NAWD spend significantly less time in the open 
arm compared to TA controls. (**) P < 0.01, n = 9-10. (D) The number of total 
arm entries in the elevated plus maze in 5 min. Statistical analysis by one-way 
ANOVA (F2,25 = 3.672, P = 0.04) with Bonferroni’s multiple comparisons post-
test found there was no significant effect on locomotor activity between any 
group.  
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Differential expression of miRNAs in the NAc and midbrain during chronic 
nicotine treatment and acute withdrawal. 
 To assess the regulation of miRNAs and mRNAs by chronic nicotine 
treatment and acute withdrawal in the mesocorticolimbic reward circuitry, we 
sequenced and performed differential expression analysis of RNAs isolated from 
the NAc and midbrain.  
 Mice treated chronically with nicotine display limited significant (FDR < 
0.01) changes in miRNA expression in both the NAc and the midbrain, compared 
to nicotine-naïve mice. In the NAc, expression of only 12 total miRNAs was 
significantly altered in Nic mice compared to TA controls, 11 being up-regulated 
(Figures 2.2A and 2.3). Chronic nicotine treatment induces modest changes in 
miRNA expression, with fold changes no more than ~1.5. None of these miRNAs 
are similarly differentially expressed when NAWD mice are compared to TA 
controls, suggesting all of these miRNAs return to baseline expression levels 
after an acute 48-hour withdrawal.  
In the midbrain, there are only 3 miRNAs significantly differentially 
expressed in Nic mice compared to TA controls, all of them up-regulated (Figures 
2.2C and 2.4). As in the NAc, the limited Nic-induced changes in miRNA 
expression level are modest, not exceeding an increase of 30%. Two of these 
miRNAs, miR-129-1-3p and miR-129-2-3p, are members of the same family. As 
in the NAc, none of the miRNAs altered by nicotine exposure are similarly altered 
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when NAWD mice are compared to TA controls, suggesting their expression 
levels return to baseline within 48 hours after nicotine treatment is ceased.  
 After a short, 48-hr withdrawal from nicotine, there are only 2 miRNAs 
significantly down-regulated in the NAc when comparing NAWD mice to TA 
controls (Figures 2.2E and 2.3). As indicated above, neither of these miRNAs 
was significantly differentially expressed in Nic mice, indicating that their down-
regulation is not an effect of the initial nicotine treatment itself. Additionally, both 
of these miRNAs, miR-5121 and miR-3473b, are similarly down-regulated when 
NAWD mice are compared to either TA- or Nic-treated mice (Figure 2.2I), further 
suggesting that altered expression is solely an effect of nicotine withdrawal. 
In contrast to the limited regulation of miRNAs in the NAc, acute nicotine 
withdrawal evoked differential expression of 59 miRNAs in the midbrain (FDR < 
0.01). Thirty-eight miRNAs are up-regulated and 21 miRNAs are down-regulated 
when NAWD mice are compared to TA controls (Figures 2.2G and 2.4). As in the 
NAc, none of these miRNAs were significantly differentially expressed in Nic 
mice, indicating that their differential expression is not a consequence of the 
initial nicotine treatment itself. Further, a subset of 18 miRNAs in the midbrain are 
significantly and similarly up- or down-regulated when NAWD mice are compared 
to either the TA- or Nic-treated group (Figure 2.2K), suggesting that their 
differential expression is an effect solely of withdrawal and chronic nicotine 
treatment itself does not induce their regulation. 
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The identity of the miRNAs regulated by nicotine treatment and withdrawal 
in the NAc and midbrain were compared. Interestingly, no miRNAs were similarly 
differentially expressed in both the NAc and the midbrain of Nic or NAWD mice 
compared to nicotine-naïve controls.  
 
 
Differential expression of mRNAs in the NAc and midbrain during chronic 
nicotine treatment and acute withdrawal. 
 Chronic nicotine treatment induces widespread changes in mRNA 
expression in the both the NAc and midbrain. To focus on mRNAs that are 
robustly differentially expressed, only mRNAs that are up- or down-regulated with 
a fold change of at least 2 are discussed. In the NAc, there are a total of 852 
genes significantly differentially expressed (FDR < 0.01) with fold changes > 2 in 
Nic compared to TA mice (Figures 2.2B and 2.5). The majority of these genes 
are repressed by nicotine, with 648 down-regulated and 204 up-regulated. Of 
these genes only 25 are similarly differentially expressed in NAWD mice 
compared to TA controls (Figure 2.7A), indicating the majority of transcriptional 
changes return to control levels 48 hours after nicotine treatment has ceased.  
In the midbrain, there are a total of 547 genes significantly differentially 
expressed with a fold change > 2 in Nic compared to TA mice (Figures 2.2D and 
2.6). In contrast to the NAc, the expression of the majority of these genes is 
enhanced, with 520 up-regulated and 27 down-regulated. Of these genes, 505 
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remain similarly differentially expressed 48 hours after nicotine is withdrawn, 
comparing NAWD to TA mice (Figure 2.7B). 
In the NAc, there are relatively few mRNAs regulated during acute nicotine 
withdrawal. There are only 32 total mRNAs significantly differentially expressed 
with a fold change > 2 when NAWD mice are compared to TA controls (Figure 
2.2F). However, as stated above, 25 (~78%) of these were regulated in a similar 
manner after nicotine treatment alone. Additionally, if nicotine withdrawal were 
the sole stimulus for a transcriptional change, it would follow that the expression 
of that mRNA should be similarly altered when NAWD are compared to TA or 
nicotine-treated mice. There are no mRNAs that are similarly altered when 
NAWD are compared to either TA or Nic mice (Figures 2.2J and 2.7A). This 
would suggest that the initial chronic nicotine treatment itself is largely 
responsible for the limited transcriptional changes observed in the NAc during 
acute nicotine withdrawal. 
 The midbrain, unlike the NAc, displays widespread transcriptional changes 
during acute nicotine withdrawal. When NAWD mice are compared to TA 
controls, there are a total of 1674 mRNAs significantly differentially expressed 
with a fold change > 2 in the midbrain (Figure 2.2H). The vast majority of genes 
were up-regulated, with only 144 exhibiting down-regulation during acute 
withdrawal. As previously discussed, 505 of these genes were differentially 
expressed after nicotine treatment alone (Figure 2.7B). Furthermore, only 30 of 
these genes are similarly differentially expressed when NAWD mice are 
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compared to TA or Nic mice (Figures 2.2L and 2.7B). All together, this suggests 
that the initial chronic nicotine treatment itself induces the majority of the mRNA 
regulation observed in the midbrain during acute nicotine withdrawal. 
The identity of mRNAs regulated by nicotine treatment and withdrawal 
were compared between the NAc and midbrain. There is only a single mRNA 
similarly regulated by chronic nicotine treatment in these brain regions. Histidine 
decarboxylase (Hdc) was up-regulated in both the NAc and the midbrain of Nic 
mice compared to TA controls. However, the expression of many mRNAs was 
oppositely regulated in Nic mice. There were 110 mRNAs that were repressed in 
the NAc and up-regulated in the midbrain after chronic nicotine treatment. Only 
one mRNA, Kelch like family member 4 (Klhl4), was oppositely regulated, being 
up-regulated in the NAc and down-regulated in the midbrain. During acute 
withdrawal, there is only one mRNA, Gm1821, similarly down-regulated in both 
the NAc and midbrain. Additionally, a limited number of mRNAs are oppositely 
regulated during acute withdrawal, with 16 being repressed in the NAc and up-
regulated in the midbrain in NAWD mice compared to TA controls.    
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Figure 2.2. Differential expression of miRNAs/mRNAs within the NAc and 
midbrain during nicotine treatment and acute withdrawal. Scatter plots 
display differential expression of miRNAs or mRNAs in the NAc (A-B, E-F, I-J) 
and midbrain (C-D, G-H, K-L) measured by deep sequencing. RNAs isolated 
from tissue punches of nicotine-treated (Nic, A-D) and acute withdrawal (NAWD, 
E-H) mice are compared to TA-treated controls. NAWD mice were also 
compared to Nic mice (I-L).  Each dot represents an individual miRNA or mRNA 
plotted as log2(RPM) or log2(TPM), respectively. All miRNAs with a FDR < 0.01 
and mRNAs with FDR < 0.01 and FC > 2 are highlighted in color. Orange dots 
are up-regulated in TA, green dots are up-regulated in Nic, and red dots are up-
regulated in NAWD in each comparison. Only miRNAs with RPM > 0 and mRNAs 
with TPM > 0 in at least half of the replicates in each treatment group are shown. 
n = 4-5, with each library synthesized using pooled RNA from 4 mice.  
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Figure 2.3. Relative expression heatmap of miRNAs altered in the NAc 
during nicotine treatment and withdrawal. Heat map displaying miRNAs that 
are significantly differentially expressed in the NAc during chronic nicotine 
treatment or withdrawal compared to TA controls (left). Each column represents 
an individual biological replicate of mice treated chronically with nicotine (Nic) or 
acute nicotine withdrawal (NAWD). Each replicate contained RNA pooled from 4 
mice. The colors represent fold change, calculated as read per million (RPM) 
normalized to the average RPM of the TA control group. Red represents up-
regulation and blue represents down-regulation. 
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Figure 2.4. Relative expression heatmap of miRNAs altered in the midbrain 
during nicotine treatment and withdrawal. Heat map displaying miRNAs that 
are significantly differentially expressed in midbrain punches enriched for the 
VTA during chronic nicotine treatment or withdrawal compared to TA controls 
(left). Each column represents an individual biological replicate of mice treated 
chronically with nicotine (Nic) or acute nicotine withdrawal (NAWD). Each 
replicate contained RNA pooled from 4 mice. The colors represent fold change, 
calculated as read per million (RPM) normalized to the average RPM of the TA 
control group. Red represents up-regulation and blue represents down-regulation. 
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Figure 2.5. Relative expression 
heatmap of mRNAs altered in the NAc 
during chronic nicotine treatment. 
Heat map displaying the 50 most up-
regulated and 50 most down-regulated 
mRNAs in the NAc during chronic 
nicotine treatment relative to TA controls 
(left). Each column represents an 
individual biological replicate of mice 
treated chronically with nicotine (Nic) or 
acute nicotine withdrawal (NAWD). Each 
replicate contained RNA pooled from 4 
mice. The colors represent fold change, 
calculated as transcript per million (TPM) 
normalized to the average TPM of the TA 
control group. Red represents up-
regulation and blue represents down-
regulation. Only mRNAs with TPM > 0 in 
more than half of the replicates were 
included. 
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Figure 2.6. Relative expression 
heatmap of mRNAs altered in 
the midbrain during chronic 
nicotine treatment. Heat map 
displaying the 50 most up-
regulated and all significantly 
down-regulated mRNAs in 
midbrain punches enriched for 
VTA during chronic nicotine 
treatment relative to TA controls 
(left). Each column represents an 
individual biological replicate of 
mice treated chronically with 
nicotine (Nic) or acute nicotine 
withdrawal (NAWD). Each 
replicate contained RNA pooled 
from 4 mice. The colors 
represent fold change, calculated 
as transcript per million (TPM) 
normalized to the average TPM 
of the TA control group. Red 
represents up-regulation and 
blue represents down-regulation. 
Only mRNAs with TPM > 0 in 
more than half of the replicates 
were included. 
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Figure 2.7. Overlap of similarly differentially expressed mRNAs between 
treatment conditions in the NAc and midbrain. Venn diagrams showing 
numbers of differentially expressed mRNAs (FDR < 0.01, FC > 2) in the NAc (A) 
and midbrain (B) in each treatment condition, designated by color. Regions 
where the circles overlap indicate that the transcripts are similarly up- or down-
regulated in both conditions. Numbers indicate the number of mRNAs 
represented. 
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Nicotine withdrawal-associated anxiety persists for at least 4 weeks.  
 To test the hypothesis that nicotine withdrawal-associated anxiety is 
persistent over a prolonged period of time, mice were treated with chronic 
nicotine in their drinking water for 6 weeks then withdrawn for 4 weeks. After 4 
weeks of abstinence, anxiety was assayed by the MBT and EPM comparing long 
withdrawal (NLWD) mice to age matched controls (TAL) (Figure 2.8A).  
 There is a trend (P = 0.0984) for NLWD mice to bury more marbles than 
TAL controls, but the MBT does not indicate a significant effect of prolonged 
nicotine withdrawal on anxiety (Figure 2.8B). However, NLWD mice spend 
significantly less time in the open arms of the EPM compared to TAL mice, 
indicating NLWD mice are more anxious (Figure 2.8C). There is no effect of long 
nicotine withdrawal on the total number of arm entries, suggesting there is no 
confounding effect of long withdrawal on the locomotor activity (Figure 2.8D).  
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Figure 2.8. Withdrawal-associated anxiety persists for at least 4 weeks. 
Anxiety was assayed by the MBT and EPM to compare mice after a long (4-week) 
withdrawal from nicotine treatment (NLWD, empty bars) to age-matched, TA 
controls (TAL, filled bars). (A) Schematic of NLWD treatment and age-matched 
TAL controls. (B) The number of marbles buried in 30 min. Statistical analysis by 
unpaired, two-tailed t-test (t37 = 1.695, P = 0.0984) found the there is no 
significant effect of long nicotine withdrawal on the number of marbles buried, n = 
19-20. (C) Time spent in open arms of the EPM in 5 min. Statistical analysis by 
unpaired, two-tailed t-test (t34 = 2.602, P = 0.0136) determined NLWD spent 
significantly less time in the open arm compared to controls. (*) P < 0.05, n = 17-
19. (D) The number of total arm entries in the EPM in 5 min. Statistical analysis 
by unpaired, two-tailed t-test (t34 = 0.7664, P = 0.4487) found there was no 
significant effect on locomotor activity. n = 17-19. 
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Differential expression of miRNA/mRNAs in the NAc and VTA after 
prolonged nicotine withdrawal. 
 In the NAc, there are a limited number of miRNAs significantly 
differentially expressed after a prolonged nicotine withdrawal compared to age-
matched controls. Only 16 miRNAs were significantly differentially expressed in 
NLWD mice compared to TAL controls, with 10 up-regulated and 6 down-
regulated (Figure 2.9A). These miRNAs displayed only small alterations in 
expression, with no changes in relative expression exceeding 30%. Additionally, 
none of these were similarly regulated at the acute withdrawal time point, 
comparing NAWD to TA controls. Strikingly, there are no miRNAs significantly 
altered after a prolonged withdrawal in the midbrain (Figure 2.9C). 
 There are 40 mRNAs differentially expressed with fold changes > 2 in the 
NAc of NLWD mice compared to TAL controls, with 14 up-regulated and 26 
down-regulated (Figure 2.9B). In the midbrain, there is only a single mRNA, 
Gm9531, that is significantly down-regulated (Figure 2.9D). In either region, none 
of the transcripts altered after a long withdrawal are similarly differentially 
expressed during acute withdrawal. 
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Figure 2.9. Differential expression of miRNAs and mRNAs in the NAc and 
midbrain of NLWD- and TAL-treated mice. Scatter plots display differential 
expression of miRNAs or mRNAs in the NAc (A, B) and VTA (C, D) measured by 
deep sequencing. miRNAs (A, C)  and mRNAs (B, D) isolated from mice after a 
long (4-week) withdrawal from nicotine (NLWD) are compared to age-matched 
TA-treated controls (TAL). Each dot represents an individual miRNA or mRNA 
plotted as log2(RPM) and log2(TPM), respectively. miRNAs (FDR < 0.01) and 
mRNAs (FDR < 0.01, FC >2) that are up-regulated (purple) and down-regulated 
(brown) in NLWD mice are highlighted. All miRNAs have RPM > 0 and all 
mRNAs have TPM > 0 in more than half of the replicates in each treatment group. 
n = 5, with each library synthesized using pooled RNA from 4 mice.  
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Gene ontology (GO) analysis of differentially expressed mRNAs in the NAc 
and midbrain 
 Gene ontology (GO) analysis was performed on differentially expressed 
mRNAs for all treatment groups in the NAc and midbrain. Comprehensive heat 
maps display all of the reduced GO terms with significant enrichment for up- and 
down-regulated genes in each brain region (Figures 2.11-2.16). To describe 
differential expression in the NAc and midbrain after chronic nicotine treatment, I 
have highlighted selected GO terms describing cellular compartments (CC, 
Figure 2.10A), molecular functions (MF, Figure 2.10B), and biological processes 
(BP, Figure 2.10C) that were significantly enriched for up- or down-regulated 
genes.  
 GO analysis of genes differentially expressed in the NAc after chronic 
nicotine treatment determined there was significant enrichment of terms related 
to neuronal structures and functions. In the CC analysis, there was significant 
enrichment of up-regulated genes related to the vesicle and myelin sheath and 
down-regulated genes related to the neuron, neuron projections, and the 
synapse. MF analysis determined there was significant enrichment of down-
regulated genes related to ion channel binding, glutamate receptor binding, and 
α-adrenergic receptor activity. BP analysis revealed there was significant over-
representation of down-regulated genes related to GO terms including regulation 
of synapse structure or activity, cell projection organization, cell communication, 
and regulation of neurotransmitter levels. The NAc of Nic mice also exhibited an 
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overrepresentation of up-regulated genes related to the mitochondria/energetics 
and the ribosome. 
 In general, the midbrain exhibited GO enrichment pattern opposite to the 
NAc after chronic nicotine treatment. Specifically, while GO terms related to the 
neuron were enriched in down-regulated genes in the NAc, the midbrain shows 
an overrepresentation of up-regulated genes in CC, MF, and BP terms related to 
the neuron, neuron projection, synapses, receptor binding. There is also an 
enrichment of down-regulated genes related to mitochondria, metabolism, and 
the ribosome in the midbrain of Nic mice.  
 GO analysis also determined there was an opposite enrichment pattern of 
additional MF terms related to binding in the NAc and midbrain during chronic 
nicotine treatment. For instance, there is an overrepresentation of genes involved 
in the binding of chromatin, proteins, kinases, transcription factors, and 
cytoskeleton proteins that are down-regulated in the NAc and up-regulated in the 
midbrain. 
 Finally, in the NAc and the midbrain there is an enrichment of both up- and 
down-regulated genes related to heterocyclic compound binding and metabolism 
during chronic nicotine treatment. 
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Figure 2.10.  Genes differentially expressed in the NAc and midbrain during 
chronic nicotine treatment are overrepresented in gene ontology terms 
related to the synaptic transmission, neuronal morphology, energetics, and 
translation. The vertical axes define the selected GO terms describing the 
cellular compartment (A), molecular function (B), or biological process (C). The 
horizontal axis plots the significance of enrichment of the GO term, plotted as      
-Log10(FDR).  
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 Because there are so few genes differentially expressed during acute 
nicotine withdrawal in the NAc, there was no significant enrichment of any GO 
terms in CC, MF, or BP analysis. In the midbrain, analysis of CC, MF, and BP 
GO terms exhibit an enrichment pattern that largely overlaps with that observed 
in the midbrain after chronic nicotine treatment alone (Figures 2.11-2.16).  
 After a prolonged withdrawal, NLWD mice display an enrichment of up-
regulated genes related neuronal GO terms in the NAc. This includes CC terms 
describing the neuron part, neuron projection, synapse, and vesicles. 
Significantly enriched BP terms include cell communication, cell projection 
communication and neuron development. There was no significant enrichment of 
down-regulated genes in any GO term.  
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Figure 2.11. Enrichment of cellular compartments with genes up-regulated 
in the NAc and midbrain. Heat map of the significance of enrichment of 
reduced GO terms describing the cellular compartment with up-regulated mRNAs 
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in the NAc and midbrain punches enriched in VTA. Each column is designated a 
specific brain region and treatment comparison (bottom). Each row is designated 
a GO term (right) reduced with a simRel cut off of 0.4 as described in the Methods 
and Materials. The number of terms combined within the single GO term, rf, is 
indicated by the green color gradient (left). The color gradient of the box (red) 
indicates the significance of enrichment as –log10(FDR). 
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Figure 2.12. Enrichment of molecular functions with genes up-regulated in 
the NAc and midbrain. Heat map of the significance of enrichment of reduced 
GO terms describing the cellular compartment with up-regulated mRNAs in the 
NAc and midbrain punches enriched in VTA. Each column is designated a 
specific brain region and treatment comparison (bottom). Each row is designated 
a GO term (right) reduced with a simRel cut off of 0.4 as described in the Methods 
and Materials. The number of terms combined within the single GO term, rf, is 
indicated by the green color gradient (left). The color gradient of the box (red) 
indicates the significance of enrichment as –log10(FDR). 
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Figure 2.13. Enrichment of biological processes with genes up-regulated in 
the NAc and midbrain. Heat map of the significance of enrichment of reduced 
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GO terms describing the cellular compartment with up-regulated mRNAs in the 
NAc and midbrain punches enriched in VTA. Each column is designated a 
specific brain region and treatment comparison (bottom). Each row is designated 
a GO term (right) reduced with a simRel cut off of 0.4 as described in the Methods 
and Materials. The number of terms combined within the single GO term, rf, is 
indicated by the green color gradient (left). The color gradient of the box (red) 
indicates the significance of enrichment as –Log10(FDR). 
  
	87 
 
Figure 2.14.  Enrichment of cellular compartments with genes down-
regulated in the NAc and midbrain. Heat map of the significance of enrichment 
of reduced GO terms describing the cellular compartment with down-regulated 
mRNAs in the NAc and midbrain. Each column is designated a specific brain 
region and treatment comparison (bottom). Each row is designated a GO term 
(right) reduced with a simRel cut off of 0.4 as described in the Methods and 
Materials. The number of terms combined within the single GO term, rf, is 
indicated by the green color gradient (left). The color gradient of the box (red) 
indicates the significance of enrichment as –Log10(FDR). 
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Figure 2.15. Enrichment of molecular functions with genes down-regulated 
in the NAc and midbrain. Heat map of the significance of enrichment of 
reduced GO terms describing the cellular compartment with down-regulated 
mRNAs in the NAc and midbrain punches enriched in VTA. Each column is 
designated a specific brain region and treatment comparison (bottom). Each row 
is designated a GO term (right) reduced with a simRel cut off of 0.4 as described 
in the Methods and Materials. The number of terms combined within the single 
GO term, rf, is indicated by the green color gradient (left). The color gradient of 
the box (red) indicates the significance of enrichment as –Log10(FDR). 
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Figure 2.16. Enrichment of biological processes with genes down-regulated 
in the NAc and midbrain. Heat map of the significance of enrichment of 
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reduced GO terms describing the cellular compartment with down-regulated 
mRNAs in the NAc and midbrain punches enriched in VTA. Each column is 
designated a specific brain region and treatment comparison (bottom). Each row 
is designated a GO term (right) reduced with a simRel cut off of 0.4 as described 
in the Methods and Materials. The number of terms combined within the single 
GO term, rf, is indicated by the green color gradient (left). The color gradient of 
the box (red) indicates the significance of enrichment as –log10(FDR). 
  
	91 
Target prediction of miRNAs differentially expressed in the NAc 
 Because miRNAs are traditionally considered to be repressors of gene 
expression, Targetscan Mouse 7.1 was used to predict MREs within the 3ʹ-UTR 
of differentially expressed mRNAs for inversely regulated miRNAs. Due to the 
fact that conservation of MREs increases the likelihood of biological function, 
only miRNAs and MREs conserved in vertebrates or mammals were considered 
in target prediction analysis.  
 In the NAc, miRNAs that are differentially expressed during chronic 
nicotine treatment are predicted to target reciprocally expressed mRNAs. Of the 
miRNAs regulated by chronic nicotine treatment in the NAc, only 8 are conserved, 
all of which were up-regulated. Targetscan Mouse 7.1 determined that each of 
these 8 miRNAs targeted at least one of 204 down-regulated mRNAs at 
conserved MREs (Table 2.2). Of these 204 predicted mRNA targets, 81 contain 
multiple MREs for a single or different miRNAs. Additionally, only 10 of these 
predicted targets remain differentially expressed during acute nicotine withdrawal 
(Table 2.2, green). 
 None of the three miRNAs regulated in the NAc of NAWD compared to TA 
or Nic mice were conserved in vertebrates or mammals. Because there were no 
conserved miRNAs that were differentially expressed during acute nicotine 
withdrawal, target prediction analysis was not performed. 
 All 16 miRNAs that were differentially expressed in the NAc of NLWD mice 
compared to TAL controls are conserved in vertebrates and mammals. However, 
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only one, miR-22-3p, was predicted to target a single conserved MRE within the 
3ʹ-UTR of an anti-correlated gene, Synaptotagmin like 4 (Sytl4) (Table 2.3). 
  
	93 
Table 2.2. Target prediction of miRNAs differentially expressed in the NAc 
after chronic nicotine exposure (Nic) compared to TA controls. mRNAs 
similarly differentially expressed in NAWD compared to TA mice are highlighted 
in green. 
 
mRNA mRNA FC mRNA FDR miRNA  miRNA FC miRNA FDR Seed Type Position in  
3ʹ-UTR 
Slc8a1 0.203 4.55E-15 miR-34b-5p 1.465 3.47E-03 7mer-m8 14840-14846 
    miR-23a-3p 1.382 6.75E-06 7mer-m8 14104-14110 
    miR-135a-5p 1.366 1.06E-03 8mer  12878-12885     miR-135a-5p 1.366 1.06E-03 7mer-A1 14659-14665     miR-384-3p 1.203 9.74E-03 7mer-A1 10334-10340 
Adcy9 0.237 1.28E-11 miR-7b-5p 1.304 6.75E-03 8mer 804-811 
    miR-7b-5p 1.304 6.75E-03 8mer 1731-1738 
Xylt1 0.250 4.28E-09 miR-34b-5p 1.465 3.47E-03 7mer-m8 488-494 
    miR-224-5p 1.437 3.04E-03 7mer-m8 5031-5037 
Arid5b 0.250 1.11E-09 miR-135a-5p 1.366 1.06E-03 7mer-m8 1890-1898 
Il6ra 0.255 9.50E-07 miR-23a-3p 1.382 6.75E-06 8mer 543-550 
    miR-382-3p 1.260 6.66E-04 7mer-m8 548-554 
Elfn2 0.255 3.34E-12 miR-7b-5p 1.304 6.75E-03 8mer 815-822 
Ankrd52 0.256 2.20E-11 miR-216a-5p 1.485 2.10E-03 7mer-m8 2254-2260 
    miR-34b-5p 1.465 3.47E-03 8mer 2936-2943     miR-23a-3p 1.382 6.75E-06 7mer-m8 1983-1989 
Irs2 0.256 9.31E-11 miR-135a-5p 1.366 1.06E-03 7mer-A1 2288-2294 
    miR-7b-5p 1.304 6.75E-03 7mer-m8 1478-1484 
    miR-7b-5p 1.304 6.75E-03 8mer 2170-2177 
Dgkh 0.260 1.95E-09 miR-135a-5p 1.366 1.06E-03 7mer-m8 246-252 
Add2 0.270 9.69E-14 miR-34b-5p 1.465 3.47E-03 7mer-m8 252-258 
    miR-23a-3p 1.382 6.75E-06 8mer 3421-3428     miR-7b-5p 1.304 6.75E-03 7mer-m8 5178-5184 
Foxn3 0.272 6.52E-10 miR-34b-5p 1.465 3.47E-03 7mer-A1 5886-5892 
    miR-135a-5p 1.366 1.06E-03 8mer 236-243     miR-135a-5p 1.366 1.06E-03 8mer 798-805     miR-7b-5p 1.304 6.75E-03 8mer 6142-6149 
    miR-384-3p 1.203 9.74E-03 8mer 1845-1852 
Fam135b 0.284 1.30E-06 miR-224-5p 1.437 3.04E-03 8mer 618-625 
    miR-384-3p 1.203 9.74E-03 7mer-A1 1059-1065 
    miR-384-3p 1.203 9.74E-03 8mer 1074-1081 
Fam168a 0.299 2.19E-10 miR-7b-5p 1.304 6.75E-03 8mer 5368-5375 
Egr3 0.299 1.30E-09 miR-216a-5p 1.485 2.10E-03 8mer 1342-1349 
    miR-23a-3p 1.382 6.75E-06 7mer-m8 2007-2013     miR-23a-3p 1.382 6.75E-06 7mer-A1 2280-2286 
    miR-7b-5p 1.304 6.75E-03 8mer 711-718     miR-382-3p 1.260 6.66E-04 8mer 2328-2335 
Kcna2 0.300 4.42E-07 miR-34b-5p 1.465 3.47E-03 7mer-m8 9136-9142 
    miR-224-5p 1.437 3.04E-03 7mer-m8 131-137 
Dyrk2 0.302 3.18E-10 miR-23a-3p 1.382 6.75E-06 7mer-A1 3713-3719 
D10Bwg1379e 0.308 1.27E-07 miR-135a-5p 1.366 1.06E-03 7mer-A1 7367-7373 
Hivep1 0.312 1.71E-10 miR-382-3p 1.260 6.66E-04 8mer 3430-3437 
Hipk2 0.313 2.48E-09 miR-23a-3p 1.382 6.75E-06 8mer 7721-7728 
Tnrc18 0.314 1.09E-08 miR-224-5p 1.437 3.04E-03 7mer-m8 512-518 
Gatad2b 0.314 2.90E-07 miR-216a-5p 1.485 2.10E-03 8mer 2375-2382 
    miR-34b-5p 1.465 3.47E-03 7mer-m8 3859-3865 
    miR-7b-5p 1.304 6.75E-03 7mer-A1 2193-2199 
Kcnma1 0.315 1.14E-09 miR-224-5p 1.437 3.04E-03 7mer-m8 206-212 
    miR-382-3p 1.260 6.66E-04 7mer-m8 550-556 
Kif3b 0.326 2.62E-10 miR-135a-5p 1.366 1.06E-03 8mer  2900-2907 
Ppargc1b 0.330 1.40E-10 miR-34b-5p 1.465 3.47E-03 8mer 291-298 
    miR-135a-5p 1.366 1.06E-03 8mer 4787-4794 
Glg1 0.333 1.57E-12 miR-216a-5p 1.485 2.10E-03 7mer-m8 4508-4514 
    miR-7b-5p 1.304 6.75E-03 7mer-m8 1617-1623 
    miR-7b-5p 1.304 6.75E-03 7mer-m8 1837-1843 
	94 
Bcl9l 0.336 1.70E-08 miR-23a-3p 1.382 6.75E-06 7mer-A1 2001-2007 
    miR-135a-5p 1.366 1.06E-03 8mer 1328-1335 
Lcor 0.344 6.84E-05 miR-224-5p 1.437 3.04E-03 7mer-m8 6991-6997 
    miR-384-3p 1.203 9.74E-03 8mer 6632-6639 
Atp8b2 0.350 2.14E-09 miR-224-5p 1.437 3.04E-03 7mer-m8 481-487 
Lemd3 0.350 3.93E-11 miR-23a-3p 1.382 6.75E-06 8mer 360-367 
    miR-7b-5p 1.304 6.75E-03 7mer-m8 60-66 
Shank1 0.354 1.39E-09 miR-135a-5p 1.366 1.06E-03 7mer-A1 319-325 
    miR-7b-5p 1.304 6.75E-03 8mer 2547-2554 
Pxdn 0.357 4.80E-09 miR-23a-3p 1.382 6.75E-06 8mer 646-653 
Nrg1 0.359 3.78E-06 miR-135a-5p 1.366 1.06E-03 8mer 4253-4260 
Ankrd50 0.361 5.69E-09 miR-23a-3p 1.382 6.75E-06 8mer 1644-1651 
Slfn5 0.361 4.42E-04 miR-135a-5p 1.366 1.06E-03 8mer 2678-2685 
Plce1 0.368 3.20E-09 miR-382-3p 1.260 6.66E-04 7mer-m8 873-879 
Slc6a17 0.368 1.50E-09 miR-34b-5p 1.465 3.47E-03 7mer-m8 1001-1007 
Adam23 0.368 4.60E-10 miR-23a-3p 1.382 6.75E-06 8mer 1260-1267 
Dio2 0.369 3.31E-07 miR-382-3p 1.260 6.66E-04 8mer 4557-4564 
G3bp2 0.371 6.08E-09 miR-23a-3p 1.382 6.75E-06 7mer-m8 78-84 
    miR-23a-3p 1.382 6.75E-06 7mer-A1 110-116     miR-7b-5p 1.304 6.75E-03 8mer 1796-1803 
Kcnb1 0.372 6.08E-09 miR-23a-3p 1.382 6.75E-06 8mer 2246-2253 
    miR-135a-5p 1.366 1.06E-03 7mer-A1 2406-2412 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 7998-8004     miR-135a-5p 1.366 1.06E-03 7mer-A1 8047-8053     miR-7b-5p 1.304 6.75E-03 7mer-m8 1451-1457 
    miR-7b-5p 1.304 6.75E-03 7mer-m8 1689-1695 
Fndc3a 0.372 1.77E-09 miR-34b-5p 1.465 3.47E-03 7mer-A1 1332-1338 
Slitrk5 0.373 2.28E-09 miR-216a-5p 1.485 2.10E-03 7mer-A1 408-414 
    miR-224-5p 1.437 3.04E-03 7mer-m8 276-282 
Hecw2 0.375 2.98E-09 miR-34b-5p 1.465 3.47E-03 7mer-A1 237-243 
Shc3 0.375 7.03E-08 miR-224-5p 1.437 3.04E-03 7mer-A1 7481-7487 
    miR-384-3p 1.203 9.74E-03 8mer 4484-4491 
Dusp8 0.376 5.31E-08 miR-135a-5p 1.366 1.06E-03 8mer 500-507 
Elmsan1 0.376 9.13E-08 miR-34b-5p 1.465 3.47E-03 7mer-m8 2952-2958 
Kcnq5 0.377 1.46E-08 miR-224-5p 1.437 3.04E-03 8mer 572-579 
    miR-135a-5p 1.366 1.06E-03 7mer-A1 37-43 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 2812-2818     miR-384-3p 1.203 9.74E-03 8mer 1110-1117 
Ddx17 0.378 3.60E-07 miR-34b-5p 1.465 3.47E-03 8mer 145-152 
Zcchc14 0.379 1.78E-09 miR-135a-5p 1.366 1.06E-03 7mer-m8 38-44 
Frrs1l 0.382 4.75E-09 miR-216a-5p 1.485 2.10E-03 8mer 5517-5524 
Hcn4 0.382 1.28E-03 miR-7b-5p 1.304 6.75E-03 7mer-A1 2335-2341 
Setd1b 0.383 3.11E-08 miR-23a-3p 1.382 6.75E-06 8mer 437-444 
Fam120a 0.384 7.67E-11 miR-7b-5p 1.304 6.75E-03 7mer-A1 861-867 
Taf4a 0.387 2.04E-07 miR-135a-5p 1.366 1.06E-03 8mer 265-272 
Slmap 0.387 2.03E-09 miR-216a-5p 1.485 2.10E-03 7mer-m8 227-233 
    miR-224-5p 1.437 3.04E-03 7mer-m8 621-627     miR-224-5p 1.437 3.04E-03 7mer-A1 928-934     miR-23a-3p 1.382 6.75E-06 7mer-m8 618-624 
Zdhhc23 0.388 6.18E-05 miR-34b-5p 1.465 3.04E-03 8mer 3056-3063 
    miR-135a-5p 1.366 1.06E-03 7mer-A1 3285-3291 
Cdh4 0.388 4.06E-09 miR-34b-5p 1.465 3.47E-03 8mer 2316-2323 
Slc9a1 0.389 1.11E-07 miR-23a-3p 1.382 6.75E-06 7mer-m8 1356-1362 
Wipf1 0.389 1.78E-09 miR-382-3p 1.260 6.66E-04 8mer 2786-2793 
Ndst1 0.390 4.94E-10 miR-34b-5p 1.465 3.47E-03 8mer 701-708 
    miR-34b-5p 1.465 3.47E-03 7mer-A1 1614-1620     miR-34b-5p 1.465 3.47E-03 7mer-m8 1798-1804 
    miR-23a-3p 1.382 6.75E-06 8mer 1552-1559 
Cdkl1 0.391 2.29E-06 miR-135a-5p 1.366 1.06E-03 8mer 3019-3026 
Kcnc3 0.392 3.04E-06 miR-135a-5p 1.366 1.06E-03 7mer-A1 261-267 
Myrip 0.392 2.99E-08 miR-34b-5p 1.465 3.47E-03 7mer-m8 29-35 
Fndc3b 0.392 3.71E-08 miR-34b-5p 1.465 3.47E-03 7mer-A1 3011-3017 
    miR-384-3p 1.203 9.74E-03 7mer-m8 164-170 
Dhcr24 0.392 2.28E-11 miR-7b-5p 1.304 6.75E-03 8mer 1917-1924 
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Col4a1 0.394 1.21E-10 miR-23a-3p 1.382 6.75E-06 8mer 792-799 
Sptbn2 0.395 4.10E-10 miR-34b-5p 1.465 3.47E-03 7mer-A1 45-51 
Pcdh1 0.395 7.72E-10 miR-34b-5p 1.465 3.47E-03 7mer-m8 1916-1922 
    miR-7b-5p 1.304 6.75E-03 7mer-m8 2981-2987 
    miR-382-3p 1.260 6.66E-04 7mer-m8 1054-1060 
Dido1 0.396 1.48E-08 miR-224-5p 1.437 3.04E-03 8mer 2668-2675 
Cacul1 0.396 3.32E-08 miR-23a-3p 1.382 6.75E-06 7mer-m8 3395-3401 
Cdk13 0.398 3.56E-08 miR-23a-3p 1.382 6.75E-06 7mer-m8 2686-2692 
Zc3h12c 0.401 1.52E-07 miR-23a-3p 1.382 6.75E-06 7mer-A1 121-127 
Ambra1 0.401 1.34E-07 miR-23a-3p 1.382 6.75E-06 7mer-m8 902-908 
    miR-7b-5p 1.304 6.75E-03 8mer 342-349 
Sik1 0.403 5.26E-08 miR-23a-3p 1.382 6.75E-06 7mer-A1 95-101 
Gucy1a2 0.403 3.55E-04 miR-135a-5p 1.366 1.06E-03 7mer-m8 5092-5098 
Syngap1 0.403 1.08E-07 miR-384-3p 1.203 9.74E-03 8mer 901-908 
Otud7a 0.403 8.43E-11 miR-34b-5p 1.465 3.47E-03 7mer-m8 605-611 
    miR-7b-5p 1.304 6.75E-03 7mer-A1 346-352     miR-384-3p 1.203 9.74E-03 7mer-A1 159-165 
Shank3 0.403 1.06E-07 miR-34b-5p 1.465 3.47E-03 8mer 540-547 
    miR-7b-5p 1.304 6.75E-03 8mer 520-527 
Tex2 0.404 6.04E-09 miR-135a-5p 1.366 1.06E-03 7mer-A1 580-586 
Satb1 0.405 2.14E-09 miR-34b-5p 1.465 3.47E-03 7mer-m8 554-560 
    miR-23a-3p 1.382 6.75E-06 8mer 655-662 
    miR-23a-3p 1.382 6.75E-06 8mer 992-999     miR-23a-3p 1.382 6.75E-06 7mer-A1 1263-1269     miR-7b-5p 1.304 6.75E-03 7mer-m8 1021-1027 
Vti1a 0.408 1.71E-07 miR-7b-5p 1.304 6.75E-03 8mer 3584-3591 
Jph1 0.411 9.13E-09 miR-23a-3p 1.382 6.75E-06 7mer-m8 122-128 
Fam168b 0.411 1.52E-09 miR-7b-5p 1.304 6.75E-03 8mer 3955-3962 
    miR-382-3p 1.260 6.66E-04 7mer-A1 241-247 
Ccdc171 0.413 8.48E-04 miR-23a-3p 1.382 6.75E-06 7mer-m8 562-568 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 290-296 
Klf12 0.414 3.66E-03 miR-34b-5p 1.465 3.47E-03 7mer-m8 3964-3970 
    miR-7b-5p 1.304 6.75E-03 8mer 3933-3940 
    miR-382-3p 1.260 6.66E-04 8mer 3456-3463 
Grin2a 0.414 3.77E-03 miR-7b-5p 1.304 6.75E-03 7mer-A1 155-161 
Zfp281 0.415 8.03E-11 miR-34b-5p 1.465 3.47E-03 8mer 56-63 
    miR-382-3p 1.260 6.66E-04 8mer 735-742 
Plec 0.417 1.59E-09 miR-7b-5p 1.304 6.75E-03 7mer-m8 113-119 
Rasal2 0.417 7.24E-08 miR-135a-5p 1.366 1.06E-03 7mer-m8 915-921 
    miR-135a-5p 1.366 1.06E-03 8mer 5315-5322 
Cpeb2 0.417 5.57E-09 miR-34b-5p 1.465 3.47E-03 7mer-A1 703-709 
    miR-23a-3p 1.382 6.75E-06 8mer 718-725     miR-7b-5p 1.304 6.75E-03 7mer-A1 3631-3637 
Kcnd3 0.417 7.05E-08 miR-34b-5p 1.465 3.47E-03 8mer 824-831 
Tbck 0.418 1.17E-03 miR-34b-5p 1.465 3.47E-03 8mer 230-237 
Hs6st3 0.418 6.02E-03 miR-23a-3p 1.382 6.75E-06 7mer-A1 6614-6620 
    miR-382-3p 1.260 6.66E-04 7mer-A1 6581-6587 
Cbfa2t3 0.419 5.72E-06 miR-34b-5p 1.465 3.47E-03 8mer 892-899 
    miR-23a-3p 1.382 6.75E-06 8mer 1879-1886 
Ccnd1 0.419 2.76E-10 miR-34b-5p 1.465 3.47E-03 7mer-A1 1856-1862 
    miR-23a-3p 1.382 6.75E-06 7mer-m8 1948-1954 
Zbtb16 0.420 1.14E-04 miR-23a-3p 1.382 6.75E-06 8mer 2446-2453 
    miR-23a-3p 1.382 6.75E-06 8mer 2810-2817 
Chsy3 0.420 2.43E-10 miR-23a-3p 1.382 6.75E-06 7mer-m8 407-413 
    miR-7b-5p 1.304 6.75E-03 8mer 165-172 
Adarb1 0.420 8.52E-08 miR-384-3p 1.203 9.74E-03 7mer-m8 414-420 
Syde2 0.421 7.26E-07 miR-224-5p 1.437 3.04E-03 8mer 862-869 
Nacc1 0.423 1.35E-08 miR-216a-5p 1.485 2.10E-03 7mer-m8 2461-2467 
    miR-23a-3p 1.382 6.75E-06 8mer 2506-2513 
Map3k5 0.423 7.20E-09 miR-23a-3p 1.382 6.75E-06 7mer-m8 397-403 
Cxcl12 0.423 5.99E-08 miR-135a-5p 1.366 1.06E-03 7mer-A1 1241-1247 
Trove2 0.424 9.86E-08 miR-7b-5p 1.304 6.75E-03 8mer 6403-6410 
Pvrl1 0.424 2.98E-09 miR-135a-5p 1.366 1.06E-03 7mer-m8 1831-1837 
Pou3f3 0.424 6.50E-07 miR-34b-5p 1.465 3.47E-03 7mer-A1 1214-1220 
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    miR-135a-5p 1.366 1.06E-03 8mer 6036-6043     miR-384-3p 1.203 9.74E-03 8mer 5126-5133 
Scn2b 0.425 4.33E-08 miR-34b-5p 1.465 3.47E-03 7mer-m8 1079-1085 
    miR-34b-5p 1.465 3.47E-03 7mer-A1 1991-1997     miR-34b-5p 1.465 3.47E-03 8mer 2005-2012 
    miR-135a-5p 1.366 1.06E-03 8mer 1650-1657     miR-7b-5p 1.304 6.75E-03 7mer-m8 3381-3387 
Crtc1 0.426 5.67E-07 miR-34b-5p 1.465 3.47E-03 7mer-m8 445-451 
Gadl1 0.427 8.44E-03 miR-384-3p 1.203 9.74E-03 7mer-A1 103-109 
Smad7 0.427 5.54E-08 miR-216a-5p 1.485 2.10E-03 7mer-m8 1280-1286 
Slit1 0.427 5.94E-11 miR-23a-3p 1.382 6.75E-06 7mer-A1 3614-3620 
    miR-7b-5p 1.304 6.75E-03 8mer 3607-3614 
Asap2 0.429 4.52E-06 miR-384-3p 1.203 9.74E-03 8mer 1849-1856 
Soga1 0.429 2.96E-06 miR-34b-5p 1.465 3.47E-03 8mer 106-113 
Fbxl14 0.429 2.76E-06 miR-23a-3p 1.382 6.75E-06 7mer-m8 1759-1765 
Sdk1 0.429 9.66E-07 miR-135a-5p 1.366 1.06E-03 8mer 2087-2094 
Agap2 0.431 1.11E-07 miR-34b-5p 1.465 3.47E-03 7mer-m8 518-524 
Diras1 0.432 3.07E-08 miR-7b-5p 1.304 6.75E-03 7mer-m8 2200-2206 
Palld 0.432 4.81E-03 miR-23a-3p 1.382 6.75E-06 7mer-m8 1742-1748 
Satb2 0.434 5.34E-03 miR-34b-5p 1.465 3.47E-03 8mer 674-681 
    miR-34b-5p 1.465 3.47E-03 8mer 2412-2419     miR-23a-3p 1.382 6.75E-06 8mer 2651-2658 
Eif4ebp2 0.434 3.04E-06 miR-23a-3p 1.382 6.75E-06 8mer 1832-1839 
    miR-7b-5p 1.304 6.75E-03 7mer-A1 1277-1283 
Gprin3 0.435 8.38E-04 miR-382-3p 1.260 6.66E-04 8mer 1459-1466 
Phlpp1 0.435 3.17E-10 miR-224-5p 1.437 3.04E-03 8mer 486-493 
    miR-382-3p 1.260 6.66E-04 7mer-A1 289-295 
Papln 0.440 2.31E-04 miR-382-3p 1.260 6.66E-04 7mer-A1 2720-2726 
Actn1 0.440 5.81E-06 miR-384-3p 1.203 9.74E-03 7mer-A1 372-378 
Scn3b 0.441 4.40E-07 miR-224-5p 1.437 3.04E-03 7mer-m8 80-86 
Pip4k2b 0.442 2.64E-07 miR-224-5p 1.437 3.04E-03 7mer-m8 3522-3528 
    miR-23a-3p 1.382 6.75E-06 8mer 3461-3468 
Tcf20 0.442 3.11E-08 miR-23a-3p 1.382 6.75E-06 8mer 467-474 
    miR-382-3p 1.260 6.66E-04 7mer-m8 674-680 
Adcy1 0.443 3.91E-07 miR-23a-3p 1.382 6.75E-06 8mer 8686-8693 
    miR-135a-5p 1.366 1.06E-03 7mer-A1 3106-3112 
Nipal3 0.448 4.16E-08 miR-7b-5p 1.304 6.75E-03 7mer-m8 377-383 
    miR-7b-5p 1.304 6.75E-03 7mer-m8 2981-2987 
Foxk1 0.448 3.41E-07 miR-23a-3p 1.382 6.75E-06 7mer-m8 5065-5071 
    miR-382-3p 1.260 6.66E-04 8mer 4702-4709 
Smad4 0.450 1.96E-08 miR-34b-5p 1.465 3.47E-03 7mer-m8 2499-2505 
    miR-224-5p 1.437 3.04E-03 7mer-m8 993-999     miR-224-5p 1.437 3.04E-03 7mer-m8 1136-1142 
    miR-135a-5p 1.366 1.06E-03 7mer-A1 2094-2100 
Csnk1a1 0.450 7.12E-07 miR-135a-5p 1.366 1.06E-03 7mer-m8 1174-1180 
Ksr1 0.452 1.12E-09 miR-7b-5p 1.304 6.75E-03 8mer 2597-2604 
    miR-23a-3p 1.382 6.75E-06 7mer-m8 2541-2547 
Zbtb14 0.453 7.39E-07 miR-224-5p 1.437 3.04E-03 8mer 429-436 
Ubr4 0.453 6.52E-08 miR-224-5p 1.437 3.04E-03 7mer-A1 282-288 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 200-206 
H6pd 0.454 3.95E-06 miR-7b-5p 1.304 6.75E-03 8mer 4083-4090 
Trio 0.454 7.79E-08 miR-135a-5p 1.366 1.06E-03 7mer-A1 1508-1514 
Adcy8 0.455 3.12E-08 miR-23a-3p 1.382 6.75E-06 8mer 920-927 
Btbd7 0.456 1.35E-03 miR-23a-3p 1.382 6.75E-06 8mer 2513-2520 
Tns1 0.456 7.21E-08 miR-382-3p 1.260 6.66E-04 7mer-A1 4276-4282 
Ppp1r9b 0.458 1.28E-06 miR-216a-5p 1.485 2.10E-03 7mer-m8 431-437 
    miR-34b-5p 1.465 3.47E-03 7mer-A1 303-309 
    miR-135a-5p 1.366 1.06E-03 7mer-A1 736-742 
Fzd5 0.459 2.86E-06 miR-216a-5p 1.485 2.10E-03 7mer-A1 4176-4182 
    miR-224-5p 1.437 3.04E-03 7mer-m8 3710-3716 
    miR-23a-3p 1.382 6.75E-06 8mer 451-458     miR-7b-5p 1.304 6.75E-03 7mer-m8 2054-2060     miR-384-3p 1.203 9.74E-03 7mer-m8 3172-3178 
Tob2 0.460 1.92E-05 miR-34b-5p 1.465 3.47E-03 8mer 1398-1405 
	97 
Nfic 0.460 5.14E-06 miR-7b-5p 1.304 6.75E-03 8mer 2498-2505 
Ddn 0.462 1.97E-08 miR-34b-5p 1.465 3.47E-03 8mer 1062-1069 
Ntn1 0.463 1.45E-08 miR-34b-5p 1.465 3.47E-03 8mer 579-586 
    miR-34b-5p 1.465 3.47E-03 8mer 1561-1568 
Stxbp5l 0.463 1.42E-03 miR-384-3p 1.203 9.74E-03 8mer 5545-5552 
Mtcl1 0.463 5.37E-07 miR-34b-5p 1.465 3.47E-03 7mer-m8 123-129 
    miR-384-3p 1.203 9.74E-03 8mer 1319-1326 
Fndc5 0.463 2.98E-09 miR-224-5p 1.437 3.04E-03 7mer-m8 1931-1937 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 1751-1757 
Cadm3 0.463 2.42E-07 miR-23a-3p 1.382 6.75E-06 8mer 1066-1073 
    miR-135a-5p 1.366 1.06E-03 8mer 1985-1992     miR-7b-5p 1.304 6.75E-03 7mer-m8 1575-1581 
    miR-7b-5p 1.304 6.75E-03 7mer-A1 1791-1797 
Arid1a 0.464 2.97E-07 miR-216a-5p 1.485 2.10E-03 7mer-m8 1146-1152 
Map3k3 0.465 6.96E-07 miR-23a-3p 1.382 6.75E-06 7mer-m8 1432-1438 
Zfp318 0.465 2.64E-07 miR-34b-5p 1.465 3.47E-03 7mer-m8 4925-4931 
Slc16a6 0.466 5.46E-05 miR-135a-5p 1.366 1.06E-03 7mer-A1 1807-1813 
Rab5b 0.467 1.20E-06 miR-135a-5p 1.366 1.06E-03 7mer-m8 1597-1603 
Oxsr1 0.467 6.75E-07 miR-34b-5p 1.465 3.47E-03 7mer-A1 78-84 
Tmem164 0.469 6.42E-06 miR-34b-5p 1.465 3.47E-03 8mer 477-484 
Cic 0.469 9.56E-07 miR-216a-5p 1.485 2.10E-03 7mer-A1 589-595 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 114-120 
Thrb 0.470 1.10E-06 miR-135a-5p 1.366 1.06E-03 8mer 1506-1513 
Shisa7 0.470 1.03E-05 miR-34b-5p 1.465 3.47E-03 7mer-m8 2639-2645 
    miR-34b-5p 1.465 3.47E-03 7mer-m8 2852-2858 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 609-615     miR-135a-5p 1.366 1.06E-03 8mer 3680-3687 
Cacnb1 0.470 2.56E-06 miR-34b-5p 1.465 3.47E-03 7mer-m8 1259-1265 
Ankhd1 0.470 2.84E-07 miR-23a-3p 1.382 6.75E-06 8mer 405-412 
Camsap2 0.471 1.52E-09 miR-23a-3p 1.382 6.75E-06 7mer-A1 2004-2010 
    miR-382-3p 1.260 6.66E-04 7mer-m8 1163-1169 
Myo1c 0.472 1.00E-07 miR-216a-5p 1.485 2.10E-03 7mer-m8 296-302 
    miR-34b-5p 1.465 3.47E-03 7mer-m8 869-875 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 337-343     miR-384-3p 1.203 9.74E-03 7mer-A1 316-322 
Pik3r2 0.472 7.72E-10 miR-135a-5p 1.366 1.06E-03 8mer 145-152 
Klf3 0.473 8.53E-06 miR-23a-3p 1.382 6.75E-06 8mer 238-245 
    miR-23a-3p 1.382 6.75E-06 7mer-A1 3570-3576     miR-135a-5p 1.366 1.06E-03 7mer-m8 3261-3267 
Pacsin1 0.473 9.29E-07 miR-7b-5p 1.304 6.75E-03 8mer 460-467 
Cmip 0.475 7.10E-07 miR-23a-3p 1.382 6.75E-06 7mer-A1 2078-2084 
Nacc2 0.476 1.14E-06 miR-23a-3p 1.382 6.75E-06 7mer-m8 69-75 
    miR-23a-3p 1.382 6.75E-06 7mer-m8 118-124     miR-23a-3p 1.382 6.75E-06 8mer 2379-2386 
Nrxn2 0.477 5.48E-08 miR-34b-5p 1.465 3.47E-03 8mer 20-27 
Lnx2 0.477 1.72E-06 miR-384-3p 1.203 9.74E-03 7mer-A1 649-655 
Enah 0.477 7.46E-07 miR-224-5p 1.437 3.04E-03 7mer-m8 1013-1019 
    miR-224-5p 1.437 3.04E-03 8mer 9295-9302 
    miR-7b-5p 1.304 6.75E-03 7mer-m8 433-439 
    miR-382-3p 1.260 6.66E-04 8mer 568-575     miR-384-3p 1.203 9.74E-03 8mer 1611-1618 
Nfix 0.478 7.38E-07 miR-23a-3p 1.382 6.75E-06 7mer-A1 3949-3955 
Slc24a4 0.478 1.12E-06 miR-216a-5p 1.485 2.10E-03 7mer-m8 5651-5657 
Arid1b 0.478 1.49E-07 miR-382-3p 1.260 6.66E-04 7mer-A1 582-588 
Mlh3 0.479 7.19E-09 miR-7b-5p 1.304 6.75E-03 8mer 671-678 
Map7d1 0.480 2.72E-09 miR-23a-3p 1.382 6.75E-06 7mer-A1 327-333 
Ints1 0.481 4.64E-07 miR-382-3p 1.260 6.66E-04 7mer-A1 4861-4867 
Spred2 0.482 7.65E-06 miR-382-3p 1.260 6.66E-04 7mer-m8 431-437 
Hcn2 0.483 1.16E-07 miR-135a-5p 1.366 1.06E-03 8mer 85-92 
Reln 0.484 1.39E-05 miR-34b-5p 1.465 3.47E-03 7mer-A1 778-784 
Adra2a 0.485 5.78E-06 miR-23a-3p 1.382 6.75E-06 8mer 1343-1350 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 825-831 
Rock1 0.486 2.69E-05 miR-34b-5p 1.465 3.47E-03 7mer-A1 984-990 
    miR-135a-5p 1.366 1.06E-03 8mer 734-741 
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Lnpep 0.486 3.19E-03 miR-216a-5p 1.485 2.10E-03 7mer-m8 5637-5643 
Fam53c 0.487 2.60E-06 miR-7b-5p 1.304 6.75E-03 8mer 1290-1297 
Nlgn2 0.489 3.07E-06 miR-7b-5p 1.304 6.75E-03 8mer 1727-1734 
Ism1 0.489 3.74E-05 miR-224-5p 1.437 3.04E-03 8mer 343-350 
    miR-23a-3p 1.382 6.75E-06 7mer-m8 340-346 
Prr12 0.489 5.10E-06 miR-384-3p 1.203 9.74E-03 7mer-A1 296-302 
Hic1 0.490 1.04E-03 miR-23a-3p 1.382 6.75E-06 8mer 461-468 
Clcn3 0.490 6.80E-09 miR-34b-5p 1.465 3.47E-03 8mer 1334-1341 
    miR-23a-3p 1.382 6.75E-06 7mer-m8 839-845 
    miR-23a-3p 1.382 6.75E-06 7mer-m8 1199-1205     miR-135a-5p 1.366 1.06E-03 8mer 1825-1832 
Hhip 0.491 3.02E-03 miR-7b-5p 1.304 6.75E-03 8mer 1621-1628 
Ago1 0.491 7.26E-06 miR-135a-5p 1.366 1.06E-03 7mer-m8 1861-1867 
    miR-7b-5p 1.304 6.75E-03 7mer-m8 707-713 
Stox2 0.492 8.20E-07 miR-7b-5p 1.304 6.75E-03 7mer-m8 6297-6303 
Kcnab3 0.494 1.21E-04 miR-135a-5p 1.366 1.06E-03 8mer 185-192 
Fbxo11 0.494 1.08E-06 miR-384-3p 1.203 9.74E-03 7mer-m8 750-756 
    miR-23a-3p 1.382 6.75E-06 7mer-m8 403-409 
Zbtb46 0.494 2.99E-05 miR-135a-5p 1.366 1.06E-03 8mer 2820-2827 
Ppfia3 0.496 2.42E-07 miR-7b-5p 1.304 6.75E-03 7mer-m8 353-359 
Ncdn 0.496 4.83E-09 miR-34b-5p 1.465 3.47E-03 8mer 850-857 
Trank1 0.497 4.98E-06 miR-34b-5p 1.465 3.47E-03 8mer 1021-1028 
    miR-34b-5p 1.465 3.47E-03 8mer 1083-1090     miR-23a-3p 1.382 6.75E-06 8mer 93-100 
Bsn 0.498 7.99E-07 miR-135a-5p 1.366 1.06E-03 7mer-m8 773-779 
    miR-135a-5p 1.366 1.06E-03 7mer-m8 1183-1189 
Cacng7 0.498 4.73E-07 miR-7b-5p 1.304 6.75E-03 8mer 833-840 
Calcrl 0.499 1.51E-04 miR-23a-3p 1.382 6.75E-06 8mer 2586-2593 
Map1a 0.499 2.97E-07 miR-34b-5p 1.465 3.47E-03 7mer-m8 838-844 
B4galt5 0.499 3.12E-05 miR-135a-5p 1.366 1.06E-03 7mer-m8 660-666 
    miR-382-3p 1.260 6.66E-04 7mer-m8 2852-2858 
Fam160a2 0.499 2.84E-07 miR-34b-5p 1.465 3.47E-03 7mer-A1 1635-1641 
 
 
 
 
 
 
 
Table 2.3. Target prediction of miRNAs differentially expressed in the NAc 
after a prolonged nicotine withdrawal (NLWD) compared to age-matched 
controls (TAL). 
 
mRNA mRNA  
FC 
mRNA  
FDR 
miRNA miRNA  
FC 
miRNA 
FDR 
Seed Type Position in 
3ʹ-UTR 
Sytl4 0.472 9.08E-04 miR-22-3p 1.195 3.10E-03 8mer 1421-1428 
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Target prediction of miRNAs differentially expressed in the midbrain 
 As for the NAc, TargetScan Mouse 7.1 was used to predict conserved 
MREs within the 3ʹ-UTRs of differentially expressed mRNAs for inversely 
regulated and conserved miRNAs in the midbrain. All 3 miRNAs that are up-
regulated in the midbrain during chronic nicotine treatment are broadly conserved 
among vertebrates. However, only one miRNA, miR-211-5p, is predicted to 
target a single conserved MRE in one inversely regulated gene, B3galt2 which 
encodes β-1,3-galactosyltransferase (Table 2.4). 
 In the midbrain, of the miRNAs differentially expressed in NAWD mice 
compared to TA controls, 45 are conserved, with 31 up- and 14 down-regulated. 
TargetScan Mouse 7.1 predicted that 16 of the conserved miRNAs up-regulated 
during acute withdrawal target at least one of 13 down-regulated mRNAs at a 
conserved MRE within the 3ʹ-UTR (Table 2.5). Twelve of the down-regulated 
mRNA targets that were predicted have multiple MREs, for a single or different 
miRNAs. All 14 conserved down-regulated miRNAs are predicted to target at 
least one of 367 up-regulated mRNAs (Table 2.5). One hundred and five (~28%) 
predicted target mRNAs are similarly differentially expressed in the in Nic-treated 
mice compared to controls (Table 2.5, green). Of these targets, only 7 (~2%) 
mRNAs are similarly up-regulated in NAWD mice compared to either TA or Nic 
(Table 2.5, orange). Multiple MREs, for a single or different miRNAs, are present 
in 186 (~51%) of the predicted targets.  
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 There are no miRNAs differentially expressed after a long withdrawal from 
nicotine, hence no target prediction analysis was performed. 
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Table 2.4. Target prediction of miRNAs differentially expressed in the 
midbrain after chronic nicotine exposure (Nic) compared to TA controls. 
 
mRNA mRNA  
FC 
mRNA  
FDR 
miRNA miRNA  
FC 
miRNA  
FDR 
Seed Type Position in 
3ʹ-UTR 
B3galt2 0.500 4.83E-06 miR-211-5p 1.288 6.75E-03 8mer 2918-2925 
 
 
 
 
 
Table 2.5. Target prediction of miRNAs differentially expressed in the 
midbrain during acute nicotine withdrawal (NAWD) compared to TA 
controls. mRNAs similarly up- or down-regulated in Nic compared to TA mice 
are highlighted in green. mRNAs highlighted in orange are similarly differentially 
expressed in NAWD compared to Nic mice. 
 
mRNA mRNA 
FC 
mRNA 
FDR 
miRNA miRNA 
FC 
miRNA 
FDR 
Seed Type Position in  
3ʹ-UTR 
TTC14 6.211 1.23E-07  miR-1224-5p 0.626 2.78E-06 8mer 670-677 
    let-7e-5p 0.678 1.81E-04 7mer-A1 2550-2556 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2550-2556 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2550-2556 
    let-7i-5p 0.754 2.96E-03 7mer-A1 2550-2556 
    miR-219a-2-3p 0.777 9.18E-03 7mer-A1 493-499 
Serpine1 5.870 4.74E-19  miR-134-5p 0.735 1.80E-04 8mer 345-352 
Lrrc8b 5.185 4.39E-23  let-7e-5p 0.678 1.81E-04 7mer-m8 965-971 
    let-7c-5p 0.725 2.96E-03 7mer-m8 965-971 
    let-7a-5p 0.737 4.64E-03 7mer-m8 965-971 
    let-7i-5p 0.754 2.96E-03 7mer-m8 965-971 
Ccdc85c 4.785 7.98E-09  miR-411-5p 0.687 1.81E-04 7mer-m8 2702-2708 
Slc16a14 4.742 1.53E-08  let-7e-5p 0.678 1.81E-04 8mer 38-45 
    let-7c-5p 0.725 2.96E-03 8mer 38-45 
    let-7a-5p 0.737 4.64E-03 8mer 38-45 
    let-7i-5p 0.754 2.96E-03 8mer 38-45 
BC037034 4.647 2.54E-22  miR-423-5p 0.746 7.22E-03 8mer 447-454 
Ap1s1 4.569 7.84E-38  miR-206-3p 0.664 2.84E-04 7mer-m8 174-180 
    let-7e-5p 0.678 1.81E-04 7mer-m8 428-434 
    let-7c-5p 0.725 2.96E-03 7mer-m8 428-434 
    let-7a-5p 0.737 4.64E-03 7mer-m8 428-434 
    let-7i-5p 0.754 2.96E-03 7mer-m8 428-434 
Lrrc20 4.498 1.99E-29  let-7e-5p 0.678 1.81E-04 7mer-m8 1046-1052 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1046-1052 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1046-1052 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1046-1052 
Ccnd1 4.432 2.04E-33  miR-206-3p 0.664 2.84E-04 7mer-A1 911-917 
    let-7e-5p 0.678 1.81E-04 7mer-A1 2003-2009 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2003-2009 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2003-2009 
    let-7i-5p 0.754 2.96E-03 7mer-A1 2003-2009 
Arid5b 4.313 2.86E-13  miR-320-3p 0.778 3.84E-03 7mer-m8 829-835 
Ncdn 4.240 2.86E-66  miR-320-3p 0.778 3.84E-03 7mer-m8 110-116 
Mex3d 4.138 9.98E-36  miR-320-3p 0.778 3.84E-03 8mer 142-149 
Chsy3 4.103 5.74E-21  miR-495-3p 0.670 8.82E-05 7mer-m8 179-185 
    let-7e-5p 0.678 1.81E-04 7mer-A1 40-46 
    let-7c-5p 0.725 2.96E-03 7mer-A1 40-46 
    let-7a-5p 0.737 4.64E-03 7mer-A1 40-46 
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    let-7i-5p 0.754 2.96E-03 7mer-A1 40-46 
    miR-320-3p 0.778 3.84E-03 7mer-A1 763-769 
Cdk20 4.044 9.55E-37  miR-21c 0.609 2.84E-04 7mer-m8 326-332 
Tmem231 3.968 3.84E-32  let-7e-5p 0.678 1.81E-04 8mer 35-42 
    let-7c-5p 0.725 2.96E-03 8mer 35-42 
    let-7a-5p 0.737 4.64E-03 8mer 35-42 
    let-7i-5p 0.754 2.96E-03 8mer 35-42 
Lnx2 3.931 7.20E-27  miR-495-3p 0.670 8.82E-05 7mer-A1 1612-1618 
Hnrnpul1 3.841 5.07E-32  miR-411-5p 0.687 1.81E-04 7mer-m8 391-397 
Ppp1r9b 3.793 3.56E-27  miR-1224-5p 0.626 2.78E-06 8mer 57-64 
Arl10 3.783 4.57E-19  miR-206-3p 0.664 2.84E-04 8mer 1225-1232 
Arhgef4 3.782 4.41E-36  miR-219a-2-3p 0.777 9.18E-03 7mer-m8 1444-1450 
Dcaf15 3.763 5.74E-35  let-7e-5p 0.678 1.81E-04 7mer-m8 31-37 
    let-7c-5p 0.725 2.96E-03 7mer-m8 31-37 
    let-7a-5p 0.737 4.64E-03 7mer-m8 31-37 
    let-7i-5p 0.754 2.96E-03 7mer-m8 31-37 
Ankrd52 3.665 6.81E-16  let-7e-5p 0.678 1.81E-04 7mer-A1 1419-1425 
    let-7c-5p 0.725 2.96E-03 7mer-A1 1419-1425 
    miR-134-5p 0.735 1.80E-04 7mer-m8 1050-1056 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1419-1425 
    miR-423-5p 0.746 7.22E-03 7mer-m8 3202-3208 
    let-7i-5p 0.754 2.96E-03 7mer-A1 1419-1425 
    miR-219a-2-3p 0.777 9.18E-03 8mer 4839-4846 
    miR-320-3p 0.778 3.84E-03 7mer-m8 1883-1889 
     miR-320-3p 0.778 3.84E-03 7mer-m8 4289-4295 
Gpr137 3.604 3.26E-32  let-7e-5p 0.678 1.81E-04 7mer-m8 253-259 
    let-7c-5p 0.725 2.96E-03 7mer-m8 253-259 
    let-7a-5p 0.737 4.64E-03 7mer-m8 253-259 
    let-7i-5p 0.754 2.96E-03 7mer-m8 253-259 
Frmd8 3.582 2.59E-36  miR-206-3p 0.664 2.84E-04 8mer 417-424 
Bcl2l1 3.581 1.81E-13  miR-495-3p 0.670 8.82E-05 7mer-A1 1219-1225 
    let-7e-5p 0.678 1.81E-04 8mer 947-954 
    let-7c-5p 0.725 2.96E-03 8mer 947-954 
    let-7a-5p 0.737 4.64E-03 8mer 947-954 
    let-7i-5p 0.754 2.96E-03 8mer 947-954 
4930426L09Rik 3.575 1.01E-11  miR-495-3p 0.670 8.82E-05 8mer 469-476 
Slc8a1 3.564 8.40E-08  miR-206-3p 0.664 2.84E-04 8mer 1800-1807 
     miR-495-3p 0.670 8.82E-05 7mer-A1 14884-14890 
     miR-495-3p 0.670 8.82E-05 7mer-A1 15119-15125 
Spred2 3.559 1.72E-27  miR-320-3p 0.778 3.84E-03 7mer-m8 2223-2229 
Ankrd13c 3.549 2.11E-20  miR-206-3p 0.664 2.84E-04 7mer-A1 2055-2061 
    miR-495-3p 0.670 8.82E-05 8mer 713-720 
    miR-495-3p 0.670 8.82E-05 7mer-A1 1022-1028 
     miR-382-5p 0.708 2.21E-05 7mer-m8 5264-5270 
Ndrg2 3.548 3.74E-27  miR-382-5p 0.708 2.21E-05 7mer-m8 820-826 
Irs2 3.526 3.33E-14  let-7e-5p 0.678 1.81E-04 8mer 475-482 
    let-7c-5p 0.725 2.96E-03 8mer 475-482 
    let-7a-5p 0.737 4.64E-03 8mer 475-482 
    let-7i-5p 0.754 2.96E-03 8mer 475-482 
Elfn2 3.526 3.33E-13  miR-423-5p 0.746 7.22E-03 7mer-m8 1246-1252 
Palm2Akap2 3.506 7.01E-04  miR-320-3p 0.778 3.84E-03 7mer-A1 783-789 
Gatad2b 3.482 1.11E-05  miR-21c 0.609 2.84E-04 8mer 3506-3513 
     miR-21c 0.609 2.84E-04 8mer 5308-5315 
Rgs16 3.467 1.51E-19  let-7e-5p 0.678 1.81E-04 7mer-m8 1405-1411 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1405-1411 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1405-1411 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1405-1411 
Kcnc3 3.462 1.58E-15  let-7e-5p 0.678 1.81E-04 7mer-m8 1556-1562 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1556-1562 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1556-1562 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1556-1562 
    miR-320-3p 0.778 3.84E-03 7mer-m8 2057-2063 
Rasl10b 3.450 3.60E-33  let-7e-5p 0.678 1.81E-04 7mer-m8 1251-1257 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1251-1257 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1251-1257 
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    miR-423-5p 0.746 7.22E-03 8mer 747-754 
     let-7i-5p 0.754 2.96E-03 7mer-m8 1251-1257 
Dyrk2 3.419 3.36E-09  miR-495-3p 0.670 8.82E-05 7mer-A1 3887-3893 
    let-7e-5p 0.678 1.81E-04 7mer-A1 3105-3111 
    let-7c-5p 0.725 2.96E-03 7mer-A1 3105-3111 
    let-7a-5p 0.737 4.64E-03 7mer-A1 3105-3111 
    let-7i-5p 0.754 2.96E-03 7mer-A1 3105-3111 
Adcy9 3.418 5.78E-10  let-7e-5p 0.678 1.81E-04 7mer-A1 2303-2309 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2303-2309 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2303-2309 
    let-7i-5p 0.754 2.96E-03 7mer-A1 2303-2309 
Ppm1f 3.388 1.89E-23  let-7e-5p 0.678 1.81E-04 8mer 2985-2992 
    let-7c-5p 0.725 2.96E-03 8mer 2985-2992 
    let-7a-5p 0.737 4.64E-03 8mer 2985-2992 
    let-7i-5p 0.754 2.96E-03 8mer 2985-2992 
    miR-320-3p 0.778 3.84E-03 7mer-m8 893-899 
Src 3.382 1.86E-31  miR-206-3p 0.664 2.84E-04 8mer 1791-1798 
Col1a2 3.379 1.44E-14  let-7e-5p 0.678 1.81E-04 8mer 415-422 
    let-7c-5p 0.725 2.96E-03 8mer 415-422 
    let-7a-5p 0.737 4.64E-03 8mer 415-422 
    let-7i-5p 0.754 2.96E-03 8mer 415-422 
Usp20 3.346 3.51E-25  miR-320-3p 0.778 3.84E-03 7mer-m8 281-287 
H6pd 3.340 3.26E-15  miR-134-5p 0.735 1.80E-04 8mer 1968-1975 
Pou3f1 3.337 3.99E-28  miR-495-3p 0.670 8.82E-05 8mer 1420-1427 
Slc25a25 3.324 1.23E-30  miR-206-3p 0.664 2.84E-04 8mer 979-986 
Tmem86a 3.267 4.98E-18  miR-1224-5p 0.626 2.78E-06 7mer-m8 1007-1013 
Tcf20 3.262 1.39E-24  miR-206-3p 0.664 2.84E-04 8mer 915-922 
    miR-219a-2-3p 0.777 9.18E-03 8mer 537-544 
Dtx2 3.234 3.28E-17  let-7e-5p 0.678 1.81E-04 8mer 233-240 
    let-7e-5p 0.678 1.81E-04 7mer-A1 341-347 
    let-7c-5p 0.725 2.96E-03 8mer 233-240 
    let-7c-5p 0.725 2.96E-03 7mer-A1 341-347 
    let-7a-5p 0.737 4.64E-03 8mer 233-240 
    let-7a-5p 0.737 4.64E-03 7mer-A1 341-347 
    let-7i-5p 0.754 2.96E-03 8mer 233-240 
    let-7i-5p 0.754 2.96E-03 7mer-A1 341-347 
Dlg4 3.191 3.84E-32  miR-206-3p 0.664 2.84E-04 8mer 336-343 
Camkv 3.174 3.17E-27  miR-495-3p 0.670 8.82E-05 8mer 1978-1985 
Hp1bp3 3.172 1.40E-21  miR-206-3p 0.664 2.84E-04 7mer-A1 1193-1199 
     miR-495-3p 0.670 8.82E-05 7mer-m8 1179-1185 
Kcnk12 3.169 6.31E-15  miR-134-5p 0.735 1.80E-04 7mer-A1 501-507 
Klhl24 3.164 4.83E-22  miR-219a-2-3p 0.777 9.18E-03 8mer 830-837 
B430305J03Rik 3.151 4.62E-05  miR-134-5p 0.735 1.80E-04 7mer-m8 250-256 
Pias4 3.136 1.82E-21  let-7e-5p 0.678 1.81E-04 7mer-m8 444-450 
    let-7c-5p 0.725 2.96E-03 7mer-m8 444-450 
    let-7a-5p 0.737 4.64E-03 7mer-m8 444-450 
    let-7i-5p 0.754 2.96E-03 7mer-m8 444-450 
    miR-219a-2-3p 0.777 9.18E-03 7mer-A1 459-465 
Dazap1 3.126 1.46E-28  miR-320-3p 0.778 3.84E-03 8mer 210-217 
B3glct 3.124 8.41E-14  miR-1224-5p 0.626 2.78E-06 8mer 2911-2918 
Unc5a 3.093 4.06E-26  let-7e-5p 0.678 1.81E-04 7mer-m8 312-318 
    let-7c-5p 0.725 2.96E-03 7mer-m8 312-318 
    let-7a-5p 0.737 4.64E-03 7mer-m8 312-318 
    let-7i-5p 0.754 2.96E-03 7mer-m8 312-318 
Fndc3a 3.079 3.18E-18  miR-206-3p 0.664 2.84E-04 8mer 2039-2046 
    let-7e-5p 0.678 1.81E-04 7mer-m8 505-511 
    let-7e-5p 0.678 1.81E-04 7mer-A1 2024-2030 
    let-7c-5p 0.725 2.96E-03 7mer-m8 505-511 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2024-2030 
    let-7a-5p 0.737 4.64E-03 7mer-m8 505-511 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2024-2030 
    let-7i-5p 0.754 2.96E-03 7mer-m8 505-511 
    let-7i-5p 0.754 2.96E-03 7mer-A1 2024-2030 
Smad6 3.068 1.30E-09  miR-134-5p 0.735 1.80E-04 7mer-m8 415-421 
Fam168b 3.050 1.20E-19  miR-206-3p 0.664 2.84E-04 7mer-m8 2620-2626 
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    miR-134-5p 0.735 1.80E-04 7mer-m8 37-43 
Bri3bp 3.043 8.56E-25  miR-206-3p 0.664 2.84E-04 7mer-m8 5496-5502 
Ambra1 3.037 1.11E-14  miR-423-5p 0.746 7.22E-03 8mer 1019-1026 
Klhl36 3.035 6.69E-23  miR-320-3p 0.778 3.84E-03 7mer-m8 62-68 
Hip1r 3.033 4.69E-21  miR-320-3p 0.778 3.84E-03 8mer 2511-2518 
Stk40 3.031 3.64E-21  miR-21c 0.609 2.84E-04 7mer-m8 393-399 
    let-7e-5p 0.678 1.81E-04 7mer-m8 268-274 
    let-7c-5p 0.725 2.96E-03 7mer-m8 268-274 
    miR-134-5p 0.735 1.80E-04 7mer-A1 1908-1914 
    let-7a-5p 0.737 4.64E-03 7mer-m8 268-274 
    let-7i-5p 0.754 2.96E-03 7mer-m8 268-274 
Dvl2 3.016 5.52E-18  miR-134-5p 0.735 1.80E-04 8mer 2497-2504 
Hyal1 3.013 1.27E-06  miR-134-5p 0.735 1.80E-04 8mer 73-80 
Numbl 3.000 1.01E-15  let-7e-5p 0.678 1.81E-04 7mer-A1 575-581 
    let-7c-5p 0.725 2.96E-03 7mer-A1 575-581 
    let-7a-5p 0.737 4.64E-03 7mer-A1 575-581 
    miR-423-5p 0.746 7.22E-03 8mer 95-102 
    let-7i-5p 0.754 2.96E-03 7mer-A1 575-581 
Rnf39 2.995 6.84E-03  let-7e-5p 0.678 1.81E-04 7mer-m8 617-623 
    let-7c-5p 0.725 2.96E-03 7mer-m8 617-623 
    let-7a-5p 0.737 4.64E-03 7mer-m8 617-623 
    let-7i-5p 0.754 2.96E-03 7mer-m8 617-623 
Slitrk5 2.988 1.49E-16  miR-495-3p 0.670 8.82E-05 7mer-m8 437-443 
    let-7e-5p 0.678 1.81E-04 7mer-m8 2273-2279 
    let-7c-5p 0.725 2.96E-03 7mer-m8 2273-2279 
    let-7a-5p 0.737 4.64E-03 7mer-m8 2273-2279 
    let-7i-5p 0.754 2.96E-03 7mer-m8 2273-2279 
Fbxl14 2.982 1.63E-13  let-7e-5p 0.678 1.81E-04 7mer-m8 690-696 
    let-7c-5p 0.725 2.96E-03 7mer-m8 690-696 
    let-7a-5p 0.737 4.64E-03 7mer-m8 690-696 
    let-7i-5p 0.754 2.96E-03 7mer-m8 690-696 
Gfod1 2.975 8.03E-12  let-7e-5p 0.678 1.81E-04 8mer 303-310 
    let-7c-5p 0.725 2.96E-03 8mer 303-310 
    let-7a-5p 0.737 4.64E-03 8mer 303-310 
    let-7i-5p 0.754 2.96E-03 8mer 303-310 
Ppara 2.975 2.21E-03  miR-21c 0.609 2.84E-04 8mer 571-578 
    let-7e-5p 0.678 1.81E-04 7mer-A1 4391-4397 
    let-7c-5p 0.725 2.96E-03 7mer-A1 4391-4397 
    let-7a-5p 0.737 4.64E-03 7mer-A1 4391-4397 
    let-7i-5p 0.754 2.96E-03 7mer-A1 4391-4397 
Nacc1 2.974 1.70E-20  miR-423-5p 0.746 7.22E-03 7mer-m8 410-416 
     miR-423-5p 0.746 7.22E-03 8mer 598-605 
Tob2 2.956 4.32E-10  let-7e-5p 0.678 1.81E-04 7mer-m8 1435-1441 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1435-1441 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1435-1441 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1435-1441 
Gas2l1 2.947 1.87E-20  miR-206-3p 0.664 2.84E-04 7mer-m8 151-157 
Evx2 2.940 8.00E-04  miR-320-3p 0.778 3.84E-03 8mer 2289-2296 
Calm3 2.898 8.84E-15  miR-495-3p 0.670 8.82E-05 7mer-m8 324-330 
     miR-320-3p 0.778 3.84E-03 7mer-m8 1301-1307 
Atp8b2 2.877 6.51E-11  miR-423-5p 0.746 7.22E-03 7mer-A1 393-399 
Bhlhe41 2.867 4.99E-23  miR-495-3p 0.670 8.82E-05 7mer-m8 1087-1093 
Nipal3 2.856 7.94E-18  miR-495-3p 0.670 8.82E-05 7mer-A1 3368-3374 
Cdk13 2.853 8.29E-20  miR-382-5p 0.708 2.21E-05 8mer 1851-1858 
    miR-320-3p 0.778 3.84E-03 8mer 103-110 
     miR-320-3p 0.778 3.84E-03 7mer-A1 1947-1953 
Cnksr3 2.852 4.58E-15  miR-134-5p 0.735 1.80E-04 7mer-A1 1074-1080 
Hs6st3 2.846 7.12E-03  miR-320-3p 0.778 3.84E-03 8mer 1434-1441 
Klf9 2.845 1.70E-20  let-7e-5p 0.678 1.81E-04 7mer-m8 2018-2024 
    let-7c-5p 0.725 2.96E-03 7mer-m8 2018-2024 
    let-7a-5p 0.737 4.64E-03 7mer-m8 2018-2024 
    let-7i-5p 0.754 2.96E-03 7mer-m8 2018-2024 
Xylt1 2.829 1.42E-04  miR-495-3p 0.670 8.82E-05 7mer-A1 5439-5445 
    let-7e-5p 0.678 1.81E-04 8mer 4158-4165 
    let-7c-5p 0.725 2.96E-03 8mer 4158-4165 
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    let-7a-5p 0.737 4.64E-03 8mer 4158-4165 
    let-7i-5p 0.754 2.96E-03 8mer 4158-4165 
Pcgf3 2.820 2.17E-11  let-7e-5p 0.678 1.81E-04 8mer 1621-1628 
    let-7c-5p 0.725 2.96E-03 8mer 1621-1628 
    let-7a-5p 0.737 4.64E-03 8mer 1621-1628 
    let-7i-5p 0.754 2.96E-03 8mer 1621-1628 
    miR-320-3p 0.778 3.84E-03 8mer 2492-2499 
Map7d1 2.820 7.03E-35  miR-423-5p 0.746 7.22E-03 8mer 183-190 
Grb2 2.818 1.28E-18  miR-320-3p 0.778 3.84E-03 7mer-m8 861-867 
Kctd13 2.817 1.79E-26  miR-206-3p 0.664 2.84E-04 8mer 168-175 
Zfp787 2.814 1.32E-28  miR-423-5p 0.746 7.22E-03 7mer-m8 29-35 
Myrip 2.793 6.31E-15  let-7e-5p 0.678 1.81E-04 7mer-A1 162-168 
    let-7c-5p 0.725 2.96E-03 7mer-A1 162-168 
    let-7a-5p 0.737 4.64E-03 7mer-A1 162-168 
    let-7i-5p 0.754 2.96E-03 7mer-A1 162-168 
Lemd3 2.782 7.19E-17  miR-21c 0.609 2.84E-04 7mer-m8 625-631 
Ddx19b 2.777 4.81E-15  let-7e-5p 0.678 1.81E-04 8mer 118-125 
    miR-382-5p 0.708 2.21E-05 7mer-m8 191-197 
    let-7c-5p 0.725 2.96E-03 8mer 118-125 
    let-7a-5p 0.737 4.64E-03 8mer 118-125 
    let-7i-5p 0.754 2.96E-03 8mer 118-125 
Dusp8 2.769 1.89E-12  miR-21c 0.609 2.84E-04 8mer 1657-1664 
Foxq1 2.765 1.34E-12  miR-320-3p 0.778 3.84E-03 8mer 627-634 
Mycl 2.765 5.51E-17  miR-21c 0.609 2.84E-04 7mer-m8 1697-1703 
    let-7e-5p 0.678 1.81E-04 7mer-A1 541-547 
    let-7c-5p 0.725 2.96E-03 7mer-A1 541-547 
    let-7a-5p 0.737 4.64E-03 7mer-A1 541-547 
    let-7i-5p 0.754 2.96E-03 7mer-A1 541-547 
Sfxn5 2.764 3.74E-14  miR-206-3p 0.664 2.84E-04 7mer-m8 2265-2271 
Zfp281 2.763 6.75E-15  miR-206-3p 0.664 2.84E-04 7mer-A1 686-692 
    miR-206-3p 0.664 2.84E-04 7mer-m8 5157-5163 
    miR-495-3p 0.670 8.82E-05 7mer-A1 138-144 
    miR-495-3p 0.670 8.82E-05 8mer 5079-5086 
    let-7e-5p 0.678 1.81E-04 8mer 3451-3458 
    let-7c-5p 0.725 2.96E-03 8mer 3451-3458 
    let-7a-5p 0.737 4.64E-03 8mer 3451-3458 
    let-7i-5p 0.754 2.96E-03 8mer 3451-3458 
    miR-320-3p 0.778 3.84E-03 7mer-m8 648-654 
     miR-320-3p 0.778 3.84E-03 7mer-A1 742-748 
Ip6k3 2.753 2.11E-09  miR-495-3p 0.670 8.82E-05 7mer-A1 865-871 
     miR-495-3p 0.670 8.82E-05 7mer-m8 924-930 
Rbms1 2.752 5.07E-16  let-7e-5p 0.678 1.81E-04 8mer 1900-1907 
    let-7c-5p 0.725 2.96E-03 8mer 1900-1907 
    let-7a-5p 0.737 4.64E-03 8mer 1900-1907 
    let-7i-5p 0.754 2.96E-03 8mer 1900-1907 
Zfp503 2.752 7.68E-20  miR-495-3p 0.670 8.82E-05 8mer 582-589 
     miR-219a-2-3p 0.777 9.18E-03 7mer-m8 738-744 
Igf1r 2.747 7.22E-11  miR-495-3p 0.670 8.82E-05 7mer-A1 6977-6983 
    let-7e-5p 0.678 1.81E-04 7mer-A1 112-118 
    let-7e-5p 0.678 1.81E-04 8mer 2724-2731 
    let-7e-5p 0.678 1.81E-04 7mer-m8 6830-6836 
    let-7c-5p 0.725 2.96E-03 7mer-A1 112-118 
    let-7c-5p 0.725 2.96E-03 8mer 2724-2731 
    let-7c-5p 0.725 2.96E-03 7mer-m8 6830-6836 
    let-7a-5p 0.737 4.64E-03 7mer-A1 112-118 
    let-7a-5p 0.737 4.64E-03 8mer 2724-2731 
    let-7a-5p 0.737 4.64E-03 7mer-m8 6830-6836 
    let-7i-5p 0.754 2.96E-03 7mer-A1 112-118 
    let-7i-5p 0.754 2.96E-03 8mer 2724-2731 
    let-7i-5p 0.754 2.96E-03 7mer-m8 6830-6836 
    miR-320-3p 0.778 3.84E-03 7mer-m8 208-214 
    miR-320-3p 0.778 3.84E-03 7mer-A1 5931-5937 
Tpcn1 2.741 2.95E-18  miR-495-3p 0.670 8.82E-05 7mer-A1 1886-1892 
     miR-423-5p 0.746 7.22E-03 7mer-m8 1775-1781 
Satb1 2.735 2.13E-16  miR-21c 0.609 2.84E-04 7mer-m8 941-947 
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    miR-495-3p 0.670 8.82E-05 8mer 459-466 
    miR-495-3p 0.670 8.82E-05 7mer-A1 1127-1133 
     miR-219a-2-3p 0.777 9.18E-03 7mer-A1 884-890 
Rgmb 2.734 7.73E-15  miR-495-3p 0.670 8.82E-05 7mer-m8 2486-2492 
Syt2 2.729 3.10E-15  let-7e-5p 0.678 1.81E-04 7mer-A1 90-96 
    let-7c-5p 0.725 2.96E-03 7mer-A1 90-96 
    let-7a-5p 0.737 4.64E-03 7mer-A1 90-96 
    let-7i-5p 0.754 2.96E-03 7mer-A1 90-96 
Crb2 2.727 3.55E-04  let-7e-5p 0.678 1.81E-04 8mer 700-707 
    let-7c-5p 0.725 2.96E-03 8mer 700-707 
    let-7a-5p 0.737 4.64E-03 8mer 700-707 
    let-7i-5p 0.754 2.96E-03 8mer 700-707 
Xpo7 2.727 2.16E-13  miR-320-3p 0.778 3.84E-03 7mer-A1 492-498 
Dyrk1b 2.725 1.26E-14  miR-423-5p 0.746 7.22E-03 7mer-m8 19-25 
Oprd1 2.724 3.04E-03  miR-423-5p 0.746 7.22E-03 7mer-m8 24-30 
Pcdh1 2.722 4.69E-21  miR-495-3p 0.670 8.82E-05 7mer-m8 3968-3974 
     miR-320-3p 0.778 3.84E-03 7mer-A1 4014-4020 
Sass6 2.720 7.10E-10  let-7e-5p 0.678 1.81E-04 7mer-m8 1986-1992 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1986-1992 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1986-1992 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1986-1992 
    miR-320-3p 0.778 3.84E-03 8mer 2730-2737 
Nudt5 2.720 8.20E-16  miR-411-5p 0.687 1.81E-04 7mer-m8 2845-2851 
Vgf 2.718 1.64E-21  miR-423-5p 0.746 7.22E-03 7mer-A1 458-464 
Dpysl3 2.711 3.35E-16  let-7e-5p 0.678 1.81E-04 7mer-A1 2094-2100 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2094-2100 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2094-2100 
    let-7i-5p 0.754 2.96E-03 7mer-A1 2094-2100 
    miR-219a-2-3p 0.777 9.18E-03 8mer 2006-2013 
    miR-320-3p 0.778 3.84E-03 7mer-A1 160-166 
Dusp4 2.702 9.71E-07  let-7e-5p 0.678 1.81E-04 7mer-A1 278-284 
    let-7c-5p 0.725 2.96E-03 7mer-A1 278-284 
    let-7a-5p 0.737 4.64E-03 7mer-A1 278-284 
    let-7i-5p 0.754 2.96E-03 7mer-A1 278-284 
Nrxn2 2.689 4.34E-21  miR-495-3p 0.670 8.82E-05 7mer-A1 983-989 
     miR-495-3p 0.670 8.82E-05 7mer-m8 1083-1089 
Jup 2.686 2.40E-20  miR-320-3p 0.778 3.84E-03 7mer-A1 245-251 
Wbp2 2.678 2.71E-21  miR-206-3p 0.664 2.84E-04 7mer-m8 424-430 
Sdk1 2.674 2.46E-12  let-7e-5p 0.678 1.81E-04 7mer-m8 402-408 
    let-7c-5p 0.725 2.96E-03 7mer-m8 402-408 
    let-7a-5p 0.737 4.64E-03 7mer-m8 402-408 
    let-7i-5p 0.754 2.96E-03 7mer-m8 402-408 
    miR-320-3p 0.778 3.84E-03 7mer-m8 950-956 
     miR-320-3p 0.778 3.84E-03 7mer-m8 1156-1162 
Ralb 2.664 1.17E-19  let-7e-5p 0.678 1.81E-04 7mer-m8 997-1003 
    let-7c-5p 0.725 2.96E-03 7mer-m8 997-1003 
    let-7a-5p 0.737 4.64E-03 7mer-m8 997-1003 
    let-7i-5p 0.754 2.96E-03 7mer-m8 997-1003 
Zswim4 2.662 1.09E-17  let-7e-5p 0.678 1.81E-04 7mer-A1 513-519 
    let-7c-5p 0.725 2.96E-03 7mer-A1 513-519 
    let-7a-5p 0.737 4.64E-03 7mer-A1 513-519 
    let-7i-5p 0.754 2.96E-03 7mer-A1 513-519 
Syvn1 2.662 3.53E-21  miR-423-5p 0.746 7.22E-03 7mer-m8 311-317 
Agap2 2.658 1.81E-20  miR-423-5p 0.746 7.22E-03 7mer-m8 989-995 
Nedd4l 2.651 5.10E-16  miR-206-3p 0.664 2.84E-04 7mer-A1 4519-4525 
    let-7e-5p 0.678 1.81E-04 7mer-m8 3550-3556 
    let-7c-5p 0.725 2.96E-03 7mer-m8 3550-3556 
    let-7a-5p 0.737 4.64E-03 7mer-m8 3550-3556 
    let-7i-5p 0.754 2.96E-03 7mer-m8 3550-3556 
Map1a 2.644 1.28E-17  miR-206-3p 0.664 2.84E-04 8mer 883-890 
Pbx2 2.643 1.17E-14  let-7e-5p 0.678 1.81E-04 7mer-A1 452-458 
    let-7e-5p 0.678 1.81E-04 7mer-m8 520-526 
    let-7c-5p 0.725 2.96E-03 7mer-A1 452-458 
    let-7c-5p 0.725 2.96E-03 7mer-m8 520-526 
    let-7a-5p 0.737 4.64E-03 7mer-A1 452-458 
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    let-7a-5p 0.737 4.64E-03 7mer-m8 520-526 
    let-7i-5p 0.754 2.96E-03 7mer-A1 452-458 
    let-7i-5p 0.754 2.96E-03 7mer-m8 520-526 
Ntn1 2.636 5.82E-14  let-7e-5p 0.678 1.81E-04 8mer 242-249 
    let-7c-5p 0.725 2.96E-03 8mer 242-249 
    let-7a-5p 0.737 4.64E-03 8mer 242-249 
     let-7i-5p 0.754 2.96E-03 8mer 242-249 
Prrc2a 2.635 1.84E-15  miR-495-3p 0.670 8.82E-05 8mer 347-354 
C2cd4c 2.633 1.78E-13  miR-495-3p 0.670 8.82E-05 7mer-m8 1291-1297 
Myl9 2.633 1.54E-03  miR-134-5p 0.735 1.80E-04 7mer-m8 37-43 
Pard3 2.631 1.25E-13  miR-134-5p 0.735 1.80E-04 8mer 1075-1082 
Mfsd12 2.630 5.45E-14  miR-423-5p 0.746 7.22E-03 7mer-m8 1163-1169 
B3gnt7 2.624 3.60E-04  let-7e-5p 0.678 1.81E-04 8mer 576-583 
    let-7c-5p 0.725 2.96E-03 8mer 576-583 
    let-7a-5p 0.737 4.64E-03 8mer 576-583 
    let-7i-5p 0.754 2.96E-03 8mer 576-583 
Pag1 2.618 1.38E-11  miR-21c 0.609 2.84E-04 8mer 994-1001 
    let-7e-5p 0.678 1.81E-04 8mer 5835-5842 
    let-7c-5p 0.725 2.96E-03 8mer 5835-5842 
    let-7a-5p 0.737 4.64E-03 8mer 5835-5842 
    let-7i-5p 0.754 2.96E-03 8mer 5835-5842 
Lhx4 2.618 3.33E-03  miR-495-3p 0.670 8.82E-05 7mer-m8 4111-4117 
Pdgfa 2.608 4.11E-23  miR-206-3p 0.664 2.84E-04 7mer-m8 69-75 
Ccdc71l 2.598 6.28E-18  let-7e-5p 0.678 1.81E-04 8mer 299-306 
    let-7c-5p 0.725 2.96E-03 8mer 299-306 
    let-7a-5p 0.737 4.64E-03 8mer 299-306 
    let-7i-5p 0.754 2.96E-03 8mer 299-306 
Tmx4 2.591 3.75E-13  let-7e-5p 0.678 1.81E-04 7mer-A1 3371-3377 
    let-7c-5p 0.725 2.96E-03 7mer-A1 3371-3377 
    let-7a-5p 0.737 4.64E-03 7mer-A1 3371-3377 
    let-7i-5p 0.754 2.96E-03 7mer-A1 3371-3377 
Ahdc1 2.591 1.58E-15  miR-423-5p 0.746 7.22E-03 7mer-m8 107-113 
Xpnpep3 2.587 2.13E-08  miR-206-3p 0.664 2.84E-04 7mer-A1 241-247 
     miR-495-3p 0.670 8.82E-05 7mer-A1 4403-4409 
Zfp36l2 2.583 4.83E-22  miR-21c 0.609 2.84E-04 7mer-m8 487-493 
     miR-206-3p 0.664 2.84E-04 7mer-A1 628-634 
Kalrn 2.580 3.37E-14  miR-206-3p 0.664 2.84E-04 7mer-m8 647-653 
Gorasp1 2.576 1.69E-16  miR-423-5p 0.746 7.22E-03 7mer-m8 1408-1414 
Rffl 2.575 5.74E-19  miR-21c 0.609 2.84E-04 7mer-m8 2005-2011 
    miR-495-3p 0.670 8.82E-05 7mer-A1 2140-2146 
    let-7e-5p 0.678 1.81E-04 7mer-m8 1590-1596 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1590-1596 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1590-1596 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1590-1596 
Mylk 2.573 2.23E-08  miR-206-3p 0.664 2.84E-04 8mer 1370-1377 
Klhl3 2.566 2.02E-03  miR-382-5p 0.708 2.21E-05 7mer-m8 337-343 
Gdnf 2.566 2.60E-03  miR-495-3p 0.670 8.82E-05 7mer-A1 1828-1834 
Setd1b 2.563 9.74E-07  miR-21c 0.609 2.84E-04 7mer-m8 1012-1018 
Tmem184b 2.558 5.86E-22  miR-134-5p 0.735 1.80E-04 7mer-A1 960-966 
Otud7a 2.557 2.59E-17  let-7e-5p 0.678 1.81E-04 7mer-m8 652-658 
    let-7c-5p 0.725 2.96E-03 7mer-m8 652-658 
    let-7a-5p 0.737 4.64E-03 7mer-m8 652-658 
    let-7i-5p 0.754 2.96E-03 7mer-m8 652-658 
     miR-320-3p 0.778 3.84E-03 7mer-m8 1898-1904 
Ptrf 2.553 2.88E-11  let-7e-5p 0.678 1.81E-04 8mer 2637-2644 
    let-7c-5p 0.725 2.96E-03 8mer 2637-2644 
    let-7a-5p 0.737 4.64E-03 8mer 2637-2644 
    let-7i-5p 0.754 2.96E-03 8mer 2637-2644 
Ehd1 2.547 4.49E-17  miR-21c 0.609 2.84E-04 8mer 665-672 
Pgrmc2 2.533 8.59E-19  miR-21c 0.609 2.84E-04 7mer-m8 1133-1139 
Crkl 2.529 3.39E-13  miR-320-3p 0.778 3.84E-03 7mer-m8 100-106 
Mapk8ip3 2.519 1.29E-15  miR-320-3p 0.778 3.84E-03 7mer-m8 110-116 
Ptprg 2.517 1.87E-17  miR-206-3p 0.664 2.84E-04 8mer 287-294 
Smad7 2.509 2.51E-10  miR-21c 0.609 2.84E-04 8mer 1165-1172 
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Slc8a2 2.505 2.54E-19  miR-206-3p 0.664 2.84E-04 8mer 582-589 
    let-7e-5p 0.678 1.81E-04 7mer-m8 609-615 
    let-7c-5p 0.725 2.96E-03 7mer-m8 609-615 
    let-7a-5p 0.737 4.64E-03 7mer-m8 609-615 
    let-7i-5p 0.754 2.96E-03 7mer-m8 609-615 
Zcchc14 2.500 2.28E-15  miR-495-3p 0.670 8.82E-05 7mer-A1 3485-3491 
     miR-382-5p 0.708 2.21E-05 7mer-m8 746-752 
     miR-382-5p 0.708 2.21E-05 7mer-m8 1687-1693 
Gpr157 2.499 4.14E-09  let-7e-5p 0.678 1.81E-04 7mer-m8 141-147 
    let-7c-5p 0.725 2.96E-03 7mer-m8 141-147 
    let-7a-5p 0.737 4.64E-03 7mer-m8 141-147 
     let-7i-5p 0.754 2.96E-03 7mer-m8 141-147 
Slc12a9 2.497 9.93E-14  let-7e-5p 0.678 1.81E-04 8mer 267-274 
    let-7c-5p 0.725 2.96E-03 8mer 267-274 
    let-7a-5p 0.737 4.64E-03 8mer 267-274 
    let-7i-5p 0.754 2.96E-03 8mer 267-274 
Creb5 2.497 2.74E-03  miR-206-3p 0.664 2.84E-04 8mer 3758-3765 
Cops7b 2.496 1.51E-11  miR-495-3p 0.670 8.82E-05 7mer-A1 1063-1069 
     miR-423-5p 0.746 7.22E-03 7mer-A1 108-114 
Epha4 2.495 3.77E-08  miR-21c 0.609 2.84E-04 8mer 2232-2239 
    let-7e-5p 0.678 1.81E-04 7mer-A1 37-43 
    let-7c-5p 0.725 2.96E-03 7mer-A1 37-43 
    let-7a-5p 0.737 4.64E-03 7mer-A1 37-43 
    let-7i-5p 0.754 2.96E-03 7mer-A1 37-43 
Ssh1 2.488 1.35E-17  let-7e-5p 0.678 1.81E-04 7mer-m8 511-517 
    let-7c-5p 0.725 2.96E-03 7mer-m8 511-517 
    let-7a-5p 0.737 4.64E-03 7mer-m8 511-517 
    let-7i-5p 0.754 2.96E-03 7mer-m8 511-517 
Rasa1 2.478 3.12E-11  miR-21c 0.609 2.84E-04 7mer-A1 191-197 
    miR-206-3p 0.664 2.84E-04 8mer 118-125 
    miR-495-3p 0.670 8.82E-05 7mer-A1 689-695 
     miR-320-3p 0.778 3.84E-03 8mer 620-627 
C1galt1 2.478 8.06E-12  miR-206-3p 0.664 2.84E-04 8mer 91-98 
    let-7e-5p 0.678 1.81E-04 8mer 1824-1831 
    let-7c-5p 0.725 2.96E-03 8mer 1824-1831 
    let-7a-5p 0.737 4.64E-03 8mer 1824-1831 
    let-7i-5p 0.754 2.96E-03 8mer 1824-1831 
Zfp180 2.454 1.45E-12  miR-495-3p 0.670 8.82E-05 8mer 1349-1356 
Golga7 2.454 3.91E-17  let-7e-5p 0.678 1.81E-04 7mer-m8 70-76 
    miR-495-3p 0.670 8.82E-05 7mer-A1 779-785 
    let-7c-5p 0.725 2.96E-03 7mer-m8 70-76 
    let-7a-5p 0.737 4.64E-03 7mer-m8 70-76 
    let-7i-5p 0.754 2.96E-03 7mer-m8 70-76 
Dnajb12 2.452 3.34E-14  miR-423-5p 0.746 7.22E-03 7mer-m8 2260-2266 
Rmdn3 2.452 4.12E-11  miR-320-3p 0.778 3.84E-03 7mer-m8 580-586 
Slc38a9 2.449 4.46E-13  let-7e-5p 0.678 1.81E-04 7mer-A1 426-432 
    let-7c-5p 0.725 2.96E-03 7mer-A1 426-432 
    let-7a-5p 0.737 4.64E-03 7mer-A1 426-432 
    let-7i-5p 0.754 2.96E-03 7mer-A1 426-432 
Dnal1 2.445 1.39E-11  let-7e-5p 0.678 1.81E-04 7mer-m8 3400-3406 
    let-7c-5p 0.725 2.96E-03 7mer-m8 3400-3406 
    let-7a-5p 0.737 4.64E-03 7mer-m8 3400-3406 
    let-7i-5p 0.754 2.96E-03 7mer-m8 3400-3406 
Scn4b 2.438 4.50E-08  let-7e-5p 0.678 1.81E-04 8mer 2190-2197 
    let-7c-5p 0.725 2.96E-03 8mer 2190-2197 
    let-7a-5p 0.737 4.64E-03 8mer 2190-2197 
    let-7i-5p 0.754 2.96E-03 8mer 2190-2197 
Slc45a4 2.436 1.11E-19  let-7e-5p 0.678 1.81E-04 7mer-m8 896-902 
    miR-382-5p 0.708 2.21E-05 7mer-A1 4015-4021 
    let-7c-5p 0.725 2.96E-03 7mer-m8 896-902 
    let-7a-5p 0.737 4.64E-03 7mer-m8 896-902 
    let-7i-5p 0.754 2.96E-03 7mer-m8 896-902 
Col4a2 2.435 2.81E-12  let-7e-5p 0.678 1.81E-04 7mer-A1 235-241 
    let-7c-5p 0.725 2.96E-03 7mer-A1 235-241 
    let-7a-5p 0.737 4.64E-03 7mer-A1 235-241 
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    let-7i-5p 0.754 2.96E-03 7mer-A1 235-241 
Carf 2.433 3.04E-13  miR-206-3p 0.664 2.84E-04 7mer-m8 2051-2057 
Pcbp1 2.431 2.98E-22  miR-21c 0.609 2.84E-04 7mer-m8 192-198 
Tmem198b 2.431 4.73E-15  let-7e-5p 0.678 1.81E-04 7mer-m8 205-211 
    let-7e-5p 0.678 1.81E-04 7mer-m8 688-694 
    let-7c-5p 0.725 2.96E-03 7mer-m8 205-211 
    let-7c-5p 0.725 2.96E-03 7mer-m8 688-694 
    let-7a-5p 0.737 4.64E-03 7mer-m8 205-211 
    let-7a-5p 0.737 4.64E-03 7mer-m8 688-694 
    let-7i-5p 0.754 2.96E-03 7mer-m8 205-211 
    let-7i-5p 0.754 2.96E-03 7mer-m8 688-694 
Hmga1 2.429 9.92E-12  let-7e-5p 0.678 1.81E-04 7mer-m8 801-807 
    let-7c-5p 0.725 2.96E-03 7mer-m8 801-807 
    let-7a-5p 0.737 4.64E-03 7mer-m8 801-807 
    let-7i-5p 0.754 2.96E-03 7mer-m8 801-807 
Cbfa2t3 2.426 7.46E-08  let-7e-5p 0.678 1.81E-04 7mer-m8 1388-1394 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1388-1394 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1388-1394 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1388-1394 
Zbtb7b 2.424 1.21E-15  miR-206-3p 0.664 2.84E-04 7mer-A1 141-147 
     miR-423-5p 0.746 7.22E-03 7mer-m8 500-506 
Sik3 2.418 3.64E-18  miR-382-5p 0.708 2.21E-05 8mer 2071-2078 
Nova2 2.412 6.66E-15  miR-219a-2-3p 0.777 9.18E-03 7mer-m8 2308-2314 
Slmo2 2.411 3.00E-12  miR-495-3p 0.670 8.82E-05 7mer-A1 59-65 
Lmtk3 2.409 4.54E-15  miR-382-5p 0.708 2.21E-05 7mer-m8 479-485 
Ppp1r15b 2.409 6.00E-14  let-7e-5p 0.678 1.81E-04 8mer 2032-2039 
    let-7c-5p 0.725 2.96E-03 8mer 2032-2039 
    let-7a-5p 0.737 4.64E-03 8mer 2032-2039 
    let-7i-5p 0.754 2.96E-03 8mer 2032-2039 
Yy1 2.409 2.95E-07  let-7e-5p 0.678 1.81E-04 8mer 1085-1092 
    let-7c-5p 0.725 2.96E-03 8mer 1085-1092 
    let-7a-5p 0.737 4.64E-03 8mer 1085-1092 
    let-7i-5p 0.754 2.96E-03 8mer 1085-1092 
    miR-219a-2-3p 0.777 9.18E-03 8mer 258-265 
Tbkbp1 2.407 4.50E-17  let-7e-5p 0.678 1.81E-04 8mer 975-982 
    let-7c-5p 0.725 2.96E-03 8mer 975-982 
    let-7a-5p 0.737 4.64E-03 8mer 975-982 
    let-7i-5p 0.754 2.96E-03 8mer 975-982 
AI606181 2.401 3.07E-13  let-7e-5p 0.678 1.81E-04 7mer-A1 1999-2005 
    let-7c-5p 0.725 2.96E-03 7mer-A1 1999-2005 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1999-2005 
    let-7i-5p 0.754 2.96E-03 7mer-A1 1999-2005 
Lphn1 2.388 1.98E-13  miR-320-3p 0.778 3.84E-03 7mer-m8 1060-1066 
Gas7 2.387 1.18E-14  let-7e-5p 0.678 1.81E-04 8mer 599-606 
    let-7c-5p 0.725 2.96E-03 8mer 599-606 
    let-7a-5p 0.737 4.64E-03 8mer 599-606 
    let-7i-5p 0.754 2.96E-03 8mer 599-606 
Fzd8 2.385 9.45E-11  miR-320-3p 0.778 3.84E-03 7mer-m8 1686-1692 
Ndst1 2.382 6.28E-09  miR-206-3p 0.664 2.84E-04 7mer-A1 1873-1879 
    miR-495-3p 0.670 8.82E-05 7mer-m8 1107-1113 
    miR-134-5p 0.735 1.80E-04 8mer 1855-1862 
     miR-423-5p 0.746 7.22E-03 7mer-A1 390-396 
Kremen1 2.378 6.23E-13  let-7e-5p 0.678 1.81E-04 7mer-m8 2858-2864 
    miR-495-3p 0.670 8.82E-05 7mer-A1 3296-3302 
    let-7c-5p 0.725 2.96E-03 7mer-m8 2858-2864 
    let-7a-5p 0.737 4.64E-03 7mer-m8 2858-2864 
    let-7i-5p 0.754 2.96E-03 7mer-m8 2858-2864 
Smad9 2.375 3.17E-12  miR-206-3p 0.664 2.84E-04 7mer-A1 2894-2900 
     miR-495-3p 0.670 8.82E-05 7mer-m8 2611-2617 
Ppp2r5e 2.355 3.97E-15  miR-134-5p 0.735 1.80E-04 8mer 1729-1736 
Mllt3 2.354 5.10E-09  miR-320-3p 0.778 3.84E-03 8mer 132-139 
Pea15a 2.352 2.27E-14  miR-206-3p 0.664 2.84E-04 7mer-m8 286-292 
Rhob 2.348 7.44E-21  miR-21c 0.609 2.84E-04 7mer-m8 1317-1323 
Mllt1 2.343 1.54E-13  miR-495-3p 0.670 8.82E-05 7mer-A1 1794-1800 
Iglon5 2.338 3.83E-10  let-7e-5p 0.678 1.81E-04 7mer-A1 1386-1392 
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    let-7c-5p 0.725 2.96E-03 7mer-A1 1386-1392 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1386-1392 
    let-7i-5p 0.754 2.96E-03 7mer-A1 1386-1392 
Sp2 2.334 2.74E-13  miR-206-3p 0.664 2.84E-04 8mer 536-543 
     miR-495-3p 0.670 8.82E-05 7mer-A1 1044-1050 
Pten 2.333 1.02E-14  miR-495-3p 0.670 8.82E-05 7mer-A1 3214-3220 
     miR-495-3p 0.670 8.82E-05 8mer 3225-3232 
     miR-219a-2-3p 0.777 9.18E-03 7mer-m8 133-139 
     miR-320-3p 0.778 3.84E-03 8mer 2806-2813 
Gpx3 2.331 8.26E-10  miR-134-5p 0.735 1.80E-04 8mer 1116-1123 
Zbtb4 2.331 4.65E-10  miR-206-3p 0.664 2.84E-04 8mer 443-450 
Usp32 2.329 1.30E-09  let-7e-5p 0.678 1.81E-04 7mer-m8 438-444 
    miR-495-3p 0.670 8.82E-05 8mer 1650-1657 
    let-7c-5p 0.725 2.96E-03 7mer-m8 438-444 
    let-7a-5p 0.737 4.64E-03 7mer-m8 438-444 
    let-7i-5p 0.754 2.96E-03 7mer-m8 438-444 
Med22 2.323 1.40E-17  miR-423-5p 0.746 7.22E-03 7mer-m8 2178-2184 
Csnk1a1 2.323 1.20E-08  miR-495-3p 0.670 8.82E-05 7mer-A1 331-337 
    miR-495-3p 0.670 8.82E-05 7mer-A1 1180-1186 
Zxdb 2.322 2.65E-12  miR-206-3p 0.664 2.84E-04 8mer 1962-1969 
Mnt 2.321 8.14E-19  let-7e-5p 0.678 1.81E-04 7mer-A1 1607-1613 
    let-7c-5p 0.725 2.96E-03 7mer-A1 1607-1613 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1607-1613 
    let-7i-5p 0.754 2.96E-03 7mer-A1 1607-1613 
Slc25a22 2.315 2.71E-14  miR-206-3p 0.664 2.84E-04 7mer-m8 225-231 
Agpat1 2.314 1.35E-16  miR-206-3p 0.664 2.84E-04 8mer 262-269 
R3hdm2 2.312 4.23E-14  miR-495-3p 0.670 8.82E-05 7mer-m8 487-493 
    miR-495-3p 0.670 8.82E-05 7mer-m8 586-592 
    miR-495-3p 0.670 8.82E-05 7mer-m8 590-596 
    miR-495-3p 0.670 8.82E-05 7mer-m8 594-600 
Las1l 2.311 3.07E-11  miR-320-3p 0.778 3.84E-03 7mer-m8 112-118 
Pdgfb 2.309 1.59E-15  let-7e-5p 0.678 1.81E-04 7mer-m8 641-647 
    let-7c-5p 0.725 2.96E-03 7mer-m8 641-647 
    let-7a-5p 0.737 4.64E-03 7mer-m8 641-647 
     let-7i-5p 0.754 2.96E-03 7mer-m8 641-647 
Cbln1 2.308 2.41E-10  miR-320-3p 0.778 3.84E-03 7mer-m8 845-851 
Glyr1 2.306 1.81E-15  miR-219a-2-3p 0.777 9.18E-03 7mer-m8 1306-1312 
Naa20 2.302 8.51E-08  miR-320-3p 0.778 3.84E-03 7mer-A1 365-371 
Magix 2.298 5.94E-04  miR-134-5p 0.735 1.80E-04 7mer-m8 994-1000 
Sez6l 2.296 5.03E-08  miR-21c 0.609 2.84E-04 7mer-A1 2782-2788 
Otud5 2.296 4.19E-18  miR-206-3p 0.664 2.84E-04 7mer-A1 236-242 
    let-7e-5p 0.678 1.81E-04 8mer 1921-1928 
    let-7c-5p 0.725 2.96E-03 8mer 1921-1928 
    let-7a-5p 0.737 4.64E-03 8mer 1921-1928 
    let-7i-5p 0.754 2.96E-03 8mer 1921-1928 
Rnf44 2.294 1.57E-13  let-7e-5p 0.678 1.81E-04 7mer-A1 2041-2047 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2041-2047 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2041-2047 
     let-7i-5p 0.754 2.96E-03 7mer-A1 2041-2047 
Rab22a 2.290 3.71E-10  miR-21c 0.609 2.84E-04 7mer-m8 2342-2348 
Cadm3 2.290 6.00E-16  miR-423-5p 0.746 7.22E-03 8mer 844-851 
     miR-423-5p 0.746 7.22E-03 8mer 1830-1837 
Ncf2 2.288 6.28E-09  miR-206-3p 0.664 2.84E-04 8mer 1105-1112 
Ift80 2.283 5.71E-10  miR-206-3p 0.664 2.84E-04 8mer 337-344 
Zyg11b 2.282 2.28E-13  miR-411-5p 0.687 1.81E-04 7mer-m8 6286-6292 
Rbfox2 2.282 7.71E-20  miR-1224-5p 0.626 2.78E-06 8mer 939-946 
    let-7e-5p 0.678 1.81E-04 7mer-A1 128-134 
    let-7c-5p 0.725 2.96E-03 7mer-A1 128-134 
    let-7a-5p 0.737 4.64E-03 7mer-A1 128-134 
    let-7i-5p 0.754 2.96E-03 7mer-A1 128-134 
Ypel2 2.278 2.69E-10  miR-206-3p 0.664 2.84E-04 7mer-m8 1919-1925 
Plec 2.273 1.42E-08  miR-423-5p 0.746 7.22E-03 8mer 1167-1174 
Hoxd1 2.273 2.69E-05  let-7e-5p 0.678 1.81E-04 7mer-m8 492-498 
    let-7c-5p 0.725 2.96E-03 7mer-m8 492-498 
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    let-7a-5p 0.737 4.64E-03 7mer-m8 492-498 
    let-7i-5p 0.754 2.96E-03 7mer-m8 492-498 
Limd2 2.263 8.80E-15  let-7e-5p 0.678 1.81E-04 7mer-m8 364-370 
    miR-382-5p 0.708 2.21E-05 7mer-m8 2353-2359 
    let-7c-5p 0.725 2.96E-03 7mer-m8 364-370 
    let-7a-5p 0.737 4.64E-03 7mer-m8 364-370 
    let-7i-5p 0.754 2.96E-03 7mer-m8 364-370 
    miR-219a-2-3p 0.777 9.18E-03 8mer 2133-2140 
Ulk1 2.262 1.57E-15  miR-320-3p 0.778 3.84E-03 7mer-m8 466-472 
Mark2 2.262 3.58E-13  miR-423-5p 0.746 7.22E-03 7mer-m8 1605-1611 
Pcdh9 2.261 2.97E-10  miR-495-3p 0.670 8.82E-05 8mer 1275-1282 
Apba1 2.260 1.05E-08  let-7e-5p 0.678 1.81E-04 7mer-m8 3102-3108 
    let-7c-5p 0.725 2.96E-03 7mer-m8 3102-3108 
    let-7a-5p 0.737 4.64E-03 7mer-m8 3102-3108 
    let-7i-5p 0.754 2.96E-03 7mer-m8 3102-3108 
Xpo1 2.259 1.08E-09  miR-1224-5p 0.626 2.78E-06 7mer-A1 669-675 
     miR-320-3p 0.778 3.84E-03 7mer-m8 656-662 
Trove2 2.258 1.64E-12  let-7e-5p 0.678 1.81E-04 7mer-A1 2753-2759 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2753-2759 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2753-2759 
    let-7i-5p 0.754 2.96E-03 7mer-A1 2753-2759 
    miR-320-3p 0.778 3.84E-03 7mer-m8 566-572 
B630019K06Rik 2.256 1.32E-14  miR-219a-2-3p 0.777 9.18E-03 8mer 223-230 
Zfp36l1 2.255 1.70E-07  miR-206-3p 0.664 2.84E-04 7mer-A1 939-945 
    miR-206-3p 0.664 2.84E-04 7mer-m8 1605-1611 
Mmp14 2.254 1.74E-06  miR-495-3p 0.670 8.82E-05 7mer-A1 1615-1621 
Lrfn4 2.248 2.61E-09  let-7e-5p 0.678 1.81E-04 7mer-A1 122-128 
    let-7c-5p 0.725 2.96E-03 7mer-A1 122-128 
    let-7a-5p 0.737 4.64E-03 7mer-A1 122-128 
    let-7i-5p 0.754 2.96E-03 7mer-A1 122-128 
Itga9 2.243 9.16E-11  miR-134-5p 0.735 1.80E-04 7mer-m8 3583-3589 
Stim2 2.239 5.08E-11  miR-320-3p 0.778 3.84E-03 7mer-A1 321-327 
     miR-411-5p 0.687 1.81E-04 7mer-m8 151-157 
Mvb12b 2.238 1.41E-20  let-7e-5p 0.678 1.81E-04 7mer-A1 1268-1274 
     miR-495-3p 0.670 8.82E-05 7mer-A1 3461-3467 
    miR-495-3p 0.670 8.82E-05 7mer-m8 3475-3481 
    let-7c-5p 0.725 2.96E-03 7mer-A1 1268-1274 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1268-1274 
    let-7i-5p 0.754 2.96E-03 7mer-A1 1268-1274 
Acsl6 2.238 1.77E-17  let-7e-5p 0.678 1.81E-04 8mer 406-413 
    miR-495-3p 0.670 8.82E-05 7mer-A1 3475-3481 
    let-7c-5p 0.725 2.96E-03 8mer 406-413 
    let-7a-5p 0.737 4.64E-03 8mer 406-413 
    let-7i-5p 0.754 2.96E-03 8mer 406-413 
Cntfr 2.232 7.33E-15  miR-21c 0.609 2.84E-04 7mer-m8 406-412 
Fam168a 2.230 1.31E-06  miR-206-3p 0.664 2.84E-04 8mer 1021-1028 
    miR-206-3p 0.664 2.84E-04 8mer 4582-4589 
    miR-134-5p 0.735 1.80E-04 7mer-A1 25-31 
Ppp2r2c 2.229 3.04E-08  miR-320-3p 0.778 3.84E-03 7mer-m8 2400-2406 
Arhgap23 2.226 5.35E-14  miR-206-3p 0.664 2.84E-04 7mer-A1 929-935 
Cdc34 2.226 2.05E-07  let-7e-5p 0.678 1.81E-04 7mer-A1 31-37 
    let-7e-5p 0.678 1.81E-04 8mer 68-75 
    let-7c-5p 0.725 2.96E-03 7mer-A1 31-37 
    let-7c-5p 0.725 2.96E-03 8mer 68-75 
    let-7a-5p 0.737 4.64E-03 7mer-A1 31-37 
    let-7a-5p 0.737 4.64E-03 8mer 68-75 
    let-7i-5p 0.754 2.96E-03 7mer-A1 31-37 
    let-7i-5p 0.754 2.96E-03 8mer 68-75 
Ctif 2.223 6.55E-11  let-7e-5p 0.678 1.81E-04 7mer-m8 3824-3830 
    let-7c-5p 0.725 2.96E-03 7mer-m8 3824-3830 
    let-7a-5p 0.737 4.64E-03 7mer-m8 3824-3830 
    let-7i-5p 0.754 2.96E-03 7mer-m8 3824-3830 
Vangl2 2.219 1.54E-09  let-7e-5p 0.678 1.81E-04 7mer-A1 2107-2113 
    let-7e-5p 0.678 1.81E-04 7mer-m8 2910-2916 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2107-2113 
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    let-7c-5p 0.725 2.96E-03 7mer-m8 2910-2916 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2107-2113 
    let-7a-5p 0.737 4.64E-03 7mer-m8 2910-2916 
    let-7i-5p 0.754 2.96E-03 7mer-A1 2107-2113 
    let-7i-5p 0.754 2.96E-03 7mer-m8 2910-2916 
Crk 2.218 2.92E-09  let-7e-5p 0.678 1.81E-04 7mer-A1 1544-1550 
    let-7c-5p 0.725 2.96E-03 7mer-A1 1544-1550 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1544-1550 
    let-7i-5p 0.754 2.96E-03 7mer-A1 1544-1550 
     miR-320-3p 0.778 3.84E-03 7mer-m8 100-106 
Usf2 2.214 1.74E-18  miR-423-5p 0.746 7.22E-03 7mer-m8 76-82 
G3bp2 2.213 6.77E-07  miR-206-3p 0.664 2.84E-04 7mer-A1 920-926 
Zfp217 2.211 1.85E-04  miR-206-3p 0.664 2.84E-04 7mer-A1 1909-1915 
Khsrp 2.202 8.74E-13  miR-206-3p 0.664 2.84E-04 7mer-m8 1385-1391 
    let-7e-5p 0.678 1.81E-04 8mer 502-509 
    let-7c-5p 0.725 2.96E-03 8mer 502-509 
    let-7a-5p 0.737 4.64E-03 8mer 502-509 
    let-7i-5p 0.754 2.96E-03 8mer 502-509 
Tom1l2 2.202 2.71E-09  miR-423-5p 0.746 7.22E-03 8mer 2562-2569 
Kank4 2.201 7.37E-06  miR-206-3p 0.664 2.84E-04 7mer-m8 114-120 
Ddn 2.201 4.78E-06  let-7e-5p 0.678 1.81E-04 7mer-m8 1391-1397 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1391-1397 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1391-1397 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1391-1397 
Nfatc4 2.200 4.17E-03  miR-423-5p 0.746 7.22E-03 7mer-m8 703-709 
Slc16a3 2.199 3.29E-13  miR-1224-5p 0.626 2.78E-06 8mer 1920-1927 
    miR-206-3p 0.664 2.84E-04 7mer-A1 174-180 
     miR-134-5p 0.735 1.80E-04 8mer 1314-1321 
Gpc4 2.191 8.69E-07  let-7e-5p 0.678 1.81E-04 7mer-A1 2291-2297 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2291-2297 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2291-2297 
    let-7i-5p 0.754 2.96E-03 7mer-A1 2291-2297 
Fndc3b 2.189 8.67E-08  miR-1224-5p 0.626 2.78E-06 8mer 2682-2689 
    miR-206-3p 0.664 2.84E-04 8mer 2915-2922 
    let-7e-5p 0.678 1.81E-04 7mer-A1 1379-1385 
    let-7e-5p 0.678 1.81E-04 7mer-A1 2897-2903 
    let-7c-5p 0.725 2.96E-03 7mer-A1 1379-1385 
    let-7c-5p 0.725 2.96E-03 7mer-A1 2897-2903 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1379-1385 
    let-7a-5p 0.737 4.64E-03 7mer-A1 2897-2903 
    let-7i-5p 0.754 2.96E-03 7mer-A1 1379-1385 
    let-7i-5p 0.754 2.96E-03 7mer-A1 2897-2903 
    miR-219a-2-3p 0.777 9.18E-03 7mer-m8 2866-2872 
Amotl2 2.184 3.91E-12  miR-495-3p 0.670 8.82E-05 7mer-A1 1628-1634 
     miR-382-5p 0.708 2.21E-05 8mer 1487-1494 
Ephb4 2.183 8.90E-06  miR-423-5p 0.746 7.22E-03 7mer-m8 475-481 
     miR-219a-2-3p 0.777 9.18E-03 7mer-m8 1412-1418 
Cacng2 2.180 1.00E-14  miR-320-3p 0.778 3.84E-03 8mer 1419-1426 
Atad2b 2.179 6.05E-03  miR-411-5p 0.687 1.81E-04 7mer-m8 3134-3140 
Palm3 2.179 1.89E-05  let-7e-5p 0.678 1.81E-04 7mer-m8 41-47 
    let-7c-5p 0.725 2.96E-03 7mer-m8 41-47 
    let-7a-5p 0.737 4.64E-03 7mer-m8 41-47 
    let-7i-5p 0.754 2.96E-03 7mer-m8 41-47 
Zfp280b 2.172 6.28E-09  let-7e-5p 0.678 1.81E-04 8mer 2452-2459 
    let-7c-5p 0.725 2.96E-03 8mer 2452-2459 
    let-7a-5p 0.737 4.64E-03 8mer 2452-2459 
    let-7i-5p 0.754 2.96E-03 8mer 2452-2459 
Eaf1 2.172 4.45E-10  miR-206-3p 0.664 2.84E-04 8mer 2394-2401 
Gse1 2.170 7.42E-11  miR-495-3p 0.670 8.82E-05 7mer-m8 787-793 
     miR-495-3p 0.670 8.82E-05 7mer-m8 826-832 
     miR-495-3p 0.670 8.82E-05 7mer-m8 830-836 
1700017B05Rik 2.169 3.68E-08  let-7e-5p 0.678 1.81E-04 8mer 279-286 
    let-7c-5p 0.725 2.96E-03 8mer 279-286 
    let-7a-5p 0.737 4.64E-03 8mer 279-286 
    let-7i-5p 0.754 2.96E-03 8mer 279-286 
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Kcnd3 2.165 9.79E-09  miR-206-3p 0.664 2.84E-04 8mer 4480-4487 
Col3a1 2.163 1.37E-04  let-7e-5p 0.678 1.81E-04 8mer 403-410 
    let-7c-5p 0.725 2.96E-03 8mer 403-410 
    let-7a-5p 0.737 4.64E-03 8mer 403-410 
    let-7i-5p 0.754 2.96E-03 8mer 403-410 
Scube3 2.163 1.58E-05  let-7e-5p 0.678 1.81E-04 7mer-m8 897-903 
    let-7c-5p 0.725 2.96E-03 7mer-m8 897-903 
    let-7a-5p 0.737 4.64E-03 7mer-m8 897-903 
    let-7i-5p 0.754 2.96E-03 7mer-m8 897-903 
Mbtps2 2.163 4.85E-07  let-7e-5p 0.678 1.81E-04 7mer-m8 1373-1379 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1373-1379 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1373-1379 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1373-1379 
Igfbp4 2.162 2.76E-07  miR-320-3p 0.778 3.84E-03 8mer 353-360 
Prex1 2.162 5.74E-13  miR-206-3p 0.664 2.84E-04 8mer 397-404 
    miR-411-5p 0.687 1.81E-04 7mer-A1 811-817 
    miR-382-5p 0.708 2.21E-05 7mer-m8 796-802 
Epha2 2.159 3.44E-03  miR-206-3p 0.664 2.84E-04 7mer-m8 645-651 
Shank1 2.158 1.85E-08  miR-423-5p 0.746 7.22E-03 8mer 424-431 
Zbtb6 2.157 1.00E-07  miR-206-3p 0.664 2.84E-04 7mer-m8 2845-2851 
     miR-219a-2-3p 0.777 9.18E-03 8mer 427-434 
Traf7 2.154 1.50E-11  miR-495-3p 0.670 8.82E-05 7mer-A1 1553-1559 
Golga7b 2.153 7.05E-14  let-7e-5p 0.678 1.81E-04 8mer 1521-1528 
    let-7c-5p 0.725 2.96E-03 8mer 1521-1528 
    let-7a-5p 0.737 4.64E-03 8mer 1521-1528 
    let-7i-5p 0.754 2.96E-03 8mer 1521-1528 
Rimbp2 2.150 4.08E-07  miR-21c 0.609 2.84E-04 7mer-A1 60-66 
Cd276 2.148 4.83E-06  let-7e-5p 0.678 1.81E-04 7mer-A1 1476-1482 
    let-7c-5p 0.725 2.96E-03 7mer-A1 1476-1482 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1476-1482 
    let-7i-5p 0.754 2.96E-03 7mer-A1 1476-1482 
Chd4 2.147 1.86E-12  let-7e-5p 0.678 1.81E-04 7mer-m8 427-433 
    let-7c-5p 0.725 2.96E-03 7mer-m8 427-433 
    let-7a-5p 0.737 4.64E-03 7mer-m8 427-433 
    let-7i-5p 0.754 2.96E-03 7mer-m8 427-433 
Ets1 2.144 1.82E-07  miR-206-3p 0.664 2.84E-04 8mer 2885-2892 
     miR-495-3p 0.670 8.82E-05 7mer-m8 648-654 
     miR-495-3p 0.670 8.82E-05 7mer-m8 3268-3274 
Mfrp 2.144 4.67E-05  miR-411-5p 0.687 1.81E-04 8mer 1738-1745 
Atl3 2.141 1.06E-10  miR-320-3p 0.778 3.84E-03 7mer-m8 283-289 
Jph1 2.140 9.74E-09  miR-21c 0.609 2.84E-04 7mer-m8 2236-2242 
Eef2k 2.134 3.30E-11  let-7e-5p 0.678 1.81E-04 7mer-m8 638-644 
    let-7c-5p 0.725 2.96E-03 7mer-m8 638-644 
    let-7a-5p 0.737 4.64E-03 7mer-m8 638-644 
    let-7i-5p 0.754 2.96E-03 7mer-m8 638-644 
B930041F14Rik 2.134 1.60E-15  let-7e-5p 0.678 1.81E-04 7mer-m8 1228-1234 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1228-1234 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1228-1234 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1228-1234 
Rai1 2.128 3.69E-10  miR-1224-5p 0.626 2.78E-06 7mer-m8 817-823 
Fam155a 2.128 3.31E-15  miR-206-3p 0.664 2.84E-04 7mer-m8 1443-1449 
    miR-320-3p 0.778 3.84E-03 7mer-m8 200-206 
Dlgap4 2.120 4.00E-12  let-7e-5p 0.678 1.81E-04 8mer 1417-1424 
    let-7c-5p 0.725 2.96E-03 8mer 1417-1424 
    let-7a-5p 0.737 4.64E-03 8mer 1417-1424 
    let-7i-5p 0.754 2.96E-03 8mer 1417-1424 
Dlgap4 2.120 4.00E-12  miR-423-5p 0.746 7.22E-03 7mer-m8 1409-1415 
Slmap 2.120 2.01E-10  miR-21c 0.609 2.84E-04 7mer-m8 916-922 
Slit1 2.116 6.62E-14  miR-495-3p 0.670 8.82E-05 7mer-A1 3403-3409 
Ell2 2.115 1.58E-08  miR-495-3p 0.670 8.82E-05 8mer 225-232 
     miR-320-3p 0.778 3.84E-03 8mer 1059-1066 
Fam117b 2.115 3.20E-09  miR-206-3p 0.664 2.84E-04 8mer 1131-1138 
     miR-320-3p 0.778 3.84E-03 7mer-m8 512-518 
Tmem64 2.114 9.62E-06  miR-320-3p 0.778 3.84E-03 7mer-A1 891-897 
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     miR-320-3p 0.778 3.84E-03 8mer 952-959 
Ppargc1b 2.113 3.99E-04  miR-495-3p 0.670 8.82E-05 7mer-m8 5889-5895 
    miR-495-3p 0.670 8.82E-05 7mer-m8 5893-5899 
    miR-495-3p 0.670 8.82E-05 7mer-m8 5897-5903 
    miR-495-3p 0.670 8.82E-05 7mer-m8 5901-5907 
    let-7e-5p 0.678 1.81E-04 7mer-A1 24-30 
    let-7e-5p 0.678 1.81E-04 7mer-A1 32-38 
    let-7c-5p 0.725 2.96E-03 7mer-A1 24-30 
    let-7c-5p 0.725 2.96E-03 7mer-A1 32-38 
    let-7a-5p 0.737 4.64E-03 7mer-A1 24-30 
    let-7a-5p 0.737 4.64E-03 7mer-A1 32-38 
    let-7i-5p 0.754 2.96E-03 7mer-A1 24-30 
    let-7i-5p 0.754 2.96E-03 7mer-A1 32-38 
Adipor2 2.109 3.70E-03  let-7e-5p 0.678 1.81E-04 7mer-A1 182-188 
    let-7c-5p 0.725 2.96E-03 7mer-A1 182-188 
    let-7a-5p 0.737 4.64E-03 7mer-A1 182-188 
    let-7i-5p 0.754 2.96E-03 7mer-A1 182-188 
Rnf217 2.108 1.39E-07  let-7e-5p 0.678 1.81E-04 7mer-A1 9027-2033 
    let-7c-5p 0.725 2.96E-03 7mer-A1 9027-2033 
    let-7a-5p 0.737 4.64E-03 7mer-A1 9027-2033 
    let-7i-5p 0.754 2.96E-03 7mer-A1 9027-2033 
Sypl2 2.098 1.25E-03  miR-134-5p 0.735 1.80E-04 8mer 2662-2669 
Shank3 2.091 2.11E-10  miR-423-5p 0.746 7.22E-03 8mer 534-541 
Slc36a4 2.087 3.04E-10  miR-320-3p 0.778 3.84E-03 7mer-A1 1920-1926 
Sox11 2.088 9.24E-09  miR-495-3p 0.670 8.82E-05 7mer-m8 6593-6599 
Stk24 2.086 6.79E-09  let-7e-5p 0.678 1.81E-04 7mer-A1 670-676 
    let-7c-5p 0.725 2.96E-03 7mer-A1 670-676 
    let-7a-5p 0.737 4.64E-03 7mer-A1 670-676 
    let-7i-5p 0.754 2.96E-03 7mer-A1 670-676 
    miR-320-3p 0.778 3.84E-03 7mer-A1 797-803 
Dpp3 2.086 8.12E-13  let-7e-5p 0.678 1.81E-04 8mer 111-118 
    let-7c-5p 0.725 2.96E-03 8mer 111-118 
    let-7a-5p 0.737 4.64E-03 8mer 111-118 
    let-7i-5p 0.754 2.96E-03 8mer 111-118 
Lrrc14 2.084 2.09E-13  miR-134-5p 0.735 1.80E-04 8mer 1638-1645 
Hipk2 2.083 1.76E-07  let-7e-5p 0.678 1.81E-04 7mer-A1 7178-7184 
    let-7c-5p 0.725 2.96E-03 7mer-A1 7178-7184 
    let-7a-5p 0.737 4.64E-03 7mer-A1 7178-7184 
    let-7i-5p 0.754 2.96E-03 7mer-A1 7178-7184 
    miR-320-3p 0.778 3.84E-03 7mer-A1 6281-6287 
    miR-320-3p 0.778 3.84E-03 7mer-A1 9410-9416 
Efnb2 2.082 9.37E-07  miR-206-3p 0.664 2.84E-04 8mer 3086-3093 
Nek9 2.081 7.86E-12  let-7e-5p 0.678 1.81E-04 7mer-A1 270-276 
    let-7c-5p 0.725 2.96E-03 7mer-A1 270-276 
    let-7a-5p 0.737 4.64E-03 7mer-A1 270-276 
    let-7i-5p 0.754 2.96E-03 7mer-A1 270-276 
Rbfox1 2.078 1.98E-08  miR-206-3p 0.664 2.84E-04 7mer-A1 718-724 
    let-7e-5p 0.678 1.81E-04 7mer-A1 202-208 
    let-7c-5p 0.725 2.96E-03 7mer-A1 202-208 
    let-7a-5p 0.737 4.64E-03 7mer-A1 202-208 
    let-7i-5p 0.754 2.96E-03 7mer-A1 202-208 
Prrc1 2.075 5.37E-12  miR-206-3p 0.664 2.84E-04 7mer-A1 159-165 
Jund 2.074 6.18E-06  miR-206-3p 0.664 2.84E-04 7mer-m8 469-475 
Icmt 2.069 8.00E-09  miR-320-3p 0.778 3.84E-03 8mer 438-445 
Metrn 2.064 2.16E-05  miR-423-5p 0.746 7.22E-03 7mer-m8 540-546 
Fstl4 2.060 1.46E-03  let-7e-5p 0.678 1.81E-04 8mer 3391-3398 
    let-7c-5p 0.725 2.96E-03 8mer 3391-3398 
    let-7a-5p 0.737 4.64E-03 8mer 3391-3398 
    let-7i-5p 0.754 2.96E-03 8mer 3391-3398 
Mgat5 2.057 4.47E-11  miR-495-3p 0.670 8.82E-05 7mer-A1 3769-3775 
     miR-206-3p 0.664 2.84E-04 8mer 4448-4455 
Pbx3 2.056 3.03E-12  let-7e-5p 0.678 1.81E-04 7mer-A1 938-944 
    let-7e-5p 0.678 1.81E-04 7mer-m8 1005-1011 
    let-7c-5p 0.725 2.96E-03 7mer-A1 938-944 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1005-1011 
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    let-7a-5p 0.737 4.64E-03 7mer-A1 938-944 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1005-1011 
    let-7i-5p 0.754 2.96E-03 7mer-A1 938-944 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1005-1011 
    miR-320-3p 0.778 3.84E-03 8mer 218-225 
    miR-320-3p 0.778 3.84E-03 8mer 929-936 
2700081O15Rik 2.053 3.99E-09  miR-21c 0.609 2.84E-04 7mer-m8 102-1108 
Adora1 2.052 8.05E-08  miR-423-5p 0.746 7.22E-03 7mer-m8 508-514 
Mesdc1 2.048 5.01E-11  let-7e-5p 0.678 1.81E-04 7mer-A1 354-360 
    let-7c-5p 0.725 2.96E-03 7mer-A1 354-360 
    let-7a-5p 0.737 4.64E-03 7mer-A1 354-360 
    let-7i-5p 0.754 2.96E-03 7mer-A1 354-360 
Ttbk1 2.043 1.64E-11  miR-134-5p 0.735 1.80E-04 7mer-m8 2592-2598 
Magi2 2.039 8.83E-14  miR-206-3p 0.664 2.84E-04 7mer-A1 2431-2437 
    miR-134-5p 0.735 1.80E-04 7mer-A1 2517-2523 
     miR-320-3p 0.778 3.84E-03 7mer-A1 783-789 
Btbd11 2.037 1.03E-07  miR-495-3p 0.670 8.82E-05 8mer 1128-1135 
Klf3 2.034 7.56E-05  miR-21c 0.609 2.84E-04 8mer 3478-3485 
     miR-1224-5p 0.626 2.78E-06 7mer-m8 3674-3680 
Shisa7 2.033 2.48E-06  miR-320-3p 0.778 3.84E-03 7mer-m8 3507-3513 
Arf3 2.030 8.81E-12  miR-206-3p 0.664 2.84E-04 7mer-A1 227-233 
    miR-206-3p 0.664 2.84E-04 7mer-m8 2398-2404 
Ranbp9 2.028 1.35E-08  miR-495-3p 0.670 8.82E-05 7mer-m8 545-552 
Sp9 2.023 5.34E-05  miR-495-3p 0.670 8.82E-05 7mer-m8 1360-1366 
C77080 2.022 2.26E-07  miR-206-3p 0.664 2.84E-04 8mer 432-439 
Mta3 2.021 6.20E-09  miR-495-3p 0.670 8.82E-05 7mer-m8 53-59 
     miR-495-3p 0.670 8.82E-05 7mer-m8 57-63 
Emilin2 2.020 1.39E-05  miR-320-3p 0.778 3.84E-03 7mer-A1 39-45 
Egln2 2.019 3.56E-10  let-7e-5p 0.678 1.81E-04 7mer-A1 484-490 
    let-7c-5p 0.725 2.96E-03 7mer-A1 484-490 
    let-7a-5p 0.737 4.64E-03 7mer-A1 484-490 
    let-7i-5p 0.754 2.96E-03 7mer-A1 484-490 
Fbxo33 2.018 2.49E-07  miR-206-3p 0.664 2.84E-04 8mer 1156-1163 
Mink1 2.018 1.17E-09  miR-495-3p 0.670 8.82E-05 7mer-A1 737-743 
     miR-219a-2-3p 0.777 9.18E-03 8mer 750-757 
Map4k4 2.018 8.77E-09  let-7e-5p 0.678 1.81E-04 8mer 976-983 
    let-7c-5p 0.725 2.96E-03 8mer 976-983 
    let-7a-5p 0.737 4.64E-03 8mer 976-983 
    let-7i-5p 0.754 2.96E-03 8mer 976-983 
Acvr1 2.017 1.12E-08  miR-382-5p 0.708 2.21E-05 7mer-m8 635-641 
AI846148 2.016 8.48E-10  let-7e-5p 0.678 1.81E-04 7mer-m8 404-410 
    let-7c-5p 0.725 2.96E-03 7mer-m8 404-410 
    let-7a-5p 0.737 4.64E-03 7mer-m8 404-410 
    let-7i-5p 0.754 2.96E-03 7mer-m8 404-410 
Skida1 2.014 3.34E-06  miR-495-3p 0.670 8.82E-05 8mer 2936-2942 
    let-7e-5p 0.678 1.81E-04 7mer-A1 318-324 
    let-7c-5p 0.725 2.96E-03 7mer-A1 318-324 
    let-7a-5p 0.737 4.64E-03 7mer-A1 318-324 
    let-7i-5p 0.754 2.96E-03 7mer-A1 318-324 
Tspan33 2.014 1.17E-10  miR-495-3p 0.670 8.82E-05 7mer-m8 906-912 
Gsg1l 2.012 1.95E-09  let-7e-5p 0.678 1.81E-04 7mer-m8 1621-1627 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1621-1627 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1621-1627 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1621-1627 
Bahd1 2.010 6.68E-09  miR-21c 0.609 2.84E-04 7mer-m8 1500-1506 
    let-7e-5p 0.678 1.81E-04 7mer-A1 387-393 
    let-7c-5p 0.725 2.96E-03 7mer-A1 387-393 
    let-7a-5p 0.737 4.64E-03 7mer-A1 387-393 
    let-7i-5p 0.754 2.96E-03 7mer-A1 387-393 
    miR-320-3p 0.778 3.84E-03 8mer 381-388 
Ephb2 2.007 2.89E-13  miR-495-3p 0.670 8.82E-05 7mer-m8 826-832 
     miR-495-3p 0.670 8.82E-05 7mer-m8 895-901 
Pptc7 2.007 1.70E-08  let-7e-5p 0.678 1.81E-04 7mer-A1 1355-1361 
    let-7c-5p 0.725 2.96E-03 7mer-A1 1355-1361 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1355-1361 
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    let-7i-5p 0.754 2.96E-03 7mer-A1 1355-1361 
Tsc22d4 2.006 1.32E-14  miR-320-3p 0.778 3.84E-03 7mer-A1 86-92 
Tfip11 2.005 1.71E-11  miR-1224-5p 0.626 2.78E-06 7mer-m8 239-245 
Bpnt1 2.005 1.74E-10  miR-206-3p 0.664 2.84E-04 7mer-m8 866-872 
Cadm1 2.005 2.34E-08  miR-21c 0.609 2.84E-04 7mer-m8 2768-2774 
Nacc2 2.005 3.93E-09  miR-495-3p 0.670 8.82E-05 7mer-m8 3667-3673 
     miR-320-3p 0.778 3.84E-03 8mer 3536-3543 
Etv5 2.005 3.38E-06  miR-134-5p 0.735 1.80E-04 8mer 622-629 
Samd4 2.004 2.04E-11  miR-495-3p 0.670 8.82E-05 8mer 4126-4133 
Osbpl7 2.002 1.73E-06  miR-206-3p 0.664 2.84E-04 8mer 818-825 
Zbtb16 2.001 3.99E-03  let-7e-5p 0.678 1.81E-04 7mer-A1 1292-1298 
    let-7e-5p 0.678 1.81E-04 7mer-m8 1874-1880 
    let-7e-5p 0.678 1.81E-04 8mer 4746-4753 
    let-7c-5p 0.725 2.96E-03 7mer-A1 1292-1298 
    let-7c-5p 0.725 2.96E-03 7mer-m8 1874-1880 
    let-7c-5p 0.725 2.96E-03 8mer 4746-4753 
    let-7a-5p 0.737 4.64E-03 7mer-A1 1292-1298 
    let-7a-5p 0.737 4.64E-03 7mer-m8 1874-1880 
    let-7a-5p 0.737 4.64E-03 8mer 4746-4753 
    miR-423-5p 0.746 7.22E-03 8mer 537-544 
    let-7i-5p 0.754 2.96E-03 7mer-A1 1292-1298 
    let-7i-5p 0.754 2.96E-03 7mer-m8 1874-1880 
     let-7i-5p 0.754 2.96E-03 8mer 4746-4753 
Spred3 2.001 1.67E-12  let-7e-5p 0.678 1.81E-04 7mer-m8 2235-2241 
    let-7c-5p 0.725 2.96E-03 7mer-m8 2235-2241 
    let-7a-5p 0.737 4.64E-03 7mer-m8 2235-2241 
    let-7i-5p 0.754 2.96E-03 7mer-m8 2235-2241 
Eme2 2.001 5.67E-11  miR-1224-5p 0.626 2.78E-06 7mer-m8 1731-1737 
     miR-134-5p 0.735 1.80E-04 8mer 2270-2277 
Zfp825 0.494 2.71E-03  miR-181c-5p 1.325 2.96E-03 8mer 155-162 
     miR-181c-5p 1.325 2.96E-03 8mer 773-780 
Pik3c2a 0.481 8.03E-07  miR-219a-5p 1.858 2.44E-10 7mer-m8 1390-1396 
    miR-195a-5p 1.476 2.07E-04 7mer-A1 367-373 
    miR-23a-3p 1.401 3.50E-04 7mer-m8 2726-2732 
    miR-15a-5p 1.375 2.96E-03 7mer-A1 367-373 
    miR-124-3p 1.335 8.42E-03 8mer 519-526 
    miR-124-3p 1.335 8.42E-03 7mer-m8 1979-1985 
    miR-124-3p 1.335 8.42E-03 7mer-A1 2467-2473 
    miR-23b-3p 1.327 1.72E-03 7mer-m8 2726-2732 
Gm6710 0.465 3.85E-07  miR-181c-5p 1.325 2.96E-03 8mer 71-78 
Slc35a1 0.460 2.33E-06  miR-135a-5p 1.522 2.22E-05 7mer-m8 430-436 
     miR-135b-5p 1.451 1.38E-04 7mer-m8 430-436 
Tmed5 0.458 1.02E-08  miR-135a-5p 1.522 2.22E-05 8mer 1575-1582 
    miR-135b-5p 1.451 1.38E-04 8mer 1575-1582 
Gcnt1 0.452 8.58E-03  miR-23a-3p 1.401 3.50E-04 8mer 1353-1360 
     miR-23b-3p 1.327 1.72E-03 8mer 1353-1360 
A230046K03Rik 0.445 9.34E-11  miR-135a-5p 1.522 2.21E-05 8mer 648-655 
    miR-135b-5p 1.451 1.38E-04 8mer 648-655 
Crip3 0.443 7.44E-03  miR-195a-5p 1.476 2.07E-04 7mer-A1 16-22 
     miR-15a-5p 1.375 2.96E-03 7mer-A1 16-22 
Diap3 0.434 8.60E-05  miR-219a-5p 1.858 2.44E-10 8mer 819-826 
     miR-301a-3p 1.389 7.38E-04 8mer 950-957 
Gm14327 0.429 1.74E-10  miR-181c-5p 1.325 2.96E-03 8mer 1685-1692 
     miR-181c-5p 1.325 2.96E-03 8mer 1769-1776 
     miR-181c-5p 1.325 2.96E-03 8mer 1853-1860 
     miR-181c-5p 1.325 2.96E-03 8mer 2020-2027 
     miR-181c-5p 1.325 2.96E-03 8mer 2104-2111 
     miR-181c-5p 1.325 2.96E-03 8mer 2187-2194 
Gbp7 0.422 4.10E-04  miR-135a-5p 1.522 2.21E-05 7mer-m8 3356-3362 
    miR-135b-5p 1.451 1.38E-04 7mer-m8 3356-3362 
    miR-23a-3p 1.401 3.50E-04 8mer 3541-3548 
     miR-23b-3p 1.327 1.72E-03 8mer 3541-3548 
Ddx3y 0.414 3.41E-09  miR-19b-3p 1.524 2.21E-05 7mer-A1 1414-1420 
    miR-19b-3p 1.524 2.21E-05 8mer 1747-1754 
    miR-29c-3p 1.503 2.10E-05 7mer-A1 1346-1352 
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    miR-195a-5p 1.476 2.07E-04 8mer 1767-1774 
    miR-19a-3p 1.384 2.96E-03 7mer-A1 1414-1420 
    miR-19a-3p 1.384 2.96E-03 8mer 1747-1754 
    miR-15a-5p 1.375 2.96E-03 8mer 1767-1774 
    miR-124-3p 1.335 8.42E-03 7mer-m8 1284-1290 
    miR-29a-3p 1.300 2.79E-03 7mer-A1 1346-1352 
    miR-29b-3p 1.278 9.08E-03 7mer-A1 1346-1352 
Gm12689 0.346 01.18E-04  miR-342-3p 1.506 2.70E-04 8mer 738-745 
    miR-23a-3p 1.401 3.50E-04 8mer 421-428 
     miR-23b-3p 1.327 1.72E-03 8mer 421-428 
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2.D. Discussion 
 
Oral nicotine administration and spontaneous withdrawal is a valid model 
of acute and prolonged nicotine withdrawal-associated anxiety 
We used a mouse model of oral nicotine administration and spontaneous 
withdrawal to determine transcriptome-wide changes in miRNA and mRNA 
expression. Our lab has previously published that treatment with oral nicotine at 
this dose (200 µg/ml) results in nicotine dependence and measurement of serum 
cotinine, a biomarker for nicotine exposure, is consistent with those observed in 
heavy smokers (Lawson et al. 1998, Zhao-Shea et al. 2015). We further 
confirmed this was a valid model of nicotine dependence and withdrawal by 
assessing anxiety, one of the most prominent affective symptoms of nicotine 
withdrawal, 48 hours after cessation of chronic oral nicotine treatment. Mice in 
acute withdrawal (NAWD) did indeed show increased anxiety, burying more 
marbles during the MBT and spending less time in the open arms of the EPM 
compared to TA controls. These results are consistent with previous data 
published by Zhao-Shea et al., showing 6-week treatment with 200 µg/ml nicotine 
drinking solution followed by precipitated or spontaneous (24-hr) withdrawal is 
sufficient to induce activation of the IPN and increase anxiety in the MBT and 
EPM (Zhao-Shea et al. 2013).  
To determine the persistence of affective withdrawal symptoms, we also 
measured anxiety after a prolonged, 4-week withdrawal from a 6-week oral 
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nicotine treatment (NLWD). Interestingly, NLWD mice displayed increased 
anxiety in the EPM, but not the MBT. This is consistent with reports of human 
patients experiencing nicotine withdrawal, with affective symptoms peaking within 
the first week of withdrawal and lasting up to 2-4 weeks (Hughes 2007). In mice, 
somatic signs of withdrawal also peak within the first few days of withdrawal and 
then subside within a week (Damaj et al. 2003). Because the MBT uses a 
physical action (digging) as a measure of anxiety, there may be a contribution of 
physical discomfort and other somatic signs to the outcome of this test. This may 
explain why the anxious phenotype of NLWD mice as measured by the MBT is 
diminished to a non-statistically significant trend. Additionally, pharmacological 
assessment of the MBT suggests that this assay may be limited in its ability to 
evaluate anxiety. Diazepam, an anxiolytic, has been shown to decrease marble 
burying (Jimenez-Gomez et al. 2011). However, βCCM, a beta carboline known 
to be anxiogenic in rodents, is unable to increase marble burying in mice 
(Jimenez-Gomez et al. 2011). To confirm the anxious phenotype of NLWD mice 
observed in the EPM, at least one additional behavioral assay for anxiety, such 
as the open field test should be performed. The open field test may be provide 
more consistent results this assay has been used to detect anxiogenic effects 
during pharmacological testing (Prut and Belzung 2003).  
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Transcriptional Regulation of mRNAs in the Reward Circuitry by Nicotine 
Treatment and Withdrawal. 
 Transcriptome-wide expression changes in the mesocorticolimbic reward 
circuit induced by chronic nicotine treatment and withdrawal were measured by 
mRNA-Seq. Differential mRNA expression analysis identified an abundance of 
mRNAs significantly up- or down-regulated (FDR < 0.01) by nicotine treatment or 
withdrawal. To narrow our focus to mRNAs that undergo robust changes in 
expression, we considered only genes that exhibit fold changes > 2.  
In the NAc, there were widespread alterations in mRNA expression during 
chronic nicotine treatment compared to TA controls. These changes in gene 
expression are likely reflective of the activation the mesocorticolimbic reward 
pathway in response to nicotine exposure. This is supported by the GO analysis 
which shows up- or down regulated genes are enriched in terms related to the 
structure and function of the synapse, vesicle, and neuron projections. In addition, 
there is an enrichment of up-regulated genes in terms related to the 
mitochondrion and ribosome. Alterations in the expression of genes related to 
metabolic processes and the mitochondrial respiratory chain are consistent with 
a previous reports looking at the regulation of RNA in neocortical neurons after 
chronic nicotine treatment (Yang et al. 2017). The regulation of genes related to 
mitochondrial and ribosomal function may reflect efforts to fulfill the increased 
demands for energy and protein products in activated neurons.  
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In contrast, there are very few alterations in gene expression in the NAc 
when mice in acute nicotine withdrawal were compared to TA controls. This 
would suggest that in the NAc, the majority of genes regulated by chronic 
nicotine exposure rapidly return to the expression levels observed in drug-naïve 
animals after nicotine cessation. However, there is a small subset of genes that 
remain similarly altered when Nic and NAWD are compared to TA controls. This 
suggests that this select group of genes is differentially expressed during chronic 
nicotine exposure and these changes in expression persist for at least 48 hours 
after nicotine is spontaneously withdrawn. If regulation of mRNA level was the 
consequence solely of nicotine withdrawal (Figure 2.13 orange), expression of a 
gene would be similarly altered when NAWD mice are compared to either TA- or 
Nic-treated mice. Because there is no commonality among the genes that are 
differentially expressed when NAWD mice are compared to TA or Nic, the initial 
nicotine exposure itself must have some contribution to all of the differential 
expression observed in acute nicotine withdrawal. The propensity for mRNA 
expression to rapidly return to control levels after nicotine exposure is ceased 
makes it unlikely that gene regulation at the transcript level in the NAc 
contributes to anxiety behaviors observed in acute nicotine withdrawal. 
 Chronic nicotine treatment also induces extensive changes in mRNA 
expression in the midbrain. In contrast to the NAc, there are few genes regulated 
in the midbrain only during chronic nicotine treatment, rapidly returning 
expression levels indistinguishable from drug-naïve animals during acute 
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withdrawal. The majority (~92%) of genes differentially expressed during chronic 
nicotine exposure are similarly altered in NAWD mice compared to TA controls. 
Hence, regulation of these mRNAs, representing ~30% of all genes differentially 
expressed during acute withdrawal, is initially a consequence of the chronic 
nicotine treatment, with the effect persisting for at least 48 hours after 
spontaneous withdrawal. Of the remaining mRNAs altered during acute nicotine 
withdrawal, a subset of only 30 mRNAs are similarly differentially expressed in 
NAWD compared to either TA or Nic mice. This indicates that only a small 
fraction (~2%) of all genes altered during acute withdrawal are up- or down-
regulated solely after nicotine is withdrawn, with no effects of nicotine treatment 
contributing to their regulation. Stated another way, chronic nicotine treatment 
itself contributes at least partly to the regulation of the majority of mRNAs 
differentially expressed during acute nicotine withdrawal. This conclusion is 
further supported by the GO analysis. In the midbrain, the terms describing the 
CC, MF and BP that are significantly enriched in genes up- or down-regulated 
during nicotine treatment or acute withdrawal are largely the same. Similar to the 
NAc, nicotine (and withdrawal) responsive genes are overrepresented in GO 
terms that likely reflect neuroadaptations induced by the activation of the 
mesocorticolimbic circuit during nicotine treatment, including those related to the 
structure and function of the synapse, vesicle, and neuron projections. 
While the majority of differentially expressed genes in both the NAc and 
midbrain are regulated as a consequence of nicotine exposure itself, the 
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persistence of these expression changes during acute nicotine withdrawal are 
only observed in midbrain punches, enriched for the VTA. Although traditionally 
thought of as part of the reward circuitry, the VTA is also interconnected with the 
habenulo-interpeduncular withdrawal circuitry and plays a role in nicotine 
withdrawal-associated anxiety (Zhao-Shea et al. 2015, Molas et al. 2017). In light 
of this dual role of the VTA, our results lead to the hypothesis that differential 
expression of mRNAs in the midbrain occurring after chronic nicotine exposure 
and acute withdrawal may be involved in the molecular mechanisms underlying 
nicotine withdrawal symptoms including anxiety. These genes and their neuronal 
functions should be the focus of future studies. 
Although the NAc and midbrain both show widespread differential 
expression of genes induced by chronic nicotine treatment, only 1 is similarly 
regulated in both brain regions. Thus, expression in NAc and midbrain are 
regulated by nicotine in a brain-region specific manner. Further supporting this, 
GO analysis revealed that reciprocally regulated mRNAs in the NAc and midbrain 
were enriched in the same CC, BP, and MF terms. For example, GO terms 
related to neuron projections, the synapse, receptor binding, regulation of 
neurotransmitter levels, and cell-to-cell communication are significantly enriched 
in genes that are down-regulated in the NAc and up-regulated in the midbrain 
during chronic nicotine treatment. This inverse relationship reflects the brain-
region specificity of neuroadaptative mechanisms induced by chronic nicotine 
exposure. Both brain regions show enrichment of CC, BP, and MF terms related 
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to heterocycle metabolism in up- and down-regulated genes. This may reflect the 
induction of compensatory mechanisms to metabolize nicotine, a heterocyclic 
compound.  
Differential expression analysis identified only 40 mRNAs in the NAc and 1 
mRNA in the midbrain that were uniquely altered after a prolonged nicotine 
withdrawal compared to age-matched TAL controls. This suggests their up- or 
down-regulation occurs over a longer time course (beyond the acute 48-hour 
time point) and persists for at least 4 weeks. Interestingly, synaptic depression in 
the NAc shell is observed in acute withdrawal (24hr) from cocaine, while 
potentiation is observed after a long (10-14 days) withdrawal (Kourrich et al. 
2007). It is believed this effect is a function of time, as further work determined 
prolonged cocaine treatment in the absence of withdrawal also induced 
potentiation at the glutamatergic synapses of NAc MSNs (Dobi et al. 2011). 
Delayed sensitization of DA responses to nicotine has also been observed in the 
NAc. Exposure to nicotine 3 weeks prior was sufficient to enhance electrically 
evoked [3H]DA release from the NAc in slice (Schoffelmeer et al. 2002). The 
differential expression observed in the NAc of NLWD mice may reflect this 
delayed sensitization to nicotine stimulation. Because mice remain anxious for 4 
weeks after withdrawal, regulation of this limited group of genes may also 
contribute to the neuroadaptations underlying persistent anxiety induced by 
nicotine withdrawal and should be the subject of future studies. 
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Regulation of miRNAs and their targets in the reward circuitry during 
chronic nicotine treatment and withdrawal. 
Integrated differential expression analysis of miRNA- and mRNA-Seq data 
was used in conjunction with TargetScan Mouse 7.1 to identify predicted targets 
of conserved miRNAs up- or down-regulated during nicotine treatment and acute 
withdrawal. Because miRNAs are traditionally negative regulators of gene 
expression (Bartel 2018), only inversely regulated mRNA targets were identified. 
Additionally, because conservation strengthens the validity of miRNA target 
prediction (Friedman et al. 2009), only conserved miRNAs and MREs were 
considered in this analysis. 
 Differential expression of miRNAs by chronic nicotine treatment and acute 
withdrawal in the NAc, follows the same pattern observed for the mRNAs. 
Generally, in the NAc, alterations in miRNA expression occur during chronic 
nicotine treatment and then rapidly return to control levels after nicotine is 
withdrawn. There are only 8 conserved miRNAs differentially expressed during 
nicotine treatment compared to TA controls. Despite their limited quantity, these 
miRNAs are predicted to target conserved MREs within the 3ʹ-UTR of at least 
one of 204 inversely regulated mRNAs. This means that ~24% of all nicotine 
responsive mRNAs are predicted targets of anti-correlated, conserved miRNAs. 
Also, all but 10 of the predicted targets return to control expression levels during 
acute nicotine withdrawal, as observed for all of the miRNAs themselves. Each of 
the miRNAs differentially expressed in the NAc during nicotine treatment are up- 
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or down-regulated with small fold changes (FC > 1.5). However, the presence of 
more than one predicted MRE within the 3ʹ-UTR of ~40% of the predicted mRNA 
targets increase the likelihood that miRNAs play a biologically important role in 
the regulation of mRNAs by chronic nicotine treatment in the NAc. 
 In contrast to the NAc, the midbrain has only 3 miRNAs differentially 
expressed by nicotine treatment. Furthermore, the expression of only one 
predicted mRNA target is anti-correlated. However, when NAWD mice are 
compared to TA controls, 54 conserved miRNAs are differentially expressed. 
Thirty of these miRNAs were predicted to target a conserved MRE within the 3ʹ-
UTR of at least one of 380 inversely regulated mRNAs. Again, all of the miRNAs 
are up- or down-regulated with modest fold changes (FC <2). However, about 
half of the mRNA targets contain multiple MREs for the same or distinct miRNAs, 
supporting the hypothesis that the limited number of modestly differentially 
expressed miRNAs contributes to the regulation of mRNAs in the midbrain during 
acute nicotine withdrawal.  
 Of the 380 predicted mRNAs predicted to be targets of inversely 
expressed miRNAs in NAWD mice compared to TA controls, 105 (~28%) are 
similarly differentially expressed during nicotine treatment alone. Additionally, 
only 7 (~2%) of the predicted mRNA targets are similarly differentially expressed 
in NAWD mice compared to either TA or Nic, meaning their regulation is in effect 
solely of withdrawal. This suggests that while miRNAs do not play a significant 
role in the initial regulation of genes in the midbrain by chronic nicotine treatment, 
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the induction of miRNAs observed during acute nicotine withdrawal contributes to 
the propensity of nicotine responsive genes to remain persistently differentially 
expressed during nicotine withdrawal.  
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Chapter 3 
Integrated miRNA-/mRNA-Seq Analysis of the Habenulo-Interpeduncular 
Circuitry During Chronic Nicotine Treatment and Withdrawal 
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3.A. Introduction 
Tobacco use is a prevalent health problem worldwide, with more than 900 
million daily smokers (Peacock et al. 2018) and an estimated 6 million deaths 
due to tobacco-related illnesses annually (WHO 2012).  The few pharmacological 
cessation aids currently available have limited efficacy (Jorenby et al. 2006, 
Cinciripini et al. 2013, Koegelenberg et al. 2014, Kotz et al. 2014), and without 
the intervention of new effective treatments, tobacco-related mortality is 
anticipated to rise to 8 million deaths per year (WHO 2012). 
 The addictive component of tobacco is nicotine, a tertiary alkaloid that is 
an agonist of nicotinic acetylcholine receptors (nAChRs), ligand-gated ion 
channels endogenously activated by acetylcholine (Albuquerque et al. 2009). 
nAChRs are enriched in the mesolimbic and habenulo-interpeduncular circuitries 
underlying nicotine reward and withdrawal, respectively (Dani and De Biasi 2013, 
Picciotto and Mineur 2014, Molas et al. 2017). Cessation of nicotine induces a 
withdrawal syndrome consisting of negative somatic, affective and cognitive 
symptoms. Affective symptoms primarily include depressed mood, irritability, 
craving and anxiety (Hughes 2007, Jackson et al. 2015). While the rewarding 
properties of nicotine dominate initial drug-taking, it is largely avoidance of 
affective withdrawal symptoms that promotes relapse and habitual use (Allen et 
al. 2008, Koob and Le Moal 2008). 
 The habenulo-interpeduncular withdrawal circuitry consists primarily of 
neurons projecting from the medial habenula (MHb), a paired epithalamic 
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nucleus, to the interpeduncular nucleus (IPN), a single symmetrical nucleus in 
the midbrain, via the fasciculus retroflexus (Antolin-Fontes et al. 2015, Molas et 
al. 2017). In mice experiencing spontaneous nicotine withdrawal, there is 
increased glutamate release from habenular axon terminals, activating 
GABAergic neurons in the IPN (Zhao-Shea et al. 2013). Activation of the IPN 
results in the increased somatic signs and anxiety observed during nicotine 
withdrawal (Zhao-Shea et al. 2013, Zhao-Shea et al. 2015). Optogenetic 
investigation of this circuit has revealed that silencing the MHb decreases 
activation of IPN neurons and decreases anxiety during nicotine withdrawal 
(Zhao-Shea et al. 2015). 
 While much is known about the neurocircuitry responsible for nicotine 
withdrawal-associated anxiety and somatic symptoms, the molecular 
mechanisms underlying the induction of these behavioral alterations are less 
clear. Chronic drug exposure induces stable neuroadaptations underlying the 
compulsion for continued use and susceptibility to relapse. These long-lasting 
changes in the addicted brain’s function are thought to require alterations of gene 
expression through regulation of transcription factors, epigenetic mechanisms, 
and non-coding RNAs (Robison and Nestler 2011, Madsen et al. 2012).   
 microRNAs (miRNAs) are non-coding RNA molecules ~22 nucleotides in 
length that repress the expression of mRNA targets by promoting mRNA decay 
or translational repression (Bartel 2018). miRNAs recognize their targets through 
imperfect base-pairing of the seed region (nucleotides 2-7) with miRNA response 
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elements (MREs) within the 3ʹ-UTRs of mRNAs (Lewis et al. 2003, Bartel 2009). 
Tobacco smoke and nicotine have been shown to regulate the expression of 
miRNAs in various cell lines, organisms, and tissues (Izzotti et al. 2009, Shan et 
al. 2009, Izzotti et al. 2011, Takahashi et al. 2013, Zhang et al. 2014) .  
 Dysregulation of miRNAs in the brain have been shown to contribute to 
neurodevelopmental and neuropsychiatric disorders, including drug addiction 
(Hollander et al. 2010, Im and Kenny 2012). However, little is known about the 
role of miRNAs in the mechanisms underlying nicotine dependence and 
withdrawal. Few studies have examined the regulation of miRNAs by nicotine in 
specific regions of the mammalian brain (Lippi et al. 2011, Hogan et al. 2014, Lee 
et al. 2015). Previously, we showed that the expression of miRNAs predicted to 
target MREs within the 3ʹ-UTRs of nAChRs was altered after chronic nicotine 
treatment in whole brain or a specific brain region (Hogan et al. 2014). Nicotine 
has been reported to regulate miRNAs and mRNAs in the MHb, with microarrays 
detecting expression changes in mice self-administering nicotine (Lee et al. 
2015). However, the targets of these miRNAs and their functions in the context of 
nicotine dependence have not been elucidated. 
 Using integrated miRNA- and mRNA-Seq, we asked whether there are 
changes in miRNA and mRNA expression in the MHb and IPN chronic nicotine 
treatment and during acute nicotine withdrawal. We hypothesize that use of 
these valuable sequencing datasets makes it possible to identify a multitude of 
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miRNAs/genes playing a role(s) in the molecular mechanisms underlying the 
neuroadaptations involved in nicotine dependence. 
 
 
3.B. Materials and Methods 
  
Materials and Methods are identical to those appearing in Chapter 2.B unless 
otherwise noted. 
 
Tissue Collection and RNA Isolation 
The same brains used for transcriptome analysis of the mesocorticolimbic 
pathway were used for these experiments. Fresh frozen brains were coronally 
sliced (~1 mm) and the MHb and IPN were dissected using a circular tissue 
punch. The MHb and IPN were each extracted using a single midline 0.75 mm 
diameter punch and expelled into lysis buffer (miRVANA Total RNA Isolation Kit). 
Each sample for sequencing consisted of punches from 4 brains combined. 
Additional mice were treated for RT-qPCR validation of the differential expression 
analysis, pooling tissue from 2 brains per sample. RNA isolation proceeded as 
described in in Chapter 2.B. 
 
Quantitative Reverse Transcription-PCR (RT-qPCR) 
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RT-qPCR for miRNAs and mRNAs was performed as previously 
described (Hogan et al. 2014). RNA was reverse transcribed by MMLV-reverse 
transcriptase (ThermoFisher Cat. # 28025013 or AM2043) using random 
decamers or miRNA-specific primers according to the manufacturer’s instruction. 
Quantitative PCR was performed on a Applied Biosystems 7500 Real-Time PCR 
System using TaqMan miRNA and gene expression assays (ThermoFisher) for 
miR-106b-5p (Assay ID 000442), Pfn2 (Assay ID Mm01289572_m1), Pfn1 
(Assay ID Mm00726691_s1), Atg7 (Assay ID Mm00512209_m1), Arf5 (Assay ID 
Mm00500199_m1), Bcl2l1 (Assay ID Mm00437783_m1), and Eif5a (Assay ID 
Mm01245535_m1). Reactions were performed in technical triplicates. Relative 
miRNA/gene expression was determined using the 2−ΔΔCt method (Livak and 
Schmittgen 2001). miRNA and mRNA expression were normalized to 
snoRNA202 (Assay ID 001232) and β-glucuronidase (Assay ID 
Mm01197698_m1), respectively, unless otherwise noted. 
 
 
3.C. Results 
 
Differential expression of miRNAs and mRNAs in the MHb and IPN after 
chronic  nicotine-treatment and acute withdrawal. 
To determine the effect of chronic nicotine treatment and withdrawal on 
the miRNA and mRNA expression in the withdrawal circuit, we sequenced RNAs 
	134 
isolated from the MHb and IPN and performed differential expression analysis. 
RNA for these sequencing libraries was extracted from tissue samples dissected 
from the same brains as those used to investigate regulation of transcripts in the 
mesocorticolimbic pathway described in Chapter 2.   
In the withdrawal circuit, there were few miRNAs differentially expressed 
after chronic nicotine treatment. In the IPN, only 8 miRNAs were significantly 
altered when Nic mice are compared to TA controls (Figure 3.1A). The majority 
of these miRNAs were only modestly regulated, with only 2 exhibiting fold 
changes > 2. Seven miRNAs were down-regulated by nicotine treatment and all 
of these are persistently repressed after a 48-hr withdrawal, when NAWD mice 
are compared to TA controls (Figures 3.1E and 3.6A). In the MHb, there were 
only 6 differentially expressed miRNAs in Nic mice compared to TA controls 
(Figure 3.1C), all with fold changes < 2. Only 1 of these miRNAs remained 
similarly regulated after nicotine was discontinued, comparing NAWD- to TA- 
treated mice (Figures 3.1G and 3.6B).  
However, after acute nicotine withdrawal, a multitude of miRNAs in the 
withdrawal circuit exhibit significant, albeit small, changes in expression level. In 
the IPN, there was a total of 87 miRNAs significantly differentially expressed in 
NAWD mice compared to TA controls (Figures 3.1E and 3.2), with only 11 being 
up- or down-regulated with a fold change > 2. The distribution between up- and 
down-regulated miRNAs is roughly equal, with 42 being enhanced and 45 
repressed. Twenty-nine (~33%) of these miRNAs were similarly differentially 
	135 
expressed when NAWD mice are compared to either TA or Nic mice (Figures 
3.1I and 3.6A). This suggests that nicotine exposure itself had no effect on their 
expression and regulation of these miRNAs in the IPN is due entirely to 
withdrawal. 
 Similar to the IPN, there were 85 miRNAs differentially expressed in the 
MHb of mice in acute nicotine withdrawal compared to TA controls (Figures 3.1G 
and 3.3). The majority of these miRNAs are only modestly regulated, with only 2 
miRNAs exhibiting fold changes > 2. Thirty-five and 50 of the miRNAs 
differentially expressed during acute nicotine withdrawal were up- and down-
regulated, respectively. Forty miRNAs were similarly differentially expressed in 
NAWD mice when compared to either TA or Nic (Figures 3.1K and 3.6B). This 
suggests that regulation of almost half the miRNAs altered during acute nicotine 
withdrawal in the MHb is solely the result of withdrawal, with no contribution of 
the chronic nicotine treatment itself. 
None of the miRNAs regulated by chronic nicotine treatment are 
differentially expressed in both the IPN and MHb, suggesting that nicotine-
induced miRNA regulation in the MHb-IPN axis occurs in a brain-region specific 
manner. Of the miRNAs regulated during acute nicotine withdrawal compared to 
TA controls, only 16 miRNAs are similarly differentially expressed in both the IPN 
and MHb. This suggests that while there are some commonly regulated miRNAs 
in the withdrawal circuit, the majority of miRNA regulation during acute nicotine 
withdrawal also occurs in a brain region-specific manner. 
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In a pattern similar to miRNAs, there were few mRNAs significantly 
differentially expressed (with a fold change > 2) by chronic nicotine treatment in 
the IPN and MHb. In the IPN, there were only 4 differentially expressed mRNAs 
in Nic mice compared to TA controls (Figure 3.1B), all of them up-regulated. 
None of these mRNAs were similarly differentially expressed in NAWD mice 
compared to TA control, suggesting all of them returned to control expression 
levels within 48 hours of nicotine withdrawal (Figure 3.6C).  
In the MHb, chronic nicotine treatment resulted in the differential 
expression of 26 mRNAs compared to TA controls (Figure 3.1D), with 18 up- and 
8 down-regulated. Only 2 of these mRNAs are similarly differentially expressed in 
NAWD mice compared to TA controls, suggesting that the majority of mRNAs 
regulated during chronic nicotine rapidly return to baseline expression levels after 
nicotine is withdrawn (Figure 3.6D). 
In contrast to chronic nicotine treatment alone, there are many mRNAs 
differentially expressed in the MHb-IPN axis during acute nicotine withdrawal. In 
the IPN, 335 genes were significantly differentially expressed with a fold change > 
2 (Figures 3.1F and 3.4). The expression of the majority of these mRNAs is 
increased, with 292 up- and 43 down-regulated. Of these mRNAs, 303 (~90%) 
were similarly altered when NAWD mice are compared to either Nic or TA mice, 
suggesting their regulation was an effect of acute nicotine withdrawal and there 
was no effect of nicotine treatment alone (Figures 3.1J and 3.6C).  
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In the MHb, there were 154 mRNAs significantly differentially expressed 
with a fold change > 2 during acute nicotine withdrawal compared to TA controls. 
Almost all mRNAs were up-regulated in NAWD mice, with only 3 exhibiting down-
regulation (Figures 3.1H and 3.5). Additionally, 122 (~79%) of genes regulated 
when NAWD is compared to TA are similarly up- or down-regulated when 
compared to Nic mice (Figures 3.1L and 3.6D). This indicates that the majority of 
genes are altered during acute withdrawal as a result of nicotine withdrawal, and 
chronic nicotine treatment itself does not contribute to their regulation. 
To determine that brain region specificity of changes in gene expression 
during chronic nicotine treatment and withdrawal in the withdrawal circuitry, the 
identity of mRNAs up- or down-regulated in the IPN and MHb were compared. 
There were no mRNAs similarly differentially expressed (FDR 0.01, FC > 2) in 
both the IPN and MHb of Nic mice compared to TA controls. Additionally, there 
were no mRNAs differentially expressed in both brain regions of NAWD 
compared to TA mice. This suggests that mRNAs are regulated by chronic 
nicotine and withdrawal in a brain region specific manner in the MHb-IPN axis. 
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Figure 3.1. Differential expression of miRNAs and mRNAs within the MHb-
IPN withdrawal axis during chronic nicotine treatment and acute withdrawal. 
Scatter plots display differential expression of miRNAs or mRNAs in the IPN (A-B, 
E-F, I-J) and MHb (C-D, G-H, K-L) measured by deep sequencing. RNAs 
isolated from tissue punches of nicotine-treated (Nic, A-D) and acute withdrawal 
(NAWD, E-H) mice are compared to TA-treated controls. NAWD mice were also 
compared to Nic mice (I-L).  Each dot represents an individual miRNA or mRNA 
plotted as log2(RPM) or log2(TPM), respectively. All miRNAs with a FDR < 0.01 
and mRNAs with FDR < 0.01 and FC > 2 are highlighted in color. Orange dots 
are up-regulated in TA, green dots are up-regulated in Nic, and red dots are up-
regulated in NAWD in each comparison. Only miRNAs with RPM > 0 and mRNAs 
with TPM > 0 in at least half of the replicates in each treatment group are shown. 
n = 4-5, with each library synthesized using pooled RNA from 4 mice.  
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Figure 3.2. Relative 
expression heatmap of 
miRNAs differentially 
expressed in the IPN 
during acute nicotine 
withdrawal. Heat map 
displaying miRNAs that are 
significantly differentially 
expressed in the IPN during 
acute withdrawal compared 
to TA controls (left). Each 
column represents an 
individual biological replicate 
of mice treated chronically 
with nicotine (Nic) or acute 
nicotine withdrawal (NAWD). 
Each replicate contained 
RNA pooled from 4 mice. 
The colors represent fold 
change, calculated as read 
per million (RPM) normalized 
to the average RPM of the 
TA control group. Red 
represents up-regulation and 
blue represents down-
regulation.  
  
N
ic
1
N
ic
2
N
ic
3
N
ic
4
N
ic
5
N
A
W
D
1
N
A
W
D
2
N
A
W
D
3
N
A
W
D
4
N
A
W
D
5
mmu-miR-199b-5p 5
mmu-miR-341-5p
mmu-miR-497a-5p
mmu-miR-540-5p
mmu-miR-34a-5p
mmu-miR-34b-5p
mmu-miR-339-5p 0
mmu-miR-15a-3p
mmu-miR-106b-5p
mmu-miR-378a-5p
mmu-miR-879-5p
mmu-miR-143-5p
mmu-miR-219a-5p
mmu-miR-490-5p
mmu-miR-93-3p
mmu-miR-484
mmu-miR-33-5p
mmu-miR-700-3p
mmu-miR-503-5p
mmu-miR-381-5p
mmu-miR-199a-5p
mmu-miR-450a-5p
mmu-miR-29c-5p
mmu-miR-7689-3p
mmu-miR-339-3p
mmu-miR-425-3p
mmu-miR-665-3p
mmu-miR-99a-3p
mmu-miR-142a-3p
mmu-miR-199b-3p
mmu-miR-199a-3p
mmu-miR-455-3p
mmu-miR-337-5p
mmu-miR-27a-3p
mmu-miR-674-5p
mmu-miR-154-5p
mmu-miR-140-5p
mmu-let-7e-3p
mmu-miR-340-3p
mmu-miR-324-5p
mmu-miR-376b-5p
mmu-miR-328-3p
mmu-miR-151-3p
mmu-let-7c-5p
mmu-miR-1981-5p
mmu-miR-9-5p
mmu-miR-485-5p
mmu-miR-344b-3p
mmu-miR-488-3p
mmu-miR-379-5p
mmu-miR-130b-5p
mmu-let-7b-5p
mmu-miR-344d-3p
mmu-miR-340-5p
mmu-miR-532-5p
mmu-let-7f-5p
mmu-miR-132-3p
mmu-miR-29b-3p
mmu-miR-129-5p
mmu-miR-7b-5p
mmu-miR-380-5p
mmu-miR-3535
mmu-miR-181b-5p
mmu-miR-181d-5p
mmu-miR-1839-5p
mmu-miR-101c
mmu-miR-135a-2-3p
mmu-miR-365-3p
mmu-miR-382-3p
mmu-miR-30a-3p
mmu-miR-541-5p
mmu-miR-30e-3p
mmu-miR-582-3p
mmu-miR-653-5p
mmu-miR-221-5p
mmu-miR-136-5p
mmu-miR-377-3p
mmu-miR-1843a-3p
mmu-miR-129-2-3p
mmu-miR-129-1-3p
mmu-miR-141-3p
mmu-miR-200a-3p
mmu-miR-200b-3p
mmu-miR-429-3p
mmu-miR-183-5p
mmu-miR-182-5p
mmu-miR-96-5p
	140 
Figure 3.3. Relative 
expression heatmap of 
miRNAs differentially 
expressed in the MHb 
during acute nicotine 
withdrawal. Heat map 
displaying miRNAs that are 
significantly differentially 
expressed in the MHb during 
acute withdrawal compared 
to TA controls (left). Each 
column represents an 
individual biological replicate 
of mice treated chronically 
with nicotine (Nic) or acute 
nicotine withdrawal (NAWD). 
Each replicate contained 
RNA pooled from 4 mice. 
The colors represent fold 
change, calculated as read 
per million (RPM) normalized 
to the average RPM of the 
TA control group. Red 
represents up-regulation and 
blue represents down-
regulation. 
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Figure 3.4. Relative expression 
heatmap of mRNAs differentially 
expressed in the IPN acute 
nicotine withdrawal. Heat map 
displaying the 50 most up-
regulated and all down-regulated 
mRNAs in the NAc during acute 
nicotine withdrawal relative to TA 
controls (left). Each column 
represents an individual biological 
replicate of mice treated chronically 
with nicotine (Nic) or acute nicotine 
withdrawal (NAWD). Each replicate 
contained RNA pooled from 4 mice. 
The colors represent fold change, 
calculated as transcript per million 
(TPM) normalized to the average 
TPM of the TA control group. Red 
represents up-regulation and blue 
represents down-regulation. Only 
mRNAs with TPM > 0 in more than 
half of the replicates were included. 
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Figure 3.5. Relative 
expression heatmap of 
mRNAs differentially 
expressed in the MHb 
during acute nicotine 
withdrawal. Heat map 
displaying the 50 most up-
regulated and all down-
regulated mRNAs in the 
MHb during acute nicotine 
withdrawal relative to TA 
controls (left). Each column 
represents an individual 
biological replicate of mice 
treated chronically with 
nicotine (Nic) or acute 
nicotine withdrawal (NAWD). 
Each replicate contained 
RNA pooled from 4 mice. 
The colors represent fold 
change, calculated as 
transcript per million (TPM) 
normalized to the average 
TPM of the TA control group. 
Red represents up-
regulation and blue 
represents down-regulation. 
Only mRNAs with TPM > 0 
in more than half of the 
replicates were included. 
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Figure 3.6. Overlap of similarly differentially expressed miRNAs and 
mRNAs between treatment conditions within the IPN and MHb. Venn 
diagrams showing numbers of differentially expressed miRNAs (FDR < 0.01) and 
mRNAs (FDR < 0.01, FC > 2) in the IPN (A,B) and MHb (C,D) in each treatment 
condition, designated by color. Regions where the circles overlap indicate that 
the transcripts are similarly up- or down-regulated in both conditions. Numbers 
indicate the number of miRNAs or mRNAs. 
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Differential expression of miRNAs/mRNAs in the MHb and IPN after 
prolonged nicotine withdrawal. 
To determine the persistence of the alterations in miRNA and mRNA 
expression following acute nicotine withdrawal, another group of mice underwent 
a long (4-week) withdrawal after chronic nicotine treatment (NLWD). Interestingly, 
there were no significantly differentially expressed miRNAs in either the IPN or 
MHb of NLWD mice compared to age-matched TA-treated (TAL) controls 
(Figures 3.7A and 3.7C). Similarly, there are no mRNAs differentially expressed 
with a fold change > 2 in the MHb of NLWD mice compared to TAL controls 
(Figure 3.7D). In the IPN, 39 genes were differentially expressed after prolonged 
withdrawal (Figure 3.7B). However, none of these genes were also similarly 
regulated after acute withdrawal. 
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Figure 3.7. Differential expression of miRNAs and mRNAs in the IPN and 
MHb of NLWD- and TAL-treated mice. Scatter plots display differential 
expression of miRNAs or mRNAs in the IPN (A, B) and MHb (C, D) measured by 
deep sequencing. miRNAs (A, C)  and mRNAs (B, D) isolated from mice after a 
long (4-week) withdrawal from nicotine (NLWD) are compared to age-matched 
TA-treated controls (TAL). Each dot represents an individual miRNA or mRNA 
plotted as log2(RPM) and log2(TPM), respectively. miRNAs (FDR < 0.01) and 
mRNAs (FDR < 0.01, FC >2) that are up-regulated (purple) and down-regulated 
(brown) in NLWD mice are highlighted. All miRNAs have RPM > 0 and all 
mRNAs have TPM > 0 in more than half of the replicates in each treatment group. 
n = 2-5, with each library synthesized using pooled RNA from 4 mice.  
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Gene ontology (GO) analysis of differentially expressed mRNAs in the IPN 
and MHb 
 Gene ontology analysis was performed on differentially expressed mRNAs 
for all treatment groups in the IPN and MHb. Comprehensive heat maps display 
all of the reduced terms describing the cellular compartments (CC, Figures 3.9 
and 3.12), molecular functions (MF, Figures 3.10 and 3.13), and biological 
processes (BP, Figures 3.11 and 3.14) with significant enrichment for up- and 
down-regulated genes in each brain region.  
 To describe differential expression in the IPN and MHb during acute 
nicotine withdrawal, I have highlighted selected GO terms describing cellular 
compartments (CC, Figure 3.8A), molecular functions (MF, Figure 3.8B), and 
biological processes (BP, Figure 3.8C) that were significantly enriched for up- or 
down-regulated genes in NAWD mice compared to TA controls. CC analysis 
determined there was significant enrichment of genes up-regulated in the IPN 
and MHb related to the mitochondrion. Up-regulated genes in the IPN were also  
enriched for MF and BP terms related to mitochondrial structure, function, and 
energetics, such as electron carrier activity, NADH dehydrogenase activity, 
hydrogen ion transport, and regulation of metabolic processes. There was also 
significant enrichment of genes up-regulated in the IPN related to ribosomal 
terms, including structural constituent of the ribosome, rRNA binding, ribosome 
biogenesis, and translation. In the MHb, genes up-regulated in NAWD mice were 
also enriched in CC terms related to the vesicle and myelin sheath. In both the 
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IPN and the MHb there was significant enrichment of down-regulated genes 
related to neuron projection development. 
 As previously discussed, there are very few genes differentially expressed 
with fold changes > 2 in the MHb and IPN during chronic nicotine treatment 
compared to TA controls. However, up-regulated genes in the MHb display 
significant enrichment of terms related the mitochondrion, vesicle, and myelin 
sheath, as observed in GO analysis of genes regulated during acute nicotine 
withdrawal. 
 There are a limited number of genes that were differentially expressed in 
the IPN after prolonged nicotine withdrawal. However, GO analysis did not reveal 
any significant enrichment of CC, MF, or BP categories.  
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Figure 3.8.  Genes differentially 
expressed in the IPN and MHb 
during acute nicotine 
withdrawal are overrepresented 
in gene ontology terms related 
to energetics, translation, and 
cell projection organization in 
the IPN and MHb. The vertical 
axes define the selected GO terms 
describing the cellular 
compartment (A), molecular 
function (B), or biological process 
(C). The number of GO terms was 
reduced combining similar terms 
using a simRel cutoff of 0.4 as 
described in the Methods and 
Materials. The horizontal axis plots 
the significance of enrichment of 
the GO term, plotted as -
log10(FDR). 
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Figure 3.9. Enrichment of cellular compartments with genes up-regulated in 
the IPN and MHb. Heat map of the significance of enrichment of reduced GO 
terms describing the cellular compartment with up-regulated mRNAs in the IPN 
and MHb. Each column is designated a specific brain region and treatment 
comparison (bottom). Each row is designated a GO term (right) reduced with a 
simRel cut off of 0.4 as described in the Methods and Materials. The number of 
terms combined within the single GO term, rf, is indicated by the green color 
gradient (left). The color gradient of the box (red) indicates the significance of 
enrichment as –log10(FDR). 
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Figure 3.10. Enrichment of molecular functions with genes up-regulated in 
the IPN and MHb. Heat map of the significance of enrichment of reduced GO 
terms describing the cellular compartment with up-regulated mRNAs in the IPN 
and MHb. Each column is designated a specific brain region and treatment 
comparison (bottom). Each row is designated a GO term (right) reduced with a 
simRel cut off of 0.4 as described in the Methods and Materials. The number of 
terms combined within the single GO term, rf, is indicated by the green color 
gradient (left). The color gradient of the box (red) indicates the significance of 
enrichment as –log10(FDR). 
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Figure 3.11. Enrichment of biological processes with genes up-regulated in 
the IPN and MHb. Heat map of the significance of enrichment of reduced GO 
terms describing the cellular compartment with up-regulated mRNAs in the IPN 
and MHb. Each column is designated a specific brain region and treatment 
comparison (bottom). Each row is designated a GO term (right) reduced with a 
simRel cut off of 0.4 as described in the Methods and Materials. The number of 
terms combined within the single GO term, rf, is indicated by the green color 
gradient (left). The color gradient of the box (red) indicates the significance of 
enrichment as –log10(FDR). 
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Figure 3.12. Enrichment of cellular compartments with genes down-
regulated in the IPN and MHb. Heat map of the significance of enrichment of 
reduced GO terms describing the cellular compartment with down-regulated 
mRNAs in the IPN and MHb. Each column is designated a specific brain region 
and treatment comparison (bottom). Each row is designated a GO term (right) 
reduced with a simRel cut off of 0.4 as described in the Methods and Materials. 
The number of terms combined within the single GO term, rf, is indicated by the 
green color gradient (left). The color gradient of the box (red) indicates the 
significance of enrichment as –log10(FDR). 
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Figure 3.13. Enrichment of molecular functions with genes down-regulated 
in the IPN and MHb. Heat map of the significance of enrichment of reduced GO 
terms describing the cellular compartment with down-regulated mRNAs in the 
IPN and MHb. Each column is designated a specific brain region and treatment 
comparison (bottom). Each row is designated a GO term (right) reduced with a 
simRel cut off of 0.4 as described in the Methods and Materials. The number of 
terms combined within the single GO term, rf, is indicated by the green color 
gradient (left). The color gradient of the box (red) indicates the significance of 
enrichment as –log10(FDR). 
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Figure 3.14. Enrichment of biological processes with genes down-regulated 
in the IPN and MHb. Heat map of the significance of enrichment of reduced GO 
terms describing the cellular compartment with down-regulated mRNAs in the 
IPN and MHb. Each column is designated a specific brain region and treatment 
comparison (bottom). Each row is designated a GO term (right) reduced with a 
simRel cut off of 0.4 as described in the Methods and Materials. The number of 
terms combined within the single GO term, rf, is indicated by the green color 
gradient (left). The color gradient of the box (red) indicates the significance of 
enrichment as –log10(FDR). 
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Target prediction of miRNAs differentially expressed in the IPN 
 Because miRNAs are traditionally considered to be repressors of gene 
expression, TargetScan Mouse 7.1 was used to predict MREs within the 3ʹ-UTR 
of differentially expressed mRNAs for inversely regulated miRNAs. Due to the 
fact that conservation of MREs increases the likelihood of biological function, 
only miRNAs and MREs conserved in vertebrates or mammals were considered 
in target prediction.  
 Chronic nicotine treatment induced differential expression of very few 
miRNAs and mRNAs in the IPN. Of the 8 miRNAs regulated by chronic nicotine 
treatment in the IPN, the 7 miRNAs that are down-regulated are conserved. 
TargetScan Mouse 7.1 predicted that only one of the 4 up-regulated mRNAs is a 
target of these conserved, down-regulated miRNAs. Shank1, a scaffolding 
protein enriched in post-synaptic densities (Jiang and Ehlers 2013), was up-
regulated in the IPN by chronic nicotine exposure. Shank1 was predicted to 
contain a conserved MRE for two different down-regulated miRNAs, miR-96-5p 
and miR-182-5p. 
Of the 88 miRNAs differentially expressed in the IPN of NAWD mice 
compared to TA controls, 52 are conserved in vertebrates or mammals. Thirty-
five of these miRNAs that are predicted to target at least one of 38 inversely 
expressed mRNAs (Table 3.2). The expression of 34 (~89%) of the predicted 
mRNA targets are altered only after nicotine withdrawal, being similarly regulated 
	156 
in NAWD compared to either TA or Nic mice (Table 3.2, orange). Eighteen of the 
predicted targets contain multiple MREs for a single or different miRNAs. 
In the IPN, none of the mRNAs differentially expressed after a prolonged 
nicotine withdrawal (NLWD) are predicted to be regulated by an inversely 
regulated miRNA. 
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Table 3.1. Target prediction of miRNAs differentially expressed in the IPN 
after chronic nicotine exposure (Nic) compared to TA controls. 
 
mRNA mRNA 
FC 
mRNA 
FDR 
miRNA miRNA 
FC 
miRNA FDR Seed Type Position in  
3ʹ-UTR 
Shank1 2.004 1.33E-09 miR-96-5p 0.511 4.79E-11 7mer-A1 2033-2039 
    miR-182-5p  0.582 1.48E-07 7mer-A1 2033-2039 
 
 
 
Table 3.2: Target prediction of miRNAs differentially expressed in IPN 
during acute nicotine withdrawal (NAWD) compared to TA controls. mRNAs 
that are similarly up- or down-regulated in NAWD mice compared to either TA or 
Nic are highlighted in orange. 
 
mRNA mRNA 
FC 
mRNA 
FDR 
miRNA miRNA 
FC 
miRNA 
FDR 
Seed Type Position in  
3ʹ-UTR 
Hbq1a 3.002 2.57E-07 miR-377-3p 0.592 1.08E-03 7mer-m8 252-258 
Rpp21 2.852 2.35E-20 miR-136-5p  0.613 9.18E-06 8mer 3537-3544 
Gchfr 2.696 9.55E-06 miR-129-1-3p 0.570 4.18E-04 7mer-m8 298-304 
   miR-129-2-3p 0.590 1.62E-05 7mer-m8 298-304 
Gm20390 2.669 2.25E-23 miR-429-3p 0.329 3.53E-12 7mer-m8 3377-3383 
    miR-429-3p 0.329 3.53E-12 8mer 4329-4336 
    miR-429-3p 0.329 3.53E-12 8mer 4714-4721 
    miR-200b-3p 0.375 6.58E-08 7mer-m8 3377-3383 
    miR-200b-3p 0.375 6.58E-08 8mer 4329-4336 
    miR-200b-3p 0.375 6.58E-08 8mer 4714-4721 
    miR-344d-3p 0.741 4.47E-03 7mer-A1 3316-3122 
Gm9726 2.627 2.76E-04 miR-29b-3p 0.726 4.41E-03 8mer 326-333 
Hist1h4h 2.505 1.18E-15 miR-9-5p 0.753 5.60E-03 7mer-m8 26-32 
Serf2 2.421 7.81E-20 miR-200a-3p 0.381 1.24E-13 7mer-m8 213-219 
    miR-141-3p 0.458 3.07E-04 7mer-m8 213-219 
    let-7f-5p 0.735 8.04E-04 8mer 2110-2117 
    let-7b-5p 0.741 6.40E-03 8mer 2110-2117 
    let-7c-5p 0.766 9.52E-03 8mer 2110-2117 
Mrps16 2.418 2.40E-15 miR-136-5p 0.613 9.18E-06 7mer-m8 86-92 
Zfp46 2.409 3.91E-12 miR-129-1-3p 0.570 4.18E-04 7mer-m8 464-470 
    miR-129-2-3p  0.590 1.62E-05 7mer-m8 464-470 
Ndufb2 2.368 2.31E-22 miR-429-3p 0.329 3.53E-12 7mer-m8 3896-3902 
    miR-200b-3p 0.375 6.58E-08 7mer-m8 3896-3902 
Esrrb 2.332 7.67E-08 let-7f-5p 0.735 8.04E-04 8mer 617-624 
    let-7b-5p 0.741 6.40E-03 8mer 617-624 
    miR-485-5p 0.753 4.04E-03 7mer-m8 55-61 
    miR-9-5p 0.753 5.60E-03 8mer 2337-2344 
    let-7c-5p 0.766 9.52E-03 8mer 617-624 
Polr2f 2.323 2.02E-26 miR-488-3p 0.752 8.56E-03 7mer-m8 485-491 
Nme1 2.305 3.32E-21 miR-200a-3p 0.381 1.24E-13 8mer 123-130 
    miR-141-3p 0.458 3.07E-04 8mer 123-130 
Gm9844 2.296 1.27E-04 miR-129-5p 0.721 1.46E-03 8mer 26-33 
Diras1 2.234 1.93E-12 miR-7b-5p 0.715 1.25E-03 7mer-m8 2200-2206 
Myl6 2.234 8.56E-15 miR-340-5p 0.741 6.55E-03 7mer-A1 851-857 
Psma2 2.174 3.46E-21 miR-132-3p 0.726 6.55E-03 7mer-A1 111-117 
Mrpl14 2.172 2.53E-14 miR-340-5p 0.741 6.55E-03 7mer-A1 2823-2829 
Ptrhd1 2.170 1.90E-13 miR-181d-5p 0.676 2.00E-04 7mer-m8 2022-2028 
    miR-181b-5p 0.680 5.42E-05 7mer-m8 2022-2028 
    miR-488-3p 0.752 8.56E-03 8mer 76-83 
Dynlt1f 2.169 1.11E-08 miR-29b-3p 0.726 4.41E-03 7mer-A1 215-221 
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Sod1 2.162 7.65E-13 miR-377-3p 0.592 1.08E-03 7mer-m8 78-84 
Cst6 2.158 6.60E-14 miR-377-3p 0.592 1.08E-03 7mer-m8 2027-2033 
    miR-181d-5p 0.676 2.00E-04 7mer-m8 2023-2029 
    miR-181b-5p 0.680 5.42E-05 7mer-m8 2023-2029 
Rpl31 2.153 6.45E-09 miR-653-5p 0.616 4.04E-03 7mer-A1 639-645 
    miR-129-5p 0.721 1.46E-03 8mer 671-678 
Tmsb4x 2.126 2.94E-14 miR-183-5p 0.319 3.96E-21 7mer-m8 327-333 
Ndufb9 2.104 7.81E-20 miR-200a-3p 0.381 1.24E-13 8mer 2453-2460 
    miR-141-3p 0.458 3.07E-04 8mer 2453-2460 
    miR-365-3p 0.654 9.94E-03 7mer-m8 2718-2724 
    miR-532-5p 0.740 2.06E-03 7mer-m8 3048-3054 
    miR-340-5p 0.741 6.55E-03 7mer-A1 1850-1856 
    miR-379-5p 0.752 6.55E-03 7mer-m8 3186-3192 
Rps12 2.097 2.19E-06 miR-96-5p 0.235 1.36E-17 7mer-m8 2285-2291 
Acot13 2.097 2.94E-07 miR-429-3p 0.329 3.53E-12 7mer-m8 4417-423 
    miR-200b-3p 0.375 6.58E-08 7mer-m8 4417-423 
    miR-653-5p 0.616 4.04E-03 7mer-A1 5139-5145 
    miR-181d-5p 0.676 2.00E-04 7mer-m8 4525-4531 
    miR-181b-5p  0.680 5.42E-05 7mer-m8 4525-4532 
Aamdc 2.094 9.88E-15 miR-485-5p 0.753 4.04E-03 7mer-m8 64-70 
Cisd3 2.093 9.98E-20 miR-9-5p 0.753 5.60E-03 7mer-A1 358-364 
Tmem151b 2.035 2.86E-07 miR-129-1-3p 0.570 4.18E-04 7mer-m8 2722-2728 
    miR-129-2-3p 0.590 1.62E-05 7mer-m8 2722-2728 
    miR-181d-5p 0.676 2.00E-04 7mer-m8 2226-2232 
    miR-181b-5p 0.680 5.42E-05 7mer-m8 2226-2233 
    miR-132-3p 0.726 6.55E-03 8mer 339-346 
    miR-29b-3p 0.726 4.41E-03 7mer-m8 2452-2458 
    miR-485-5p 0.753 4.04E-03 8mer 2089-2096 
Erh 2.031 1.69E-09 miR-181d-5p 0.676 2.00E-04 7mer-m8 118-124 
    miR-181b-5p 0.680 5.42E-05 7mer-m8 118-124 
Tomm5 2.011 4.37E-19 miR-151-3p 0.770 6.36E-03 7mer-m8 383-389 
Gosr2 0.374 1.22E-11 miR-27a-3p  1.421 8.66E-04 8mer 94-101 
Nkx2-1 0.459 1.19E-03 miR-503-5p 1.581 1.48E-03 7mer-m8 74-80 
Prkag1 0.488 8.60E-03 miR-34a-5p  1.941 7.79E-08 7mer-m8 42-48 
    miR-34b-5p 1.893 1.43E-06 7mer-m8 42-48 
Lurap1l 0.489 1.18E-06 miR-497a-5p  2.053 3.09E-13 8mer 60-67 
    miR-503-5p 1.581 1.48E-03 7mer-A1 61-67 
Pfn2 0.496 8.36E-09 miR-106b-5p  1.789 9.32E-11 7mer-m8 452-458 
    miR-106b-5p  1.789 9.32E-11 7mer-m8 1197-1203 
Zbtb9 0.496 3.34E-05 miR-497a-5p 2.053 3.09E-13 7mer-m8 42-48 
    miR-497a-5p 2.053 3.09E-13 7mer-m8 45-51 
    miR-106b-5p  1.789 9.32E-11 8mer 822-829 
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Target prediction of miRNAs differentially expressed in the MHb 
 As in the IPN, TargetScan Mouse 7.1 was used to identify targets of 
differentially expressed, conserved miRNAs that are inversely regulated by 
chronic nicotine treatment and withdrawal in the MHb. In a pattern similar to the 
IPN, very few miRNAs and mRNAs exhibit significant alterations expression level 
after chronic nicotine treatment. Of the 6 miRNAs differentially expressed in the 
MHb of Nic mice compared to TA controls, 5 are broadly conserved in 
vertebrates. However, there are no inversely regulated mRNAs  (with FC > 2)  
that  contain conserved MREs for these miRNAs in the IPN or MHb. 
 During acute nicotine withdrawal, there are 85 differentially expressed 
miRNAs in the MHb and 59 of these are conserved. Of these, TargetScan Mouse 
7.1 predicted that 32 miRNAs target at least one of 50 different mRNAs inversely 
expressed (FC > 2) in NAWD mice compared to TA controls (Table 3.3). The 
regulation of the majority (72%) of the predicted targets is an effect solely of 
nicotine withdrawal, being similarly regulated in NAWD mice compared to either 
TA- or Nic-treated mice (Table 3.3, orange). Twenty-six (52%) of the predicted 
targets contain multiple MREs or are predicted to be targeted by more than one 
inversely expressed miRNA. 
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Table 3.3. Target prediction of miRNAs differentially expressed in the MHb 
during acute nicotine withdrawal (NAWD) compared to TA controls. mRNAs 
that are similarly differentially expressed during chronic nicotine treatment (Nic) 
compared to TA mice are highlighted in green. mRNAs are similarly up- or down-
regulated in NAWD mice are compared to either TA or Nic are highlighted in 
orange. 
 
mRNA mRNA 
FC 
mRNA 
FDR 
miRNA miRNA 
FC 
miRNA 
FDR 
Seed Type Position in  
3ʹ-UTR 
Arf5 4.543 1.01E-24 miR-29b-3p  0.650 4.95E-06 8mer 392-399 
Pcolce2 4.447 9.69E-19 miR-340-5p 0.618 2.19E-10 7mer-A1 329-335 
    miR-146b-5p 0.721 1.68E-04 7mer-A1 3039-3045 
Tom1l1 4.011 2.74E-21 miR-340-5p  0.618 2.19E-10 7mer-A1 397-403 
    miR-340-5p  0.618 2.19E-10 8mer 2622-2629 
    miR-181b-5p 0.763 2.71E-03 8mer 371-378 
    miR-142a-5p 0.765 8.25E-03 7mer-A1 2622-2628 
    miR-181c-5p 0.770 3.26E-03 8mer 371-378 
Rasd1 3.629 3.25E-11 miR-377-3p 0.558 4.71E-04 7mer-m8 572-578 
    miR-30c-5p 0.710 2.01E-04 8mer 465-472 
    miR-384-5p 0.735 3.14E-04 8mer 465-472 
Pcna 3.195 6.07E-16 miR-137-3p  0.652 9.24E-08 8mer 420-427 
Spns1 3.031 1.55E-11 miR-29b-3p  0.650 4.95E-06 8mer 266-273 
Ppp2cb 3.022 5.91E-20 miR-183-5p 0.551 2.97E-06 8mer 152-159 
    miR-142a-5p 0.765 8.25E-03 7mer-A1 142-148 
Steap3 2.857 2.10E-06 miR-377-3p 0.558 4.71E-04 7mer-A1 704-710 
Dnajc9 2.787 7.78E-14 miR-132-3p 0.710 1.32E-04 7mer-m8 1040-1046 
Rpa1 2.704 2.98E-15 miR-30c-5p 0.710 2.01E-04 7mer-m8 1195-1201 
    miR-384-5p 0.735 3.14E-04 7mer-m8 1195-1201 
    miR-361-5p 0.762 2.72E-03 7mer-m8 591-597 
    miR-361-5p 0.762 2.72E-03 7mer-A1 627-633 
Net1 2.675 4.10E-07 miR-340-5p  0.618 2.19E-10 7mer-A1 31-37 
    miR-135a-5p  0.631 7.96E-09 8mer 831-838 
    miR-135b-5p 0.645 4.36E-05 8mer 831-838 
Gpx4 2.617 1.68E-17 miR-374b-5p 0.549 2.62E-05 7mer-A1 833-839 
Ogfod2 2.613 3.97E-11 miR-340-5p 0.618 2.19E-10 493-500 8mer 
Sin3a 2.598 2.68E-09 miR-211-5p 0.492 7.97E-12 7mer-m8 870-876 
    miR-183-5p 0.551 2.97E-06 7mer-m8 644-650 
    miR-493-5p 0.699 3.98E-03 7mer-m8 724-730 
    miR-493-5p 0.699 3.98E-03 8mer 840-847 
Eif5a 2.561 5.52E-19 miR-495-3p  0.472 8.00E-16 7mer-A1 589-595 
Gosr2 2.511 5.84E-16 miR-493-5p 0.699 3.98E-03 8mer 1649-1656 
Chst15 2.455 2.63E-07 miR-342-3p 0.704 8.42E-05 8mer 1364-1371 
Tmem159 2.443 1.65E-04 miR-135a-5p 0.631 7.96E-09 7mer-m8 607-613 
    miR-135b-5p 0.645 4.36E-05 7mer-m8 607-613 
Rab40b 2.414 3.16E-05 miR-211-5p 0.492 7.97E-12 8mer 336-343 
Rabl6 2.413 2.15E-08 miR-30c-5p 0.710 2.01E-04 8mer 371-378 
    miR-384-5p 0.735 3.14E-04 8mer 371-378 
Id3 2.400 5.82E-11 miR-340-5p  0.618 2.19E-10 7mer-A1 489-495 
Htra2 2.381 6.59E-05 miR-410-3p  0.667 4.11E-07 7mer-A1 160-166 
Kctd3 2.355 2.23E-08 miR-29b-3p 0.650 4.95E-06 7mer-A1 432-438 
    miR-30c-5p 0.710 2.01E-04 7mer-m8 411-417 
    miR-384-5p 0.735 3.14E-04 7mer-m8 411-417 
Atg16l1 2.346 3.04E-12 let-7k 0.615 1.81E-04 7mer-A1 235-241 
    miR-410-3p 0.667 4.11E-07 8mer 1100-1107 
    miR-142a-5p 0.765 8.25E-03 7mer-m8 872-878 
Srl 2.344 8.98E-04 miR-211-5p 0.492 7.97E-12 8mer 2918-2925 
    miR-136-5p 0.582 2.87E-08 8mer 818-825 
    miR-136-5p 0.582 2.87E-08 8mer 4468-4475 
Marcksl1 2.271 1.11E-08 miR-23b-3p 0.740 1.75E-03 8mer 576-583 
    miR-23a-3p 0.755 3.09E-03 8mer 576-583 
Ccdc32 2.241 2.68E-07 miR-377-3p 0.558 4.71E-04 7mer-m8 165-171 
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Prpf19 2.227 2.45E-17 miR-377-3p 0.558 4.71E-04 8mer 2354-2361 
    miR-421-3p 0.701 6.33E-03 8mer 2841-2848 
    miR-203-3p 0.732 7.63E-04 7mer-m8 120-126 
Tbc1d8b 2.222 2.86E-03 miR-340-5p 0.618 2.19E-10 8mer 2336-2343 
    miR-142a-5p 0.765 8.25E-03 7mer-m8 1016-1022 
    miR-142a-5p 0.765 8.25E-03 7mer-A1 2336-2341 
Kdelr1 2.222 7.47E-08 miR-340-5p 0.618 2.19E-10 7mer-A1 313-319 
    miR-335-5p 0.637 4.58E-06 7mer-A1 715-721 
Gm2a 2.184 1.22E-07 miR-6395 0.682 5.46E-03 8mer 591-598 
Zfp622 2.170 1.71E-11 miR-181b-5p 0.763 2.71E-03 8mer 410-417 
    miR-181c-5p 0.770 3.26E-03 8mer 410-417 
Gap43 2.163 3.62E-03 miR-23b-3p 0.740 1.75E-03 7mer-m8 433-439 
    miR-23a-3p 0.755 3.09E-03 7mer-m8 433-439 
Grasp 2.157 9.32E-04 miR-132-3p 0.710 1.32E-04 7mer-m8 668-674 
Gpr182 2.134 4.61E-03 miR-30c-5p 0.710 2.01E-04 7mer-A1 2658-2664 
    miR-384-5p 0.735 3.14E-04 7mer-A1 2658-2664 
Metap1 2.125 1.20E-06 miR-211-5p 0.492 7.97E-12 7mer-m8 1354-1360 
    miR-382-3p 0.528 3.46E-11 7mer-m8 1373-1379 
    miR-181b-5p 0.763 2.71E-03 7mer-m8 1334-1340 
    miR-142a-5p 0.765 8.25E-03 7mer-m8 1221-1227 
    miR-181c-5p 0.770 3.26E-03 7mer-m8 1334-1340 
Chid1 2.123 5.05E-07 miR-142a-5p 0.765 8.25E-03 7mer-m8 2673-2679 
Tmem184a 2.121 3.51E-03 miR-137-3p 0.652 9.24E-08 8mer 2889-2896 
    miR-410-3p 0.667 4.11E-07 7mer-A1 3706-3712 
    miR-493-5p 0.699 3.98E-03 7mer-m8 2883-2889 
    miR-487b-3p 0.702 4.08E-04 8mer 3684-3691 
Htr2c 2.106 2.43E-10 miR-382-3p 0.528 3.46E-11 8mer 1230-1237 
    miR-137-3p  0.652 9.24E-08 8mer 2964-2971 
    miR-23b-3p 0.740 1.75E-03 8mer 1871-1878 
    miR-23a-3p 0.755 3.09E-03 8mer 1871-1878 
Alpl  2.103 3.66E-06 miR-211-5p 0.492 7.97E-12 8mer 655-662 
Ddah2 2.093 1.58E-08 miR-29b-3p  0.650 4.95E-06 7mer-m8 69-75 
Zkscan4 2.087 1.94E-05 miR-29b-3p  0.650 4.95E-06 7mer-A1 390-396 
Atg7 2.087 1.98E-05 miR-211-5p 0.492 7.97E-12 8mer 1454-1461 
    miR-382-3p  0.528 3.46E-11 7mer-m8 1438-1444 
    miR-142a-5p 0.765 8.25E-03 7mer-m8 879-885 
Galnt18 2.083 1.04E-04 miR-340-5p  0.618 2.19E-10 7mer-A1 245-251 
Thg1l 2.060 1.05E-03 miR-340-5p 0.618 2.19E-10 7mer-A1 280-286 
Slc25a18 2.045 5.08E-05 let-7k 0.615 1.81E-04 8mer 106-113 
Api5 2.023 3.22E-09 miR-203-3p 0.732 7.63E-04 8mer 1699-1706 
Bcl2l1 2.020 8.98E-07 miR-495-3p 0.472 8.00E-16 7mer-A1 1219-1225 
    miR-377 0.558 4.71E-04 7mer-m8 1242-1248 
    miR-377 0.558 4.71E-04 8mer 1424-1431 
    let-7k 0.615 1.81E-04 8mer 947-954 
    miR-342 0.704 8.42E-05 7mer-m8 1243-1249 
Cat 2.014 3.45E-06 miR-23b-3p 0.740 1.75E-03 8mer 793-800 
    miR-23a-3p 0.755 3.09E-03 8mer 793-800 
Ccdc80 2.011 6.43E-03 miR-29b-3p  0.650 4.95E-06 8mer 213-220 
    miR-433-3p 0.673 1.45E-05 8mer 1243-1250 
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Validation of alterations in miRNA/mRNA expression in the IPN and MHb 
during acute nicotine withdrawal 
 To confirm the up- and down-regulation of transcripts during acute nicotine 
withdrawal, relative expression levels were measured by RT-qPCR. According to 
miRNA-Seq differential expression analysis, miR-106b-5p was up-regulated by 
~80% in the IPN of mice in acute nicotine withdrawal compared to TA controls. 
This miRNA was similarly up-regulated when NAWD mice are compared to Nic-
treated mice, indicating it is only regulated by nicotine withdrawal. According to 
TargetScan Mouse 7.1, miR-106b-5p is predicted to target two distinct MREs 
within the 3ʹ-UTR of Profilin 2 (Pfn2) (Table 3.2, bolded). Pfn2 was significantly 
down-regulated by approximately 50% by acute withdrawal, when NAWD is 
compared to either TA or Nic mice. RT-qPCR validated that in acute withdrawal, 
miR-106b-5p was significantly up-regulated by a fold change of 1.773 ± 0.153 in 
the IPN of NAWD mice compared to nicotine-naïve controls (Figure 3.15A). 
Expression of Pfn2 was significantly down-regulated with a fold change of 0.7833 
± 0.05379 (Figure 3.15B), confirming the reciprocal relationship of miR-106b-5p 
and its predicted target during acute nicotine withdrawal. 
 The differential expression of mRNAs induced by acute nicotine 
withdrawal in the MHb was validated using the same approach. Sequencing 
revealed that 122 genes, including Arf5, Atg7, Bcl2l1, and Eif5a, were 
differentially expressed when NAWD are compared to either TA or Nic mice. The 
up-regulation of these 4 genes by acute nicotine withdrawal compared to TA-
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treated controls, was validated by RT-qPCR (Figure 3.16). Arf5 was significantly 
up-regulated by a fold change of 1.243 ± 0.07349 (Figure 3.16A). Atg7 was 
significantly up-regulated by a fold change of 1.515 ± 0.186 (Figure 3.16B). 
Bcl2l1 was significantly up-regulated by a fold change of 1.542 ± 0.06557 (Figure 
3.16C). Eif5a was significantly up-regulated by a fold change of 1.428 ± 0.1239 
(Figure 3.16D). 
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Figure 3.15. Reciprocal relationship between miR-106b-5p and Pfn2 transcript 
expression in the IPN following acute withdrawal from nicotine. Total RNA was 
isolated from IPN tissue punches from TA (filled bars) and NAWD-treated (empty bars) 
mice. Relative gene expression was measured by RT-qPCR. Data are presented as 
mean ± SEM, normalized to TA controls. Unpaired, two-tailed t-test was used to 
compare the expression of miR-106b-5p (A, t4 = 3.269, P = 0.0308) and Pfn2 (B, t12 = 
2.21, P = 0.0473) in NAWD mice compared to TA controls. (*) P < 0.05; n = 3-7, with 
each sample containing tissue pooled from 2 mice. 
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Figure 3.16. Relative quantitation of genes up-regulated in the MHb during 
acute nicotine withdrawal. RNA was isolated from MHb tissue punches of TA 
(filled bars) and NAWD-treated (empty bars) mice. Relative gene expression 
levels were measured by RT-qPCR. Data are presented as mean ± SEM, 
normalized to the TA control. Statistical analysis was performed using unpaired, 
two-tailed t-test to compare expression of Arf5 (A, t8 = 2.713, P = 0.0265), Atg7 
(B, t12 = 2.598, P = 0.0233), Bcl2l1 (C, t8 = 4.873, P = 0.0012), and Eif5a (D, t8 = 
3.041, P = 0.0160) in NAWD mice compared to TA controls. (*) P < 0.05; (**) P < 
0.01; n = 5-7, with each sample containing tissue pooled from 2 mice. 
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3.D. Discussion 
 
Acute nicotine withdrawal induces widespread differential expression of 
mRNAs in the habenulo-interpeduncular withdrawal circuit. 
 We employed mRNA-sequencing and differential expression analysis to 
measure transcriptome-wide changes in gene expression induced by chronic 
nicotine treatment and withdrawal in the habenulo-interpeduncular withdrawal 
circuit. In both the IPN and the MHb, there are very few mRNAs that are 
significantly altered by chronic nicotine treatment with fold changes > 2. Of the 
few mRNAs that are regulated by chronic nicotine exposure, the majority return 
expression levels to those of drug naïve animals after a 48-hour withdrawal. 
Specifically, only 2 mRNAs are similarly differentially expressed in both Nic and 
NAWD mice compared to TA controls in the MHb, indicating their regulation by 
chronic nicotine treatment persists for at least 48 hours after withdrawal. 
After acute nicotine withdrawal, there are widespread changes in gene 
expression. Many of these mRNAs are similarly regulated when NAWD mice are 
compared to either TA- or Nic-treated mice, further suggesting that their 
regulation is solely the consequence of nicotine withdrawal and chronic nicotine 
treatment itself does not contribute to their up- or down-regulation. Gene 
ontology analysis identified significant enrichment of up-regulated genes in the 
IPN of NAWD mice related to ribosome structure and translation, further 
supporting the body of evidence suggesting that stable neuroadaptations 
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associated with drug addiction require de novo protein synthesis (Madsen et al. 
2012). Thus, it is possible that up-regulation of ribosomes and other regulators of 
translation is an effort to fulfill the increased demand for protein products in the 
activated neurons of the IPN during nicotine withdrawal. In addition, in the MHb 
and IPN, there is significant enrichment of up-regulated genes related to the 
mitochondria. The functions of activated neurons, including maintenance of 
membrane resting potential, intracellular calcium buffering, and synaptic vesicle 
recycling, are highly energy-demanding (Harris et al. 2012, Devine and Kittler 
2018). To meet the increased demand, neurons increase oxidative metabolism, 
but cannot up-regulate glycolysis (Magistretti and Allaman 2015). The enrichment 
of up-regulated genes related to mitochondria and oxidative energy production 
may reflect an effort to fulfill the increased energy demands of the highly active 
synapses of the IPN during nicotine withdrawal. 
To confirm the validity of the sequencing and differential expression 
analysis, the relative expression of select genes was quantified by RT-qPCR. 
The expression of Pfn2 in the IPN and Arf5, Atg7, Bcl2l1, and Eif5a in the MHb 
were significantly up- and down-regulated as observed in the differential 
expression analysis of sequencing data. However, in all cases, the fold changes 
observed in RT-qPCR experiments are lower than observed in the RNA-Seq data 
analysis. This is likely due to the  necessity for a stably expressed endogenous 
control gene for normalization in calculating relative expression levels by the 2-
∆∆Ct method. Because nicotine exposure and withdrawal has widespread effects 
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on the expression of mRNAs, selection of a completely stable endogenous 
control is problematic. Using the sequencing data, Gusb was selected as an 
optimal reference gene for its stable expression across treatments and brain 
regions. However, there might be non-significant alterations in Gusb expression 
that explain the differences in fold changes calculated by RT-qPCR and the 2-∆∆Ct 
method. Future validation of expression changes by RT-qPCR may be performed 
using several different endogenous controls that are stably expressed according 
to the RNA-Seq data analysis.  
All of the genes differentially expressed in the MHb and IPN during acute 
nicotine withdrawal return to control expression levels after a prolonged 4-week 
period of abstinence. Only in the IPN were there a limited number of genes 
significantly and uniquely differentially expressed in NLWD mice compared to 
age-matched TAL controls. This suggests that, 
 for a subset of genes in the IPN, changes in mRNA expression induced 
by nicotine withdrawal are delayed and persist for at least 4 weeks. This 
subpopulation of genes displaying delayed/persistent dysregulation by nicotine 
treatment and withdrawal may contribute to the enduring anxiety behaviors 
observed in these mice (Figure 2.4) and the susceptibility to relapse that plagues 
nicotine addicts. 
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Differential expression of miRNAs in the habenulo-interpeduncular 
pathway is induced by chronic nicotine exposure and acute withdrawal. 
In a pattern mirroring mRNA expression, miRNA-Seq and differential 
expression analysis identified many miRNAs that were differentially expressed 
after acute nicotine withdrawal, and relatively few miRNAs significantly 
differentially expressed by chronic nicotine exposure compared to TA controls. 
Approximately 33% and 47% of miRNAs differentially expressed in the IPN and 
MHb, respectively, of NAWD compared to TA mice are similarly regulated when 
compared to Nic mice. This suggests that these miRNAs are regulated only by 
withdrawal from nicotine, with no effect of the chronic nicotine treatment. In both 
the IPN and MHb, there are no miRNAs differentially expressed after a prolonged 
withdrawal from nicotine, indicating all miRNAs have returned to expression 
levels similar to age-matched drug naïve animals 4 weeks after cessation of 
nicotine treatment. Therefore, it is unlikely that alteration in miRNA expression 
does not play a role in the persistently anxious phenotype of mice after prolonged 
nicotine withdrawal. Taken together, in the MHb-IPN axis, miRNAs are regulated 
primarily during acute nicotine withdrawal, mirroring the effects of withdrawal on 
mRNA expression. 
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Differentially expressed miRNAs are predicted to target inversely regulated 
mRNAs in the IPN and MHb during acute nicotine withdrawal. 
 TargetScan Mouse 7.1 identified conserved MREs within the 3ʹ-UTRs of 
differentially expressed mRNAs for inversely regulated miRNAs during acute 
nicotine withdrawal. In the IPN, 38 mRNAs differentially expressed in NAWD 
mice compared to TA controls were predicted contain at least one MRE for at 
least one of 25 inversely regulated miRNAs. In the MHb, 50 mRNAs altered in 
NAWD compared to nicotine-naïve controls were predicted to contain a 
conserved MRE for at least one of 32 conserved, inversely expressed miRNAs. 
In both regions, the majority of predicted targets are altered only during nicotine 
withdrawal. This suggests that in the MHb-IPN withdrawal axis, miRNAs may 
play an important role in the regulation of gene expression in response to 
nicotine withdrawal. This contrasts to the extremely limited number of 
miRNAs/mRNAs regulated and targets predicted after chronic nicotine treatment 
alone in these brain regions. 
 In many cases in the MHb and IPN, predicted mRNA targets contain 
multiple MREs for the same miRNA or are targeted by multiple miRNAs. For 
example, the 3ʹ-UTR of Pfn2 contains 2 predicted MREs for miR-106b-5p. In 
addition to the conservation of the MRE and the anti-correlation of miRNA/mRNA 
expression, the existence of additional MREs for a miRNA increases the 
probability that the miRNA is a biologically functional regulator of the predicted 
target. These miRNAs and their targets should be top candidates for future 
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studies investigating their roles in the molecular mechanisms underlying the 
neuroadaptations of nicotine withdrawal and withdrawal-associated anxiety. 
  
	172 
CHAPTER 4 
 
A Novel Role For Profilin 2 (Pfn2) In Nicotine Withdrawal-Associated Anxiety 
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4.A. Introduction 
 
 The differential expression analysis of mRNA-Seq data presented in 
Chapter 3 found that Profilin 2 (Pfn2) was down-regulated in the IPN specifically 
during acute nicotine withdrawal, with no effects of chronic nicotine treatment 
itself. In addition, expression of miR-106b-5p, which was predicted to target 2 
MREs within the 3ʹ-UTR of Pfn2, was up-regulated after acute nicotine 
withdrawal. In light of the reciprocal expression of a predicted miRNA regulator, 
along with the known roles of Pfn2 in the modulation of synaptic 
activity/morphology, we asked whether Pfn2 plays a role in the induction of 
nicotine-withdrawal associated behaviors. 
  
Regulation of the Synapse by Profilin 2 (Pfn2) 
Pfn2 is a member of the profilin family of small, actin monomer-binding 
proteins (Honore et al. 1993, Witke 2004). While Pfn1 is ubiquitously expressed 
throughout the body, Pfn2 is most highly expressed in the brain (Witke et al. 
2001). Pfn2 is also the dominantly expressed profilin, representing approximately 
75% of the profilin in the brains of rodents (Witke et al. 2001, Tariq et al. 2016).  
Importantly, the mouse Pfn2 sequence is 94% identical to human Pfn2 (Di Nardo 
et al. 2000).  
Profilin’s function as a regulator of the neuronal cytoskeleton arises in part 
from its ability to act as a globular-actin monomer (G-actin) binding molecule. 
Profilin regulates actin polymerization by binding and sequestering G-actin. 
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Alternatively, profilins can also promote actin filament elongation by accelerating 
ADP-ATP nucleotide exchange on G-actin 1000-fold compared to the rates of 
simple diffusion (Mockrin and Korn 1980, Goldschmidt-Clermont et al. 1992), 
facilitating the addition of ATP-actin monomers to the growing filament (Witke 
2004). In addition to its ability to bind G-actin monomers, Pfn2 possesses a poly-
L-proline binding domain which permits interaction with a plethora of other 
ligands whose functions contribute to synaptic morphology and function (Witke 
2004) (Figure 4.1).  
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Figure 4.1. Molecular interactions of profilin. Schematic of proteins known to 
interact with profilins 1 and 2 grouped by cellular location and/or complexes. 
Direct interactions are indicated by solid lines and potential direct interactions are 
indicated by dashed lines. Abbreviations: AF-6: All-1 fusion partner from 
chromosome 6; EVL: EnaVASP-like; FMRP: Fragile X mental retardation protein; 
FRL: Formin-related gene in leukocytes; HSP: Heat-shock protein; Mena: Mouse 
homolog of Drosophila enabled; POP: Partner of profilin; SMN: Survival of motor 
neuron; VASP: Vasodilator-stimulated phosphoprotein; VCP: Valosine-containing 
protein; WASP: Wiskott-Aldrich syndrome protein; WAVE: WASP family 
verprolin-homologous protein; WIP: WASP-interacting protein.  
 
Reprinted from Trends in Cell Biology, Vol 14/Issue 8, Walter Witke, “The role of 
profilin complexes in cell motility and other cellular processes”, Pages 461-469, 
Copyright (2004), with permission from Elsevier  
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In addition to binding G-actin monomers, Pfn2 regulates actin 
polymerization at the synapse by direct interaction with the WAVE-complex (Pilo 
Boyl et al. 2007) (Figure 4.1), which in turn activates the Arp2/3 complex to 
promote actin nucleation. Interestingly, Arpc3, a component of the Arp2/3 
complex, is a confirmed target of miR-29a/b, which is up-regulated in the mouse 
brain after acute nicotine injection, regulating dendritic spine morphology (Lippi et 
al. 2011). Additionally, WAVE-complexes can be activated by Arf5 GTPases 
(Koronakis et al. 2011). Our differential expression analysis revealed that Arf5, 
like Pfn2, is down-regulated in the IPN of mice in acute nicotine withdrawal, 
further suggesting that cytoskeletal dynamics are a key feature of the underlying 
mechanisms of nicotine withdrawal.  
Pfn2 is expressed pre- and post-synaptically (Pilo Boyl et al. 2007). Post-
synaptically, Pfn2 accumulates in the dendritic spines of activated neurons 
(Ackermann and Matus 2003, Lamprecht et al. 2006), and plays a role in 
determining spine complexity through the regulation of cytoskeletal dynamics 
(Michaelsen et al. 2010, Michaelsen-Preusse et al. 2016). Changes in dendritic 
spine morphology are important for experience-dependent synaptic plasticity 
(Ottersen and Helm 2002, Trachtenberg et al. 2002). While Pfn2 -/- mice display 
normal number of dendritic spines (Pilo Boyl et al. 2007), knockdown of Pfn2 in 
primary hippocampal neurons decreases dendritic complexity, through pruning of 
already existing dendrites (Michaelsen et al. 2010). Additionally, Pfn2-deficient 
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primary hippocampal neurons exhibit abnormally motile spines, increased spine 
length and increased spine width (Michaelsen-Preusse et al. 2016). 
Pfn2 interacts directly with ROCK, a RhoA-GTPase effector, regulating 
neuritogenesis in response to physiological stimuli (Da Silva et al. 2003) (Figure 
4.1). Studies have shown that regulation by RhoA/ROCK contributes to the ability 
of Pfn2 to modify actin filament stability and act as a brake for neurite outgrowth 
(Da Silva et al. 2003, Nolle et al. 2011). Specifically, Pfn2 -/- hippocampal 
neurons display increased number of highly branched neurites of increased 
length, while over-expression of Pfn2  decreases neurite number and length (Da 
Silva et al. 2003). Interestingly, inhibition of ROCK in the mouse brain induces 
anxiety (Saitoh et al. 2006).  
Our GO analysis revealed an enrichment of down-regulated genes related 
to cellular projection organization and neuron projection development in the IPN 
during nicotine withdrawal (Figure 3.8). In light of the known roles of Pfn2 in the 
regulation of dendritic spine complexity and neuritogenesis described above, 
repression of Pfn2 expression in the IPN during acute nicotine withdrawal may 
contribute to the molecular mechanisms underlying the biological processes 
related to neuron projections identified in the GO analysis. 
Pre-synaptically, Pfn2 can influence synaptic vesicle release, with Pfn2 -/- 
mice displaying higher vesicle exocytosis and hyperactivation of the striatum 
(Pilo Boyl et al. 2007). Consistent with this, Pfn2 has been shown to directly 
interact with dynamin 1, a GTPase involved in clathrin-mediated vesicle 
	178 
formation, and other ligands regulating endocytosis and vesicle recycling (Witke 
et al. 1998, Gareus et al. 2006) (Figure 4.1). Regulation of the actin cytoskeleton 
has been linked to endocytosis, possibly by stabilizing the membrane curvature 
(Qualmann et al. 2000, Engqvist-Goldstein et al. 2004, Yarar et al. 2005, Gareus 
et al. 2006). Specifically, Pfn2 over-expression inhibits endocytosis in HeLa cells, 
and cultured cortical neurons from Pfn2 -/- mice display increased endocytosis 
(Gareus et al. 2006). 
Pfn2 can also influence the composition of neurotransmitter receptors at 
the post-synaptic surface (Witke 2004). For example, Pfn2 has been shown to 
decrease surface localization of excitatory kainite glutamate receptors through 
regulation of endocytosis and membrane trafficking (Mondin et al. 2010). Pfn2 
has also been shown to interact with members of the membrane scaffold, such 
as gephyrin	(Mammoto et al. 1997), anchoring receptors to the cytoskeleton.    
The synaptic roles of Pfn2 and its link to behaviors such as anxiety led us 
to hypothesize that down-regulation of Pfn2 expression during acute nicotine 
contributes to the neural activation observed in the IPN during withdrawal, 
increasing anxiety-associated behaviors.  
  
	179 
4.B. Materials and Methods 
 
Animals 
All experiments were conducted in accordance with the guidelines for care 
and use of laboratory animals provided by the National Research Council as well 
as with an approved animal protocol from the Institutional Animal Care and Use 
Committee of UMMS. WT male C57BL/6J (Jackson) were group-housed and 
were kept on a 12-h light/dark cycle (lights ON 7 A.M.) with food and water 
provided ad libitum.  
 
Quantitative Reverse Transcription-PCR (RT-qPCR) 
RT-qPCR for miRNAs and mRNAs was performed as previously described 
(Hogan et al. 2014). RNA was reverse transcribed by MMLV-reverse 
transcriptase (ThermoFisher Cat. # 28025013 or AM2043) using random 
decamers or miRNA-specific primers according to the manufacturer’s instruction. 
Quantitative PCR was performed on a Applied Biosystems 7500 Real-Time PCR 
System using TaqMan miRNA and gene expression assays (ThermoFisher) for 
miR-106b-5p (Assay ID 000442), Pfn2 (Assay ID Mm01289572_m1), and Pfn1 
(Assay ID Mm00726691_s1), in triplicate. Relative miRNA/gene expression was 
determined using the 2−ΔΔCt method (Livak and Schmittgen 2001). miRNA and 
mRNA expression were normalized to snoRNA202 (Assay ID 001232) and β-
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glucuronidase (Assay ID Mm01197698_m1), respectively, unless otherwise 
noted in figure legends. 
 
Cloning  
The 3ʹ-UTR of Pfn2 was amplified from mouse genomic DNA and cloned 
into the pMIR-REPORT Luciferase plasmid (Applied Biosystems). The WT Pfn2 
3ʹ-UTR was amplified using Phusion High-Fidelity DNA polymerase (NEB Cat. 
No. M0530) with a 1-min denaturing step at 98°C followed by 35 cycles of a 10-
sec 98°C melting step, a 30-sec 57°C annealing step and a 30-sec 72°C 
extension step, and a final extension step at 72°C for 5 min. The PCR product 
was gel purified using a commercially available kit (QIAquick Gel Extraction Kit, 
Qiagen Cat. No. 28704). The PCR fragment and pMIR-REPORT Luciferase 
plasmid were digested with SpeI-HF and MluI-HF and ligated using T4 DNA 
ligase (NEB Cat. No. M0202) as previously described (Hogan et al. 2014). 
Ligation products were transformed into DH5α Escherichia coli (E. coli) 
(Invitrogen) and plated on LB agar plates containing 100 µg/ml ampicillin. 
Colonies were grown in LB medium supplemented with 100 µg/ml ampicillin and 
the plasmid was isolated using a commercially available kit (Plasmid Miniprep kit, 
Qiagen Cat. No. 27104). The WT Pfn2 3ʹ-UTR luciferase expression plasmid was 
verified by Sanger sequencing (Genewiz).  
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Pfn2 3ʹ-UTR PCR Primers: 
F: 5ʹ-ttggaggcggattgaataagaag-3ʹ 
R: 5ʹ-ctctaccctccaagatcaacaata-3ʹ 
 
Site-directed Mutagenesis (SDM) 
SDM was performed using a QuickChange Site-Directed Mutagenesis Kit 
(Agilent Cat. No. 200519) according to manufacturer’s instructions. Primers 
substituted four nucleotides within two distinct predicted MREs:  MRE1 and 
MRE2. Three mutant MRE/luciferase constructs were generated:  single mutants 
for MRE1 or MRE2, and double mutant MRE1/2. 
Briefly, the WT Pfn2 3ʹ-UTR luciferase constructs were mixed with 10X 
reaction buffer, dNTP mix, PfuTurbo DNA polymerase, and primers. The parental 
DNA was digested with DpnI and transformed into XL1-Blue supercompetent E. 
coli cells (Invitrogen), grown in LB supplemented with 100 µg/ml ampicillin and 
isolated by Plasmid Mini Prep (Qiagen). Mutant luciferase constructs were 
verified by Sanger sequencing (Genewiz). 
Pfn2 MRE1 SDM primers:  
F: 5ʹ-gagccaaggaaatgctccattgttttgaaaagacactgatcgagttagagac-3ʹ  
R: 5ʹ-agtctctaactcgatcagtgtcttttcaaaacaatggagcatttccttggctc-3ʹ. 
Pfn2 MRE2 SDM primers: 
F: 5ʹ-actgtatcccagatgtaacattgtttagggaaagaaatggacaaatcagcaacaagatttg-3ʹ  
R: 5ʹ-caaatcttgttgctgatttgtccatttctttccctaaacaatgttacatctgggatacagt-3ʹ. 
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Cell Culture and Transfection 
For transfection of miRNA mimics, the mouse septal cholinergic cell line 
SN17 (Hammond et al. 1990) was grown in Dulbecco’s Modified Eagle’s Medium 
(1X DMEM, Corning Cat. No. 10-017-CV) supplemented with 10% fetal bovine 
serum (FBS) and 100 U/ml penicillin/streptomycin. SN17 cells were transfected 
in duplicate with 10 nM miR-106b-5p mimic (ThermoFisher, mirVana Assay ID 
MC10067) or control scramble miRNA mimic (ThermoFisher, miRVana, Negative 
control #1), introduced using Lipofectamine 2000 Reagent (Invitrogen Cat. No. 
11668027) in Opti-MEM reduced serum medium (Gibco, Cat. No. 31985062). 
After 24 hours, cells were harvested and RNA was isolated using an RNAqueous 
Total RNA Isolation kit (Ambion, AM1912) for RT-qPCR. 
For luciferase reporter gene assays, HEK293T cells were grown in 1X 
DMEM supplemented with 10% FBS and 100 U/ml penicillin/streptomycin. Cells 
were seeded at a density of 17,000 cells per well into 96-well plates. Cells were 
co-transfected in duplicate with 20 ng pMIR-REPORT Luciferase construct and 
20 ng pMIR-REPORT-β-galactosidase control plasmid (Applied Biosystems, 
AM5795), in combination with 10 nM miR-106-5p miRNA mimic or a scramble 
control mimic as described by Hogan et al., 2014. The plasmids and mimics were 
co-transfected in HEK293T cells using Opti-MEM and 0.08 µl of Lipofectamine 
2000 per well. Cells were harvested and lysed using 20 µl of 1X Reporter Buffer 
(Promega) 24 hours post-transfection and assayed for luciferase and β-
galactosidase activities.  
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Reporter Gene Assays 
Luciferase and β-galactosidase activity were assayed in duplicate, using 
commercially available kits (Luciferase Assay Kit, Promega Cat. No. 6066706; 
Galacto-Light Plus, Invitrogen Cat. No. T1007) on an MLX Microtiter Plate 
Luminometer (Dynex Technologies). To correct for transfection variability, 
luciferase activity was normalized to β-galactosidase activity in each sample. 
 
Knockdown of Pfn2 in SN17 cells by Lenti-GIPZ-shRNA 
 To test the efficacy of shRNAs targeting Pfn2, SN17 cells were infected 
lots of commercially available lentiviral particles expressing one of three distinct 
shRNAs directed against Pfn2 or a scramble shRNA control (Lenti-pGIPZ-shRNA, 
Dharmacon). The shRNA source clones targeted the following sequences: 
V3LMM_494366 5ʹ-TTTCCTACAATCATATCTA-3ʹ, V3LMM_494367 5ʹ-
TATCCACGTAGCTCTGCCA-3ʹ, V3LMM_494369 5ʹ-
CTGATCACAGAACACTTCT-3ʹ. SN17 cells (passage 5) were seeded at a 
density of 2.5 x 104 cells per well in a 24-well plate and incubated overnight. 
Cells were transduced with lentivirus (multiplicity of infection 0.4) in technical 
duplicates using 8 µg/ml polybrene in a total of 250 µl per well. After 5 hours, an 
additional 1 ml of complete growth medium was added to each well. 
Approximately 48 hours after transduction, medium was aspirated and replaced 
with 0.5 ml of complete growth medium containing 2.5 µg/ml puromycin to select 
for cells successfully transduced with lentivirus. Puromycin selection was 
	184 
performed for a total of 5 days, changing medium every other day. On day 5, 
cells were harvested and total RNA was isolated using the RNAqueous Total 
RNA Isolation Kit (ThermoFisher AM1912), eluting in 60 µl RNA (125 ng) was 
reverse transcribed using M-MLV Reverse Transcriptase (ThermoFisher Cat No. 
28025013) according to manufacturer’s instructions. Relative expression of Pfn2 
was measured by RT-qPCR. 
 
shRNA-mediated inhibition of Pfn2 in vivo 
To inhibit Pfn2 expression in vivo, we employed lentiviral delivery of 
shRNA targeting Pfn2 (sense sequence 5ʹ-AGAAGTGTTCTGTGATCAG-3ʹ) to 
the IPN or VTA. Lenti-pGIPZ-Pfn2-shRNA-tGFP (2.37x108 TU/ml, 
V3LMM_494369, Dharmacon) or a control virus expressing a non-silencing 
shRNA (lenti-pGIPZ-scramble-tGFP, 9.06x108 TU/ml, RHS4348, Dharmacon) 
were injected into IPN or VTA and expressed for 4 weeks prior to all experiments. 
After behavioral testing, a subset of mice were used to confirm knockdown 
of Pfn2 expression in vivo. Fresh frozen brains were cryosectioned (12-µm), fixed 
in ice-cold acetone, and dehydrated in ethanol (70%, 90%, 100%) and xylenes. 
Areas expressing tGFP were isolated by laser capture microdissection (LCM; 
Arcturus). RNA was isolated using RNAqueous-Micro Total RNA Isolation Kit 
(Ambion) for RT-qPCR.  
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Stereotaxic Lentiviral Injection  
Stereotaxic injections were performed under aseptic conditions on mice 
aged 6 weeks  as otherwise described by Molas et al. (Molas et al. 2017). Virus 
was injected in the IPN or VTA (unilateral) at coordinates measured from the 
Bregma (in mm, anterioposterior, mediolateral, dorsoventral at 0°): IPN  (-3.47, 
±0, -4.77), VTA (-3.45, 0.5, -4.2) using a 26s gauge 10-µl syringe (701RN, 
Hamilton) to deliver 300 nl of virus at a controlled rate of 60 nl/min. Unilateral 
VTA injections were equally distributed on the left and right within each treatment 
group.  
 
Behavioral Assays  
 All behavioral testing was performed during the light phase in dim white 
light after habituation to the testing room (≥30 min). On the first test day, mice 
underwent the marble-burying test (MBT) followed by the elevated plus maze 
(EPM). Approximately 48 hours later, mice underwent object novelty preference 
testing. Testing was performed in two cohorts of virus-injected mice, with 
balanced treatment groups by an experiementer blinded to the treatment groups. 
Lenti-virus expression was confirmed by fluorescence microscopy of tGFP. Mice 
with no virus expression in the brain region of interest were excluded from 
analysis.  
MBT. For 2 days prior to testing, mice were habituated to individual 
standard mouse cages, filled 5-6 cm with bedding material, for approximately 1 
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hour per day. On the test day, 15 sterilized 1.5-cm diameter glass marbles were 
placed in the cages, equally spaced in a 3 x 5 grid arrangement. Mice were 
placed in the test cage for 30 min. then returned to their home cage. The number 
of marbles buried at least 75% with bedding were counted by an experimenter 
blinded to treatment. 
EPM. Testing was performed on a sanitized, black Plexiglas apparatus 
consisting of 2 open (30 x 5 x 0.25 cm) and 2 closed arms with high walls (30 x 5 
x 15 cm), arranged in a perpendicular arrangement, 45 cm above the floor. Mice 
were placed individually in the junction (5 x 5 cm) facing the open arms and 
allowed to freely explore the maze for 5 min. Time spent in each arm and the 
number of arm entries was recorded by MED-PC IV software (MED Associates, 
Inc.). 
Object Novelty Preference Test. Testing was performed using a protocol 
modified from previously established methods used in our laboratory(Molas et al. 
2017). A T-shaped maze (three arms, each 9 x 30 x 20 cm, connected through a 
9 x 9 cm central zone) made of white Plexiglas was used to examine interest in 
familiar and novel inanimate objects under dim red light conditions. First, the 
mouse was habituated to the apparatus for 5 min and removed. Two identical 
plastic objects were placed in the ends of the T-maze, one in each end. The 
mouse was immediately placed back into the maze for 5 min and allowed to 
investigate the two identical novel objects (N1). The mouse was removed and 
one object was replaced by a novel object in the same location as the previous 
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object (counter-balanced). The mouse was immediately placed in the T-maze 
and allowed to investigate the familiar (F1) and novel (N2) objects. All sessions 
were video recorded from above (HDR-CX4440 camera, Sony) and mouse 
behavior was tracked automatically using EthoVision XT 11.5 (Noldus Apparatus). 
A blind experimenter manually scored the times the mouse explored the familiar 
and novel objects. Exploration was defined as sniffing with the nose directed at 
the object from a distance of less than 2 cm. Simply sitting or resting next to the 
object was not counted as exploration. The novel object preference ratio was 
calculated as: (total novel object investigation – total investigation)/(total 
investigation) over the third 5-min session. The apparatus and objects were 
cleaned with Micro-90 solution (International Products Corporation) to eliminate 
olfactory traces after each session. 
 
 
 
IV. C. Results 
 
miR-106b-5p represses the expression of Pfn2 in vitro.  
To test the hypothesis that miR-106b-5p negatively regulates the 
expression of Pfn2, SN17 cells were transfected with miR-106b-5p mimic 
followed by measurement of Pfn2 expression by RT-qPCR. In cells transfected 
with 10 nM miRNA mimic, miR-106b-5p expression was significantly up-
	188 
regulated by a fold change of 329.6 ± 107.6 compared to cells transfected with 
scramble control (Figure 4.1A). Transfection with miR-106b-5p mimic significantly 
repressed Pfn2 (Figure 4.1B) expression by a fold change of 0.5547 ± 0.1047. 
Importantly, expression of profilin1 (Pfn1), a Pfn2 paralog, was not significantly 
altered (Figure 4.1C). 
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Figure 4.1. Over-expression of miR-106b-5p down-regulates Pfn2, but not 
Pfn1, expression in SN17 cells. SN17 cells were transfected with 10 nM miR-
106b-5p mimic (empty bars) or scramble control (filled bars). Total RNA was 
isolated and relative gene expression was measured by RT-qPCR. Data are 
presented as mean ± SEM, normalized to scramble control. Unpaired, two-tailed 
t-test was used to compare relative expression of miR-106b-5p (A, t6 = 3.053, P = 
0.0224), Pfn2 (B, t6 = 4.639, P = 0.0035) and Pfn1 (C, t6 = 0.9684, P = 0.3702) in 
cells transfected with mimic compared to scramble controls. (*) P < 0.05, (**) P < 
0.01; n = 4.  
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To test the hypothesis that one or both of the predicted MREs are required 
for the repression of Pfn2 expression by miR-106b-5p, we employed a luciferase 
assay screen. HEK293T cells were co-transfected with miR-106b-5p mimic and a 
luciferase reporter containing the 3ʹ-UTR of Pfn2 with the WT MRE sequences, a 
single MRE mutant (MRE1 or MRE2), or a double mutant (MRE1/2) (Figure 4.2A). 
Co-transfection with a miR-106b-5p mimic and reporter for WT or MRE1 Mutant 
3ʹ-UTR, resulted in significant repression of luciferase activity compared to co-
transfection of the WT reporter with scramble control. However, mutation of 
MRE2 individually or in combination with MRE1 results in de-repression of 
luciferase activity when co-transfected with miR-106b-5p mimic. This indicates 
that MRE2 at nucleotide position 1197-1203, but not MRE1, is required for 
repression of Pfn2 by miR106-5p. 
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Figure 4.2. MRE2 at position 1197-1203 within the Pfn2 3ʹ-UTR is required 
for repression of Pfn2 by miR-106b-5p. (A) There are two predicted MREs for 
miR-106b-5p within the 3ʹ-UTR of Pfn2. The miR-106b-5p sequence is bolded. 
The predicted MRE seeds are highlighted in gray, and their positions within the 
3ʹ-UTR are listed. A WT luciferase reporter containing the WT sequences at 
MRE1 and MRE2 is shown in black. Mutant Pfn2 3ʹ-UTR reporters for each MRE 
individually (MRE1 Mut, MRE2 Mut) and combined (MRE1/2 Mut) were 
generated by site-directed mutagenesis of 4 nucleotides, indicated in red. (B) 
Predicted MREs were tested for miRNA-mediated repression of luciferase activity 
in HEK293T cells. Each bar represents normalized luciferase activity of cells co-
transfected with the indicated luciferase/Pfn2 3ʹ-UTR reporter and a miR-106-5p 
mimic, or a negative control scramble miRNA mimic. Data are presented as 
mean ± SEM, normalized to the WT Pfn2 3ʹ-UTR reporter co-transfected with the 
scramble miRNA mimic. One-way ANOVA indicates there were significant 
differences between the mean relative luciferase activities detected in the 
indicated transfection groups (F4,26 = 3.532, P = 0.0198). Dunnett’s post-test was 
used for statistical analysis comparing each treatment to the WT Pfn2 3ʹ-UTR 
reporter co-transfected with the scramble miRNA mimic. (*) P < 0.05, n = 5-9. 
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Down-regulation of Pfn2 in the IPN is sufficient to induce anxiety.  
Withdrawal from nicotine has been shown to induce anxiety in mice 
through activation of the IPN (Zhao-Shea et al. 2015). Using our treatment 
paradigm, WT NAWD mice displayed increased anxiety compared to nicotine- 
and TA-treated controls, as measured by the marble burying test and EPM 
(Figure 2.1). Because Pfn2-/- mice display increased synaptic vesicle exocytosis 
and hyperactivation of neurons (Pilo Boyl et al. 2007), we hypothesized that 
repression of Pfn2 in the IPN is sufficient to induce anxiety, mimicking the 
behaviors observed in NAWD mice.  
To knockdown Pfn2 expression, the efficacies of three different 
commercially available shRNAs were tested in SN17 cells, a neuronal cell line 
derived from mice that exhibits endogenous expression of Pfn2. Transduction of 
SN17 cells with lenti-pGIPZ-Pfn2-shRNA-tGFP (Dharmacon) expressing 3 
distinct shRNAs revealed shRNA494369 produced significant knockdown by 
80.85% ± 0.4578 compared to cells transduced with lentivirus expressing a 
scramble control shRNA (Figure 4.3).  
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Figure 4.3. Transduction of Lenti-pGIPZ-Pfn2-shRNA494369-tGFP results in 
approximately 80% knockdown of Pfn2 in SN17 cells. SN17 cells were 
transduced with the indicated lenti-pGIPZ-Pfn2-shRNA-tGFP or lenti-pGIPZ-
Scramble-tGFP negative control as described in the Supplemental Methods and 
Materials. Total RNA was isolated and relative expression of Pfn2 was 
determined by RT-qPCR. Data are presented as mean ± SEM, relative to lenti-
scramble control. Statistical analysis was performed using a one-way ANOVA 
(F3,4 = 31.49, P = 0.0031) with Dunnett’s post-test, (**) P < 0.01; (n = 2) 
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To test the hypothesis that knockdown of Pfn2 in the IPN is sufficient to 
induce anxiety, the IPN of nicotine-naïve mice was injected with lenti-pGIPZ-
Pfn2-shRNA494369-tGFP or control virus (Figure 4.5A). After 4 weeks of 
expression, mice underwent behavioral testing for anxiety and were sacrificed to 
confirm virus injection location and in vivo knockdown of Pfn2. Injection of the 
IPN with lenti-pGIPZ-Pfn2-shRNA494369-tGFP resulted in 54.32% ± 12.49 
knockdown of Pfn2 expression in areas of the IPN enriched in cells expressing 
tGFP (Figure 4.5B) compared to mice injected with control virus. Virus 
expression was limited to the IPN and immediately surrounding brain areas, with 
no spread to distant midbrain regions, as detected by fluorescence microscopy 
(Figure 4.6).  
When Pfn2 was knocked down in the IPN, mice spent significantly less 
time in the open arms of the EPM compared to controls (Figure 4.5C). 
Importantly, there was no significant difference in the number of total arm entries, 
indicating the results are not confounded by non-specific effects on locomotor 
activity (Figure 4.5C). To control for effects of lentiviral spread into the 
neighboring VTA, anxiety was measured in mice injected with lenti-pGIPZ-Pfn2-
shRNA494369-tGFP in the VTA unilaterally (Figure 4.7). Any expression of 
lentivirus in the IPN resulted in exclusion from this control experiment. When 
Pfn2 was knocked down in the VTA unilaterally, there was no significant effect on 
the amount of time spent in the open arms of the EPM or total number of arm 
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entries (Figure 4.5D). There was no significant effect of Pfn2 KD in the IPN or 
VTA on the number of marbles buried in the marble bury test (Figure 4.8). 
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Figure 4.5. Knockdown of Pfn2 in the IPN is sufficient to increase anxiety in 
the elevated plus maze. (A) Representative midbrain coronal section schematic 
and fluorescence microscopy image of WT mouse injected with lenti-pGIPZ-
Pfn2-shRNA-tGFP (green) in the IPN. Nuclei were labeled with DAPI (blue). (B) 
Knockdown of Pfn2 expression was measured by RT-qPCR using RNA from 
laser-captured IPN tissue infected with lenti-pGIPZ-Pfn2-shRNA-tGFP compared 
to lenti-pGIPZ-scramble-tGFP control. mRNA expression was normalized to β-2-
microglobulin. Statistical analysis using an unpaired, two-tailed t-test compared 
lenti-Pfn2 shRNA mice to lenti-scramble controls (t11 = 2.272, P = 0.0441). (*) P < 
0.05; n = 6-7. (C) Average time spent in the open arms and total number of arm 
entries in the elevated plus maze of mice injected with either lenti-Pfn2 shRNA 
(open bars) or lenti-scramble shRNA control (filled bars) in the IPN. Data are 
presented as the mean ± SEM. Statistical analysis used an unpaired two-tailed t-
test to compare time spent in open arms (t33 = 3.583, P = 0.0011) and total 
number of arm entries (t33 = 0.7355, P = 0.4672) of lenti-Pfn2 shRNA mice to 
lenti-scramble controls. (**) P < 0.01 n = 16-19. (D) Average time spent in the 
open arms and average total number of arm entries in the elevated plus maze of 
mice unilaterally injected with either lenti-Pfn2 shRNA (open bars) or lenti-
scramble shRNA control (filled bars) in the VTA. Data are presented as the mean 
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± SEM. Unpaired, two-tailed t-test was used for statistical analysis of time spent 
in open arms (t16 = 1.09, P = 0.2918) and total arm entries (t16 = 0.4153, P = 
0.6835). n = 9. 
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Figure 4.6. Lenti-pGIPZ-Pfn2-shRNA-tGFP injected in the IPN does not 
spread to distant brain regions within the midbrain. Representative midbrain 
coronal section from a WT mouse injected with lenti-pGIPz-Pfn2-shRNA-tGFP 
(green) in the IPN. There is no expression of virus above background levels in 
the MGV of the same slice represented in Fig. 4.5. DG: dentate gyrus; GrDG: 
granular layer of the dentate gyrus; MGV: medial geniculate complex, ventral part; 
PoDG: polymorph layer of the dentate gyrus. 
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Figure 4.7. Lenti-pGIPZ-Pfn2-shRNA-tGFP injection of the VTA. 
Representative midbrain coronal section from a WT mouse infected with lenti-
pGIPZ-Pfn2-shRNA-tGFP in the VTA (green).  Nuclei were labeled with DAPI 
(blue).  IF: interfascicular nucleus, IPN: interpeduncular nucleus; PN: paranigral 
nucleus; VTA: ventral tegmental area. 
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Figure 4.8. Knockdown of Pfn2 in the IPN is not sufficient to increase 
anxiety in the marble burying test. Prior to testing on the EPM, WT mice 
injected with lenti-pGIPZ-Pfn2-shRNA-tGFP or lenti-scramble control were 
assayed in the marble burying test. Knockdown of Pfn2 expression in the IPN (A) 
or VTA (unilateral; B) did not significantly alter the number of marbles buried 
compared to controls. Data are presented as the mean ± SEM. Statistical 
analysis used an unpaired, two-tailed t-test to compare number of marbles buried 
after knockdown of Pfn2 expression in the IPN (t33 = 1.612, P = 0.1165, n = 16-19) 
or VTA (unilateral, t16 = 0.5177, P = 0.6117, n = 9) compared to lenti-scramble 
controls.  
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Knockdown of Pfn2 in the IPN is not sufficient to alter object novelty 
preference. 
Because the IPN is also a prominent brain region in the circuitry 
underlying novelty preference (Molas et al. 2017) and novelty seeking behaviors 
are altered in Pfn2 knockout mice (Pilo Boyl et al. 2007), we also tested the effect 
of Pfn2 knockdown on object novelty preference. Briefly, during the test round of 
this assay, mice are allowed to explore a T-maze containing a novel and familiar 
object and the time spend actively investigating each is measured (Figure 4.9A). 
Expression of lenti-pGIPZ-Pfn2-shRNA494369-tGFP in the IPN did not 
significantly affect the time spent exploring the familiar or novel objects, the novel 
object preference ratio (calculated as described in the materials and methods), or 
the total time spent investigating the objects compared to controls (Figures 4.9B-
D).  
  
	202 
 
 
Figure 4.9. Knockdown of Pfn2 in the IPN is not sufficient to alter object 
novelty preference. (A) Schematic of experimental protocol described in the 
Supplemental Methods and Materials. Mice expressing lenti-pGIPZ-Pfn2-shRNA-
tGFP (open bars) in the IPN were compared to those expressing control virus 
(filled bars). (B) The time of investigation of the familiar (F1) and novel (N2) 
objects were manually scored by a blind experimenter for 5 minutes. Statistical 
testing by two-way ANOVA found there was significant effect of the row factor 
(object novelty) on the time of investigation (F1,66 = 321.2, P < 0.0001). However, 
there is no significant effect of the column factor (virus injection) on the time of 
investigation (F1,66 = 0.1425, P = 0.7071) (C) There is no difference in the novel 
object preference (t33 = 1.039, P = 0.3064, unpaired two-tailed t-test). (D) There 
is no difference in total time investigating the familiar and novel objects combined 
(t33 = 0.3692, P = 0.7143, unpaired two-tailed t-test). All data are presented as 
the mean ± SEM. n = 16-19. 
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4.D. Discussion 
 
 As an example of the utility of our miRNA/mRNA-Seq data analysis 
described in Chapters 2 and 3, we focused upon one gene regulated by acute 
nicotine withdrawal in the IPN, which was also predicted to be a target of an 
inversely expressed miRNA. Differential expression analysis of mRNA 
sequencing revealed Pfn2 was down-regulated by 50.4% in the IPN of mice 
experiencing acute nicotine withdrawal compared to drug-naïve controls. Pfn2 is 
a predicted target of miR-106b-5p, which was up-regulated by 78.9% during 
acute nicotine withdrawal. We demonstrated that over-expression of miR-106-5p 
repressed Pfn2 expression in a cholinergic cell line. While transfection of cells 
with miRNA mimic increased the relative expression of miR-106b-5p to a level far 
beyond what is physiological or what is observed during nicotine withdrawal, the 
expression of Pfn1, a paralog that does not contain an MRE, was unaffected. 
This would support the hypothesis that over-expression of miR-106b-5p 
selectively represses its predicted targets, including Pfn2. 
To determine if one or both of the predicted MREs within the 3ʹ-UTR of 
Pfn2 are required for repression by miR-106b-5p, we used a luciferase assay 
with reporters containing the 3ʹ-UTR of WT Pfn2, single MRE mutants, and a 
double MRE mutant. This assay determined an intact MRE2 at nucleotide 
position 1197-1203, but not MRE1, was required for repression of Pfn2 3ʹ-UTR 
reporter by miR-106b-5p. Further supporting MRE2 as a biologically functional 
target of miR-106b-5p, TargetScan mouse 7.1 ranked MRE2 with a higher 
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probability of conserved targeting (PCT) (Friedman et al. 2009) of 0.83. 
Comparatively, MRE1 at position 452-458 had a PCT of 0.63. Additionally, there is 
a strong preference for miRNAs to target MREs located in close vicinity to the 
stop codon and polyadenylation sites (Majoros and Ohler 2007). This further 
supports that MRE2, located nearer to the 3ʹ-end of the transcript, is likely to be 
biologically functional. 
We hypothesized that down-regulation of Pfn2 by acute nicotine 
withdrawal in the IPN contributes to nicotine withdrawal-induced 
neuroadaptations underlying anxiety behaviors. Pfn2 is an actin monomer-
binding protein, enriched in the central nervous system, that acts a regulator of 
cytoskeletal dynamics (Witke et al. 2001, Witke 2004). Through an additional 
poly-L-proline binding domain, Pfn2 also interacts with a variety of other ligands 
with functions in synaptic morphology and function (Witke 2004). For example, 
Pfn2 accumulates in the dendritic spines of activated neurons (Ackermann and 
Matus 2003, Lamprecht et al. 2006), regulating their complexity (Da Silva et al. 
2003, Michaelsen et al. 2010). Additionally, through interactions with specific 
effectors, Pfn2 regulate neuritogenesis in response to physiological stimuli (Da 
Silva et al. 2003). Interestingly, our GO analysis (discussed in Chapter 3) 
revealed an enrichment of down-regulated genes related to cellular projection 
organization and neuron projection development in the IPN during nicotine 
withdrawal (Figure 3.4). We hypothesized that this enrichment may reflect 
changes in neuron morphology regulated by expression changes including the 
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repression of Pfn2. However, further studies are needed to determine the 
morphological changes of neurons in the IPN during acute nicotine withdrawal.  
The IPN is activated during acute nicotine withdrawal, resulting in 
increased anxiety (Zhao-Shea et al. 2013, Zhao-Shea et al. 2015). Pfn2 has also 
been shown to play a role in modulating synaptic activity. Through its interactions 
with a variety effectors involved in vesicle formation and the membrane scaffold, 
Pfn2 can regulate synaptic vesicle release and the composition of receptors at 
the synaptic membrane (Mammoto et al. 1998, Witke et al. 1998, Witke 2004, 
Gareus et al. 2006, Mondin et al. 2010). In addition, Pfn2 -/- mice show increased 
vesicle exocytosis and hyperactivation of the striatum (Pilo Boyl et al. 2007). In 
light of this evidence, we hypothesized that down-regulation of Pfn2 expression 
during acute nicotine contributes to activation of the IPN during withdrawal, 
increasing anxiety-associated behaviors. Supporting this hypothesis, we show 
that knockdown of Pfn2 expression in the IPN of nicotine-naïve mice was 
sufficient to increase anxiety as measured by EPM, mimicking behaviors 
observed in WT mice during acute nicotine withdrawal. However, the MBT did 
not detect effect of Pfn2 knockdown in the IPN on anxiety. As discussed in 
Chapter 2, the somatic symptoms of acute, spontaneous nicotine withdrawal may 
contribute to increased marble burying and the MBT may have limitations in 
detecting anxiogenic effects of drugs (Jimenez-Gomez et al. 2011). Thus, 
although the EPM is the gold-standard for measuring anxiety in mice, future 
experiments should confirm this result using additional behavioral assays, such 
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as the open field test. The effect of repressing Pfn2 expression in the IPN on 
behavior is specific for anxiety with no alterations in locomotor activity or object 
novelty preference, another behavior controlled by the IPN (Molas et al. 2017). 
To deepen our understanding of the functional consequences of Pfn2 knockdown, 
future studies should focus on assessing the activation and morphology of 
neurons expressing Pfn2 shRNA.. 
 To control for the effects of lentiviral spread into the neighboring VTA, 
lenti-Pfn2 shRNA was injected into the VTA unilaterally and anxiety was 
measured. Unilateral knockdown of Pfn2 in the VTA did not significantly affect 
increase anxiety, but there was a trend towards a decreased time spent in the 
open arms in the EPM. Future studies should examine the anxiogenic effects of 
repressing Pfn2 expression in the VTA bilaterally. 
In addition to the knockdown of Pfn2 using a lentiviral shRNA, future 
experiments may use an inducible Pfn2 knockout mouse employing they Cre-lox 
system as a complementary approach. For example, generation of a mouse line 
with loxp sites flanking the Pfn2 gene would allow for the conditional knockout of 
Pfn2 in the IPN of adult mice via the injection of AAV expressing Cre 
recombinase.   
Taken together, our results suggest a role for the down-regulation of Pfn2 
by miR-106b-5p in the IPN in the induction of nicotine withdrawal-associated 
anxiety behaviors. However, the specific mechanisms underlying the effects of 
Pfn2 expression on neuronal activity and morphology in the IPN has yet to be 
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elucidated. Further work should focus on determining the effect of nicotine 
withdrawal, repression of Pfn2, and over-expression of miR-106b-5p on 
activation, organization, and morphology of the neurons and synapses of the IPN. 
Additionally, future experiments should investigate the effectors interacting with 
Pfn2. For example, Pfn2 interacts directly with ROCK, a Rho GTPase effector 
whose inhibition in the mouse brain has been shown to induce anxiety (Da Silva 
et al. 2003, Saitoh et al. 2006). The role of ROCK and other ligands of Pfn2 in 
nicotine withdrawal-induced behaviors must be pursued to fully understand the 
molecular mechanisms underlying the function of Pfn2 and identify additional 
targets for pharmaceutical treatments of affective withdrawal symptoms.  
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CHAPTER 5 
Discussion and Future Directions 
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5.A. Discussion and Conclusions 
 
Nicotine addiction is a chronic relapsing disease during which many users 
cycle through periods of use and withdrawal when attempting to quit (Koob and 
Le Moal 2008). While the positive rewarding effects dominate early use of a 
nicotine, it is avoidance of the negative withdrawal symptoms that motivate 
continued use and relapse (Hughes 2007, Piper et al. 2011, Aguirre et al. 2015). 
Nicotine acts on nAChRs which are concentrated in the mesocorticolimbic 
reward and habenulo-interpeduncular withdrawal circuits in the brain (Marks et al. 
1998, Dani and Bertrand 2007), mediating the two phases of the disease process 
of addiction. There is a great body of evidence describing the circuitry underlying 
behaviors associated with nicotine reward and withdrawal. However, the majority 
of current literature focuses on the up-regulation and activation of specific nAChR 
subtypes and other neurotransmitter receptors within these circuits, leaving much 
to be uncovered about alternative molecular mechanisms underlying the 
neuroadaptations of nicotine dependence. For example, miRNAs have been 
shown to be regulated by nicotine exposure (Lippi et al. 2011, Im and Kenny 
2012, Lee et al. 2015), but their targets and functions in nicotine reward or 
withdrawal have not been confirmed. In an effort to identify novel mechanisms 
underlying the neuroadaptations of nicotine dependence, we sequenced miRNAs 
and mRNAs of brain regions comprising the mesocorticolimbic reward and 
habenulo-interpeduncular withdrawal circuits. This work presents integrated 
	210 
differential expression and target prediction analyses of miRNAs/mRNAs within 
the NAc, midbrain, MHb and IPN during chronic nicotine treatment and 
withdrawal. We propose that this dataset represents a valuable resource, aiding 
in the identification of candidates regulated by nicotine treatment and withdrawal, 
such as Pfn2, for detailed future study. 
 
The mesocorticolimbic transcriptome is regulated primarily by chronic 
nicotine exposure. 
In Chapter 2, I presented differential expression analysis of miRNAs and 
mRNAs in the NAc and midbrain (enriched in VTA), prominent brain regions in 
the mesocorticolimbic DAergic reward pathway. In the NAc, chronic nicotine 
treatment induced limited changes in miRNA expression. However, there was 
widespread up- or down-regulation of mRNAs with fold changes > 2  induced by 
chronic nicotine treatment in the NAc. These altered mRNAs are enriched for GO 
categories including those related to neuron projection organization, synapse 
activity, binding of neurotransmitter receptors, and regulation of neurotransmitter 
levels. These changes in mRNA expression are likely reflective of the increased 
activation of the NAc in response to nicotine exposure, and these genes may 
contribute to the molecular mechanisms underlying the rewarding properties of 
nicotine, tolerance or sensitization.  
After a short withdrawal of just 48 hours, approximately 97% of nicotine 
responsive genes in the NAc return to levels of expression observed in nicotine-
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naïve animals. This would suggest that the increased anxiety behavior exhibited 
by mice in acute nicotine withdrawal is not due to regulation of gene expression 
at the transcript level in the NAc. Alternatively, it remains possible that chronic 
nicotine induces transient alterations in gene expression that result in persistent 
changes in the neuronal function beyond the level of the transcript. This may 
include persistent changes in protein levels, localization, and activation state, 
influencing neuronal and synaptic function and morphology. These possible 
alterations of the synapse during chronic nicotine exposure may create a new 
homeostatic state which is disturbed by subsequent withdrawal of nicotine, 
resulting in neuronal dysfunction and behavioral disturbances including anxiety. 
The midbrain is similar to the NAc, in that chronic nicotine treatment 
induces widespread changes in mRNA expression, with very few alterations in 
miRNA expression. Again, the induction of transcriptional changes in the 
midbrain is likely reflective of the activation of the mesocorticolimbic DAergic 
pathway in response to nicotine treatment. However, the identity of up-or down-
regulated genes in the midbrain is dissimilar to the NAc, indicating that regulation 
of gene expression by chronic nicotine treatment occurs in a brain-region specific 
manner within the reward pathway. This is also reflected in the GO analysis. For 
example, in the midbrain there is an overrepresentation of up-regulated mRNAs 
related to neuronal and synaptic activity and structure. Interestingly, these same 
categories are enriched in down-regulated genes in the NAc. Because both of 
these regions are activated by nicotine exposure (De Biasi and Dani 2011, 
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Pistillo et al. 2015), this inverse relationship of GO enrichment is somewhat 
surprising. This further supports brain-region specific molecular mechanisms 
underlying the nicotine-induced changes in neuronal function within the reward 
circuit.  
Unlike the NAc, there is widespread differential expression of mRNA and 
miRNA expression in the midbrain during acute nicotine withdrawal. The majority 
of mRNA regulation in the midbrain of NAWD mice is due at least in part to the 
persistent effects of the initial chronic nicotine treatment. For instance, 
approximately 92% of the mRNAs that are up- or down-regulated during chronic 
nicotine treatment remain similarly altered in NAWD mice. In addition, only 2% of 
mRNAs regulated in NAWD mice compared to nicotine-naïve controls are 
regulated solely as an effect of nicotine withdrawal, being similarly differentially 
expressed in NAWD mice compared to either TA- or Nic-treated mice. This 
suggests that chronic nicotine treatment induces changes in gene expression 
that persist for at least 48 hours of withdrawal, possibly contributing to the 
induction of affective symptoms experienced during acute withdrawal, including 
anxiety. While traditionally thought of as a core component of the reward circuit, 
the VTA has been shown to project to at least a subset of neurons within the IPN, 
regulating nicotine withdrawal-associated anxiety (Zhao-Shea et al. 2015). The 
transcriptional regulation of RNAs isolated from midbrain punches enriched in 
VTA during acute nicotine withdrawal may reflect its interconnectedness with the 
traditional withdrawal circuit. 
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Similar to the time course of self-reported symptoms in human patients 
(Hughes 2007), nicotine dependent mice continue to display increased anxiety 
after 4 weeks of nicotine abstinence. Intriguingly, after a prolonged withdrawal 
period, all transcripts differentially expressed in the midbrain and NAc during 
acute nicotine withdrawal return to levels observed in age-matched nicotine 
naïve mice. This suggests that regulation of these miRNAs and mRNAs at the 
transcript level does not contribute to the persistent anxiety associated with 
nicotine withdrawal. Again, alterations in gene expression during the initial 
chronic nicotine treatment or withdrawal may contribute to alterations in neuronal 
function beyond the RNA level, including protein quantity, localization, and 
activation state, not detected by RNA-sequencing. There are 16 and 1 mRNAs 
uniquely differentially expressed in NAc and midbrain, respectively, of NLWD 
mice compared to age-matched controls. This suggests that this small subset of 
transcripts exhibit delayed regulation which persists for at least 4 weeks. This 
delayed response to nicotine exposure may reflect the delayed synaptic 
potentiation observed in the NAc (Schoffelmeer et al. 2002, Kourrich et al. 2007). 
The regulation of these mRNAs may contribute to the long lasting increase in 
anxiety associated with nicotine withdrawal and should be the focus of future 
studies. 
In summary, Chapter 2 provides data showing chronic nicotine treatment 
induces extensive differential expression of mRNAs in both the NAc and midbrain. 
The majority of these effects are reversed by nicotine withdrawal in the NAc, 
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while they persist in the midbrain. This contrast in the general pattern of 
differential expression, as well as the specific identity of these nicotine 
responsive mRNAs, exemplify the brain region-specific regulation of the 
transcriptome within the reward circuit. These region-specific alterations in 
transcript expression in response to nicotine exposure may reflect changes in 
neural activity and neuroadaptations contributing to nicotine reward-associated 
behaviors, as well as a dual role for the VTA in both the reward and withdrawal 
circuitries. One caveat of the differential expression analysis of the mRNA-Seq is 
the application of a fold change threshold > 2. While we chose to focus on only 
robust changes in gene expression, smaller alterations in gene expression that 
may contribute to nicotine-invoked synaptic plasticity may be overlooked. 
One major limitation of the differential expression analysis of the miRNA- 
and mRNA-Seq experiments is the use of tissue punches. Punches are 
heterogeneous tissue samples containing multiple brain sub-regions, neuron-
types, as well as non-neuronal cell types like glia. Different subregions of the 
mesocorticolimbic DAergic circuit play distinct roles in the manifestation of 
reward behavior. For example, activation of the NAc shell is important for nicotine 
reward (Ikemoto et al. 1997, Ikemoto 2007), while the core is involved in cue-
conditioned motivated behaviors (Sesack and Grace 2010). Additionally, 
activation of the pVTA, as opposed to the aVTA, is important for nicotine reward-
associated behaviors (Ikemoto et al. 2006, Zhao-Shea et al. 2011). Tissue 
punches captured all sub-regions of the NAc and midbrain (enriched for VTA). 
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Region-specific alterations in gene expression during chronic nicotine treatment 
and withdrawal can not be discerned and may not be detected in RNA extracted 
from the heterogeneous tissue sample. Additionally, specific neuron-types 
contribute to the detailed microcircuitry of the mesocorticolimbic pathway 
underlying nicotine-reward associated behaviors, as discussed in Chapter 1. The 
heterogeneous population of cell types may result in the masking of important 
cell-type specific changes in expression. Further bioinformatic analyses may 
determine the relative contribution of distinct cell types to the total RNA 
population by evaluating the expression of cell type-specific markers. These may 
include neuron type-specific markers such as TH (DAergic), DAT (DAergic), 
GAD65/67 (GABAergic), ChAT (cholinergic), vGlut1/2 (glutamatergic), and TPH 
(serotonergic). Additionally, expression of glial markers such as Olig1-3 
(oligodendrocytes), GFAP (astrocytes), and CD11b (microglia) should be 
determined to evaluate the proportion of glial cells present in tissue punches. 
Future sequencing experiments should use a more targeted approach, using 
RNA extracted from specific subregions or cell-types, or more advanced 
technologies may be employed to perform single-cell sequencing. 
 
Acute nicotine withdrawal induces differential expression of miRNAs and 
mRNAs in the habenulo-interpeduncular circuit. 
In Chapter 3, I presented differential expression analysis of miRNAs and 
mRNAs in the habenulo-interpeduncular withdrawal circuit during chronic nicotine 
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treatment and withdrawal. Interestingly, the IPN and the MHb display similar 
patterns of transcript regulation. Chronic nicotine treatment induces very limited 
alterations in miRNA expression. Additionally, there are few mRNAs up- or down-
regulated with fold changes > 2 in either region. However, after acute withdrawal 
from nicotine, there are widespread alterations in miRNA and mRNA expression 
compared to drug naïve animals. Furthermore, in both regions, a large proportion 
of this regulation is an effect solely of nicotine withdrawal, with no significant 
contribution of the chronic nicotine treatment itself. For instance, 33% of miRNAs 
and 91% of mRNAs regulated in the IPN of mice experiencing acute nicotine 
withdrawal compared to drug naïve mice are similarly altered when compared to 
nicotine-treated mice. Likewise, 47% of miRNAs and 79% of mRNAs differentially 
expressed in the MHb of NAWD mice compared to TA controls are similarly 
regulated when compared to mice exposed to chronic nicotine.  
The withdrawal-specific differential expression occurring in the MHb and 
IPN is reflective of the activation of the habenulo-interpeduncular circuit in acute 
nicotine withdrawal. This is also manifested in the GO analysis of the genes up- 
or down-regulated in the IPN and MHb of NAWD mice. In both regions, there is 
an enrichment of up-regulated genes related to the vesicle and myelin sheath. 
There is also an overrepresentation of down-regulated genes in the IPN and 
MHb in GO terms related to neuron projection development. This pattern of 
enrichment may represent neuroadaptations affecting synaptic transmission, 
signal transduction, and morphology occurring when these regions are activated 
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by nicotine withdrawal. In addition, there is enrichment of GO terms related to the 
structure and function of ribosomes and mitochondria in both the IPN and MHb. 
This may be indicative of the neurons responding to the increased demand for 
protein products and energy when activated during nicotine withdrawal. However, 
when comparing the specific identity of nicotine and withdrawal responsive 
mRNAs, there are no genes similarly regulated in both the IPN and MHb. This 
suggests that although there are similar alterations in the molecular functions and 
biological processes throughout the withdrawal circuit, the molecular 
mechanisms underlying these neuroadaptations during acute nicotine withdrawal 
are brain-region specific. One important caveat of this differential expression 
analysis was the application of a fold change threshold > 2. Although this allows 
us to focus on robust changes in gene expression, smaller fold changes which 
might be relevant to neuronal morphology and synaptic function may be 
overlooked.  
Taken together, differential expression of miRNAs and mRNAs in the 
regions comprising the mesocorticolimbic reward and habenulo-interpeduncular 
withdrawal circuits during chronic nicotine treatment and withdrawal reflect the 
activation and known functions of each brain region. This is most striking in the 
MHb-IPN withdrawal axis, where the majority of robust transcript regulation 
occurs only when nicotine is withdrawn. In contrast, largely transient differential 
expression occurs in the NAc, a prominent reward center, in response to chronic 
nicotine treatment. The VTA, traditionally thought of as a member of the 
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mesocorticolimbic circuit, actually has a dual role in reward and withdrawal 
through its connectivity with the IPN (Zhao-Shea et al. 2015). Differential 
expression analysis of the sequencing results support this dual role. A multitude 
of transcripts are regulated in midbrain punches enriched for VTA in response to 
chronic nicotine treatment, as observed in the NAc. However, the persistence of 
these expression changes during acute nicotine withdrawal resembles the 
widespread alterations in gene expression observed in the IPN and MHb of 
NAWD mice. 
As in the transcriptome analysis of NAc and midbrain in the 
mesocorticolimbic pathway, the use of tissue punches for miRNA- and mRNA-
sequencing is a major limitation that must be considered when interpreting gene 
regulation of the withdrawal circuit. As discussed above, punches are 
heterogeneous tissue samples containing multiple brain sub-regions, neuron-
types, as well as non-neuronal cell, including glia. To determine sub-region-and 
neuron type-specific alterations in gene expression future sequencing 
experiments will need to be performed using RNA isolated from subregions, cell 
types, or single cells. As previously discussed, the existing sequencing dataset 
can be used to evaluate the expression of cell type-specific markers to determine 
their contribution to the tissue sample. 
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Integrated prediction analysis identified mRNAs that are predicted targets 
of inversely regulated miRNAs in the reward and withdrawal circuits. 
Integration of the differential expression analyses of miRNAs and mRNAs, 
along with TargetScan Mouse 7.1, a miRNA target prediction algorithm, was 
used to identify mRNAs that were predicted to be inversely regulated by miRNAs. 
Like differential expression analysis alone, the miRNA target prediction reflects 
the known activation and functions of each region within the reward and 
withdrawal circuits. 
In the NAc, 852 mRNAs were differentially expressed during chronic 
nicotine exposure with fold changes > 2. The expression of only 8 conserved 
miRNAs was significantly altered. Although there are relatively few conserved 
miRNAs that are nicotine responsive, all of which are up-regulated, each of these 
miRNAs was predicted to target at least one of 204 down-regulated mRNAs. As 
in the majority of the predicted mRNA targets, the alterations in miRNA 
expression induced by nicotine treatment return to control levels after acute 
withdrawal. In light of the fact that miRNAs may have multiple targets (Lim et al. 
2005), this prediction analysis suggests that even a few differentially expressed 
miRNAs may impart widespread regulation of gene expression in the NAc during 
chronic nicotine treatment, contributing to the mechanisms underlying the 
neuroadaptations of nicotine reward.  
In contrast to the NAc, there is only one predicted mRNA target of an 
inversely regulated miRNA during chronic nicotine exposure in the IPN, and none 
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in the MHb. However, there are hundreds of mRNAs differentially expressed in 
the IPN and MHb of NAWD mice compared to drug-naïve controls that are 
predicted targets of inversely regulated miRNAs. In both regions, the majority of 
the mRNA targets are regulated as a sole consequence of nicotine withdrawal. 
Taken together, this integrated target prediction analysis suggests that miRNAs 
contribute to the withdrawal-induced regulation of mRNAs in the IPN and MHb, 
reflecting changes in neuronal function during acute nicotine withdrawal that 
induce behavioral dysfunction including anxiety. 
Like the differential expression analysis, the target prediction analysis of 
miRNAs differentially expressed in the midbrain allude to the dual role of the VTA 
in the reward and withdrawal circuits. After chronic nicotine treatment alone, 
there are few conserved, differentially expressed miRNAs. Hence, out of all the 
mRNAs regulated in the midbrain of Nic mice compared to TA controls, only one 
is a predicted target of an inversely expressed miRNA. However, 45 conserved 
miRNAs are up- or down-regulated in acute nicotine withdrawal compared to 
drug naïve controls. Of these, 29 are predicted to target at least one of 380 
reciprocally expressed mRNAs, most of which are up-regulated. In contrast to the 
regulation observed in the MHb-IPN withdrawal circuit, the initial chronic nicotine 
treatment contributes at least in part to the differential expression of the majority 
of predicted mRNA targets in the midbrain during acute withdrawal. For instance, 
about 28% of these mRNA targets were similarly regulated with a fold change > 2 
after chronic nicotine treatment alone. In addition, only 7 (~2%) of the predicted 
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mRNA targets are regulated only during acute withdrawal, being similarly 
differentially expressed in the midbrain of NAWD- compared to either TA- or Nic-
treated mice. Since none of the miRNAs themselves are significantly regulated 
by chronic nicotine treatment, it is possible that the induction of up- or down-
regulation of miRNAs by nicotine withdrawal contributes to the propensity for 
nicotine responsive mRNAs to remain differentially expressed even after nicotine 
treatment has stopped. Hence, while contributing little to the mechanisms 
underlying the neuroadaptations of nicotine reward, regulation of miRNAs in the 
midbrain may play a role in the pathophysiology of nicotine withdrawal and the 
associated symptoms, including anxiety.  
One limitation of the integrated target prediction analysis is the inability to 
detect differential expression of specific isoforms of mRNAs in the current 
analyses. Interestingly, GO analysis identified a significant enrichment of up-
regulated genes related to RNA processing in the IPN during nicotine withdrawal. 
If nicotine treatment and withdrawal promotes alternative splicing, differential 
expression of individual gene isoforms would not have been detected by the 
analyses performed in this study. Additionally, most genes contain multiple 
functional polyadenylation sites, and alternative polyadenylation events have 
been shown to cause widespread lengthening of 3'-UTRs in the mammalian brain 
(Miura et al. 2013). Lengthening of  3'-UTRs may in brain may contain additional 
MREs that were not included in the integrated target prediction analysis. Future 
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bioinformatic analysis should determine the differential expression of splice and 
polyadenylation variants for target prediction. 
Many genes differentially expressed in the NAc, midbrain, MHb, and IPN 
during chronic nicotine treatment and withdrawal were not predicted to be targets 
of inversely expressed miRNAs. Therefore, alternative mechanisms contributing 
to the regulation of these genes, and also those that are predicted targets of 
miRNAs, should be considered. Possible alternative mechanisms include the 
induction of transcription factors, epigenetic mechanisms, and neurotoxicity.  
Transcription factors bind to specific DNA sequences and regulate 
transcription of RNA through interactions with RNA polymerase II (Mitchell and 
Tjian 1989). Transcription factors are induced or repressed by environmental 
stimuli, including nicotine (Madsen et al. 2012). In particular, nicotine and 
withdrawal has been shown to alter the expression and phosphorylation of CREB 
(Pandey et al. 2001, Brunzell et al. 2003, Brunzell et al. 2009), as well as the Fos 
family of early immediate genes (Marttila et al. 2006). The RNA-Seq data 
presented here may be used to perform a transcription factor binding enrichment 
analysis to determine if there is an over-representation of differentially expressed 
genes containing known motifs associated with transcription factor binding sites.  
In addition to the regulation of transcription factors, other epigenetic 
mechanisms of gene regulation by nicotine treatment and withdrawal should be 
considered. Regulation of histone modifications, such as acetylation, methylation, 
phosphorylation, ubiquitination and sumoylation, signal the recruitment of 
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transcription factors and determine the accessibility of DNA to the transcription 
complex (Madsen et al. 2012). Nicotine has been shown to increases histone 
acetylation (Levine et al. 2011) and methylation (Jung et al. 2016) at specific 
transcription factor binding sites. The effect of nicotine treatment and withdrawal 
on the regulation of epigenetic mechanisms and their role in the widespread 
alterations of gene expression in the mesocorticolimbic and habenulo-
interpeduncular circuits should be examined in future studies.  
Finally, the neurotoxic effects of nicotine should be considered as a 
possible mechanism underlying the alterations in gene expression and behaviors 
during chronic nicotine treatment and withdrawal. Specifically, nicotine treatment 
induces selective degeneration of the Fr, composed of axons projecting from the 
MHb to the IPN (Carlson et al. 2000). The toxic effects of nicotine on the 
habenular axons in the withdrawal circuit may contribute to the altered neural 
activation, gene regulation, and behaviors during acute nicotine withdrawal. 
 
Repression of Pfn2 expression in the IPN is sufficient to induce anxiety. 
 In Chapter 4, we demonstrate the utility of this sequencing screen by 
focusing on a single differentially expressed gene for detailed study. Pfn2, a 
regulator of cytoskeletal dynamics and synaptic activity (Witke 2004), was 
identified as an ideal candidate. Selection of Pfn2 was based on its conservation, 
robust overall expression level, known functions, and differential expression in 
the IPN during nicotine withdrawal. Based on sequencing data, acute nicotine 
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withdrawal induced a ~50% down-regulation of Pfn2 expression in NAWD mice 
compared to both nicotine-naïve and nicotine-treated mice. Integrated target 
analysis identified 2 conserved MREs for miR-106b-5p, which was up-regulated 
by approximately 80% in the IPN during acute nicotine withdrawal. Results of in 
vitro miRNA over-expression and luciferase assay experiments suggest that miR-
106b-5p is a negative regulator of Pfn2 expression through at least one of the 
predicted MREs located at nucleotide position 1197-1203.  
 Pfn2 is a regulator of cytoskeletal dynamics enriched in the brain (Witke et 
al. 2001, Tariq et al. 2016). Pfn2 has been shown to play a role in neuronal 
morphology and function, being involved in the regulation of dendritic spines, 
neuritogenesis, synaptic receptor composition, and synaptic vesicle exocytosis 
(Witke 2004). These neuronal functions of Pfn2 align with the findings of the GO 
analysis, identifying enrichment of down-regulated genes related to neuron 
projection organization. Whole-body Pfn2 knockout mice exhibit increased 
synaptic vesicle exocytosis, as well as hyperactivation of the striatum (Pilo Boyl 
et al. 2007). Importantly, the neurons in the IPN are activated during acute 
nicotine withdrawal, inducing anxiety (Zhao-Shea et al. 2015, Molas et al. 2017). 
Thus, we hypothesized that down-regulation of Pfn2 contributes to the activation 
of the IPN during acute nicotine withdrawal, resulting in anxiety. To test the 
hypothesis that down-regulation of Pfn2 in the IPN plays a role in the molecular 
mechanisms underlying the pathophysiology of withdrawal-associated anxiety, 
we used lentiviral delivery of a shRNA to knock down Pfn2 expression in the IPN 
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and assayed anxiety behavior. We found that repression of Pfn2 expression in 
the IPN was sufficient to increase anxiety behavior in the EPM. However, unlike 
NAWD mice, KD of Pfn2 in the IPN was not sufficient to increase anxiety in the 
MBT. Future experiments may use additional behavioral assays, such as the 
open field test, to confirm the anxiogenic effect of Pfn2 KD in the IPN. 
Additionally, Pfn2 KD did not affect object novelty preference, another behavior 
controlled by the IPN (Molas et al. 2017). This suggests that the role of Pfn2 in 
the IPN is specific to influencing anxiety. Further work is needed to determine the 
specific effects of Pfn2 expression on neuronal activation and morphology in the 
IPN during nicotine withdrawal-induced anxiety. These results presented in 
Chapter 4 illustrate how the integration of differential expression and target 
prediction analyses in the reward and withdrawal circuits can be used to identify 
novel roles for genes and their miRNA regulators in the neuroadaptations 
underlying the pathophysiology of nicotine addiction. 
 
 
5.B. Future Directions 
 
 We used integrated miRNA-/mRNA-sequencing to determine 
transcriptome-wide expression changes in the mesocorticolimbic reward and 
habenulo-interpeduncular withdrawal pathways during chronic nicotine treatment 
and withdrawal. However, all of these experiments were performed on male mice. 
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Currently, men smoke tobacco at higher rates than women (Sieminska and 
Jassem 2014). However, women have a harder time quitting than men (Smith et 
al. 2015), reporting higher levels of craving and negative affect during nicotine 
abstinence and in response to stress and other environmental smoking cues (Xu 
et al. 2008, Doran 2014, Wray et al. 2015). Neuroimaging studies have revealed 
gender differences in activation of the mesolimbic dopamine system while 
smoking (Cosgrove et al. 2014). Gender differences in brain activity may underlie 
the differences in susceptibility to relapse between men and women. 
Understanding the gender-specific neuroadaptations of nicotine exposure and 
withdrawal is essential to designing optimal smoking cessation aids. Hence, the 
sequencing studies presented in Chapters 2 and 3 should be repeated using 
female mice. 
We found that there are widespread alterations in miRNA and mRNA 
expression in the NAc, VTA, MHb, and IPN during nicotine treatment or acute 
withdrawal, in a brain region-specific manner. However, it is still unknown 
whether this effect is mediated through nAChR signaling or some other 
mechanism, including the neurotoxic effects of nicotine. To investigate this, 
studies employing mecamylamine, a non-selective nAChR antagonist, and other 
receptor subtype antagonists should be performed. For example, differential 
expression of miRNAs/mRNAs may be determined by sequencing or RT-qPCR 
in Nic and NAWD mice being administered nAChR antagonists through osmotic 
minipumps during nicotine treatment and withdrawal. If regulation of a transcript 
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is the result of nAChR signaling, one would hypothesize that nAChR antagonists 
would prevent the differential expression of that transcript when compared to 
controls.  
 Future studies should determine if the miRNA/mRNA regulation in the NAc, 
midbrain, MHb and IPN is a specific effect of nicotine or are a common effect of 
all drugs of abuse. Addictive drugs commonly result in increased extracellular DA 
in the NAc, promoting positive and rewarding emotions (Di Chiara and Imperato 
1988, Pontieri et al. 1996). In addition, increased anxiety is a common feature of 
acute withdrawal in all major drugs of abuse (Koob and Volkow 2010). Nicotine 
has also been shown to act as a “gateway drug,” with nicotine pretreatment 
increasing behavioral and synaptic responses to cocaine (Levine et al. 2011). 
Future work should employ mRNA- and miRNA-sequencing to measure 
differential expression in the mesocorticolimbic circuit and MHb-IPN axis of mice 
treated chronically and withdrawn from other drugs of abuse, such as cocaine, 
amphetamine, opioids, and ethanol. The induction of similar miRNA/mRNA 
regulation in response to other drugs may contribute to molecular mechanisms 
underlying co-abuse with nicotine and nicotine’s role as a “gateway drug.”  
All of the studies presented used RNA extracted from whole tissue 
punches. As described in Chapter 1, each brain region is composed of different 
sub-regions and neuronal cell types. To improve our understanding of the 
microcircuitry underlying responses to nicotine treatment and withdrawal, the 
sequencing experiments should be repeated in a sub-region- and neuron-type-
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specific manner. To achieve this, laser capture microdissection can be employed 
to isolate specific sub-regions or neuron types, identified by immune-labeling or 
using mouse lines expressing fluorescent reporter fusion proteins. Alternatively, 
10X Genomics technology is a high-throughput technology to achieve single cell 
gene expression analysis. However, the low overall level of transcripts detected 
is a limitation of any single-cell sequencing experiment. 
Brain circuits other than the classical mesocorticolimbic reward pathway 
and the MHb-IPN withdrawal axis underlie nicotine dependence and symptoms 
of nicotine withdrawal. For example, the amygdala, within the arousal-stress 
system, and the hypothalamic-pituitary-adrenal axis are activated by the 
withdrawal of all drugs of abuse and these effects are mediated by the stress 
hormone, CRF (Koob and Volkow 2010). Activation of the hypothalamic-pituitary-
adrenal axis during nicotine withdrawal contributes to somatic signs such as 
alterations in appetite, as well as affective symptoms, such as depression 
(Miyata et al. 1999, Semba et al. 2004). These broader hypothalamic effects may 
contribute to withdrawal signs that confound the behavioral assays we used to 
measure anxiety. Future studies should monitor body weight and other physical 
signs, such as body temperature, heart rate and other somatic withdrawal signs. 
In addition to anxiety tests, a more comprehensive analysis of behaviors, 
including depression and locomotor activity assays, may be used to assess 
behaviors during various stages of nicotine withdrawal and to characterize the 
effects of candidate gene regulation. To better understand these broader effects 
	229 
of withdrawal, future studies may use sequencing to perform transcriptome-wide 
differential expression analysis in additional brain regions including the amygdala 
and hypothalamus. 
In the NAc and midbrain of the mesocorticolimbic limbic reward pathway,  
mRNA-Seq identified a plethora of genes regulated my chronic nicotine treatment. 
Using the differential expression and GO analyses, candidate genes that are 
differentially expressed in the NAc and midbrain of Nic mice should be identified 
for validation by RT-qPCR and other further lines of investigation. Priority should 
be given to candidates that are conserved, robustly expressed overall, more 
highly up- or down-regulated, and related to enriched GO terms. GO terms of 
highest interest relate to regulation of neuron projections, regulation synaptic 
structure or activity, regulation of neurotransmitter levels and binding of 
receptors/ion channels. Although there are only a few miRNAs regulated after 
chronic nicotine treatment, many anti-correlated mRNAs are predicted to be 
targets of these miRNAs in the NAc. When ranking candidates for further studies, 
priority should also be given to mRNA candidates predicted to be targets of 
inversely expressed miRNAs. In light of the known function of the reward circuitry 
and identification of a multitude of nicotine responsive transcripts in the NAc and 
midbrain, the effects of each candidate genes’ expression level on nicotine 
reward and sensitization behaviors should be determined. Behavioral testing may 
include nicotine self-administration, conditioned place preference, and nicotine-
induced locomotor activity assays. 
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Although classically thought of as a member of the reward circuitry, the 
VTA is also interconnected to the MHb-IPN withdrawal axis, as previously 
discussed. The majority of mRNAs differentially expressed during chronic 
nicotine treatment remain similarly up- or down-regulated during acute nicotine 
withdrawal. Therefore, the effect of mRNA regulation in the midbrain of Nic- and 
NAWD-treated mice on MHb-IPN axis’ neuronal activity and withdrawal-induced 
anxiety should be determined. Candidates should be identified and prioritized as 
described above. Based on the GO analysis, focus should again largely be on 
genes related to the regulation of neuron projections, regulation of synaptic 
structure or activity, regulation of neurotransmitter levels and binding of 
receptors/ion channels. During acute withdrawal, many miRNAs are inversely 
regulated to their predicted targets. Again, priority should be given to genes that 
are predicted targets of differentially expressed miRNAs. 
In Chapter 3, sequencing and differential expression analysis identified a 
multitude of changes in miRNA/mRNA expression during acute nicotine 
withdrawal. As discussed for the analysis of the mesocorticolimbic reward 
pathway, mRNA and miRNA candidates should be identified and prioritized for 
validation and future studies. We had chosen to focus on mRNAs that were 
regulated solely as an effect of nicotine withdrawal, validating the differential 
expression of selected genes in the IPN and MHb. However, future experiments 
may also choose to focus on other genes whose differential expression is due at 
least in part to the effect of the initial chronic nicotine treatment itself. Chapter 4 
	231 
serves as an example of the initial follow-up experiments that should be pursued 
with each candidate. In addition to conservation, overall expression level, and 
fold change, GO analysis can be used to prioritize candidates for further 
investigation and determine the specific experimental plan. For example, in the 
IPN, up-regulated mRNAs are enriched in GO terms describing the mitochondria 
and energetics. Future experiments might include observing the effect of acute 
nicotine withdrawal on mitochondrial morphology, number or membrane potential 
in neurons of the IPN. Then, to test the hypothesis that up-regulation of 
candidate mRNAs contributes to these effects, genes can be over-expressed in 
the IPN of WT mice via lentiviral delivery and the effects on mitochondria and 
anxiety behaviors can be measured. Additionally, in the IPN and MHb there is an 
overrepresentation of down-regulated genes related to cell/neuron projection 
organization and development. An example of a down-regulated candidate gene 
in the IPN that has functions related to cytoskeletal dynamics and synaptic 
morphology was described in Chapter 4, and similar experimental strategies can 
be applied to other candidates identified in the sequencing data analyses.  
In Chapter 4, we present evidence that Pfn2 expression in the IPN plays a 
role in the modulation of nicotine withdrawal-induced anxiety. Relative 
quantification of expression by sequencing and RT-qPCR, shows that Pfn2 is 
down-regulated in the IPN of NAWD mice compared to drug-naïve controls. 
Further, we show that knockdown of Pfn2 in the IPN is sufficient to induce 
anxiety as measured by the EPM, mimicking the behavioral effects of nicotine 
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withdrawal. To strengthen this result, a Pfn2 rescue experiment should be 
performed, over-expressing Pfn2 in the IPN via lentiviral delivery during nicotine 
treatment and acute withdrawal. The amelioration of nicotine withdrawal-
associated anxiety behavior by the over-expression of Pfn2 in the IPN would add 
further support to the conclusion that down-regulation of Pfn2 in the IPN during 
nicotine withdrawal plays in important role in the mechanisms underlying nicotine 
withdrawal-associated anxiety.  
The effect of Pfn2 knockdown on neural activity and morphology in the 
IPN are as yet unknown. Future studies should employ electrophysiology to 
make measurements including action potential frequency and 
frequency/amplitude of excitatory postsynaptic potentials to asses neuronal 
activity and neurotransmitter release in IPN neurons infected with lenti-GIPZ-
Pfn2-shRNA-tGFP. Neurons in whole animal Pfn2 -/- mice exhibit increased 
synaptic vesicle release and hyperactivation (Pilo Boyl et al. 2007). Thus, I would 
hypothesize that neurons expressing Pfn2 shRNA would display similar features. 
Because previous studies have shown that Pfn2 contributes to regulation of 
dendritic spines (Ackermann and Matus 2003) and neuritogenesis (Da Silva et al. 
2003), microscopy should be used to observe changes in synaptic morphology.  
Differential expression analysis of miRNA-sequencing data revealed 
down-regulation of miR-106b-5p in the IPN, which was confirmed by RT-qPCR. 
TargetScan Mouse 7.1 predicted that miR-106b-5p targets anti-correlated 
mRNAs, including Pfn2 which possesses two MREs within its 3ʹ-UTR. In Chapter 
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4, I presented data suggesting that miR-106b-5p targets at least one MRE within 
the 3ʹ-UTR of Pfn2, repressing its expression in vitro. However, the repression of 
Pfn2 expression by miR-106b-5p must be confirmed in vivo. To do this, miR-
106b-5p should be over-expressed and inhibited in the IPN using lentiviral or 
AAV delivery of miRNA mimics and anti-miRs. Pfn2 expression can then be 
measured at the transcript and protein level. To confirm the regulation of Pfn2 by 
miR-106b-5p through interaction with MRE2 at nucleotide position 1197-1203, 
CRISPR-Cas9 gene editing technology could be used to introduce mutations to 
the predicted MREs, in a similar fashion to our luciferase screen. The failure of 
miR-106b-5p over-expression to repress Pfn2 expression in mutant MRE mice 
would further support our conclusions that miR-106b-5p is a negative regulator of 
Pfn2.  
In addition to expanding on our understanding of the regulation of Pfn2 by 
miR-106b-5p, future work should determine the upstream role of miR-106b-5p on 
neural function and nicotine withdrawal-associated behaviors. Similar to the 
studies described using lentiviral delivery of shRNA to inhibit expression of Pfn2, 
miR-106b-5p should be over-expressed in the IPN of WT mice using viral 
delivery of miRNA mimic. Because KD of Pfn2 in the IPN increases anxiety in 
WT mice, I hypothesize that over-expression of miR-106b-5p is also sufficient to 
induce anxiety in nicotine-naïve mice, mimicking the effects of nicotine 
withdrawal. Conversely, I would hypothesize that inhibition of miR-106b-5p in the 
IPN by viral delivery of anti-miR or tough decoy would ameliorate the increase in 
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anxiety of mice in acute nicotine withdrawal. Effects on neuronal activity and 
morphology should also be determined as described for KD and overexpression 
of Pfn2. 
Pfn2 is expressed in all regions of the brain (Witke et al. 2001, Pilo Boyl et 
al. 2007). However, studies exploring the effects of Pfn2 down-regulation in 
specific sub-regions or neuron cell-types within the IPN will further our 
understanding of its function as a regulator of habenulo-interpeduncular 
withdrawal circuit activity and nicotine withdrawal-induced anxiety. First, patterns 
in Pfn2 expression should be identified using FISH and/or immunohistochemistry. 
A Cre-lox expression system can then be used to determine the cell-type specific 
effects of Pfn2 KD on neural activity, cell morphology, and anxiety behaviors.  
 As discussed here, the results of the sequencing screens described in 
Chapters 2 and 3 may inspire seemingly endless lines of future investigation. 
Individualized pursuit of nicotine and withdrawal responsive genes in the reward 
and withdrawal circuits, as proposed for Pfn2, are certain to lead to discovery of 
novel molecular mechanisms underlying nicotine dependence and associated 
behaviors.  
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